SAN FRANCISCO, CA–(Marketwire – September 1, 2010) –  Eye M.D.s are intent on finding better ways to diagnose and treat glaucoma, a complex, potentially blinding disease. September’s Ophthalmology journal includes new data from the Rotterdam Study that will help doctors better predict visual field loss in glaucoma patients. Johannes R. Vingerling, MD, PhD, Erasmus Medical Center, The Netherlands, and his colleagues followed 6,630 participants for ten years. The patients had optic nerve damage but no VFL when they joined the study. Ophthalmology is the journal of the American Academy of Ophthalmology. 

Worldwide, glaucoma is the most frequent cause of preventable blindness, but up to 80 percent of people who have the disease are unaware of it and so do not receive treatment that could help save their sight. Primary open angle glaucoma (POAG) is the most common form of the disease in the United States and many other countries. Visual field loss (VFL) is the shrinking of the “scope” of what a person can see; it usually begins as a loss of side (peripheral) vision in people who have POAG.

If untreated, POAG causes irreversible blindness. This occurs through progressive loss of the nerve cells in the eye’s retina, which leads to abnormal changes in the optic nerve. Over time, these changes can reduce the field of vision (visual field) and also disrupt the transmission of images to the brain’s vision center. 

“In this patient population, the risk of developing VFL was related to higher intraocular pressure (pressure within the eye, IOP), older age, a high level of myopia (nearsightedness), male gender, a family history of glaucoma, and a higher vertical cup-to-disk ratio (a measurement of the optic nerve head),” said Dr. Vingerling. His team’s data also provide an estimate of the long-term incidence of VFL in an older, white European population.

Higher IOP often contributes to POAG, and patients with high IOP (a condition also called ocular hypertension) are carefully monitored by their ophthalmologists.

Eye M.D.s also use the visual field test as a screening device to identify patients who might be developing glaucoma (or other eye diseases that affect the visual field) and who need comprehensive eye exams to determine their exact diagnosis.

Eds: Full text of the study is available from the Academy’s media relations department.

About the American Academy of Ophthalmology
The American Academy of Ophthalmology is the world’s largest association of eye physicians and surgeons — Eye M.D.s — with more than 29,000 members worldwide. Eye health care is provided by the three “O’s” — opticians, optometrists and ophthalmologists. It is the ophthalmologist, or Eye M.D., who can treat it all: eye diseases and injuries, and perform eye surgery. To find an Eye M.D. in your area, visit the Academy’s Web site at www.aao.org.

CALGARY, ALBERTA–(Marketwire – Sept. 1, 2010) –

WHAT: Next Wednesday, September 8, marks the grand opening of Brite Studios’ (Brite’s) new location. Brite Studios, formerly known as Calgary Children’s Centre, is Calgary’s premier childcare and recreational facility. At their launch event, Brite will demonstrate how they are working to improve the quality and amount of childcare services in our ever-growing city. 

As part of the event, there will be a creative ribbon-cutting ceremony as well as a brief performance by some of the children who attend Brite Studios. There will also be interactive artwork involving the attendees. The Honourable Ron Liepert and Alderman Joe Connelly will be in attendance to show their support. They will be addressing the audience with a few words on the importance of Brite Studios.

Representatives of Brite Studios, local and provincial government and academics will be gathering to celebrate the new name and location of this important centre for child learning and recreation.

WHO: In attendance will be:

Alberta Energy Minister Ron Liepert

Alderman Joe Connelly

Lisa Davis, Founder and CEO of Brite Studios

WHEN: Wednesday, September 8, 2010 

10:00 a.m. 

*Media are requested to arrive at 9:45 a.m. sharp.

WHERE: 

Brite Studios

Unit 148, 30 Springborough Blvd SW

Calgary, AB T3H 0N9

*Photo opportunities are available.

*Click here for map.

LOS ANGELES, CA–(Marketwire – August 31, 2010) –  That back to school time of year is here again and whether you are a student, a parent, or a burnt-out employee, the return to a regular schedule generates feelings of renewal and promise. Back to school (or back to work) resolutions focus more on improving stress management and decreasing the aches and pains associated with deskwork than their sibling New Year’s resolutions. 

Chantal Donnelly, a physical therapist and host of the new DVD “Pain Free At Work,” offers tips on making the most effective back to school resolutions.

“Come Labor Day, you may find it more difficult to push the pause button on stress than you did on vacation, but you can make changes that will decrease stress, neck pain, back pain, headaches and arm pain as well as improve your mood and productivity at work,” states Donnelly, the owner of Body Insight Inc., a company dedicated to injury prevention through exercise. Among her favorite back to work resolutions, Donnelly recommends committing to more micro-breaks while working at a computer. “Studies have shown that taking short, more regular breaks can decrease discomfort and increase typing speed (so there is no loss of productivity). Take 30-second long breaks every 45 minutes as well as longer, five-minute breaks every two hours. Computer rest break programs are a great way to keep tract of break times. These downloadable programs remind you when it is time to rest and will guide you through desk exercises during the longer break periods,” suggests Donnelly.

Here are some more tips for back to school and work resolutions from Chantal Donnelly:

“Learn how to type properly. If you are a two-fingered typist and have to constantly look down at the keys to write, you are placing excessive strain on your neck joints and are at risk for disc injuries. Try free, online typing lessons or check your local community college for classes.

“Get some form of physical activity DURING your workday. The brain is stimulated by exercise. Your creativity, problem solving and thinking skills will improve if you move. Try a brisk 10-minute walk during a meeting with a coworker, a game of basketball during lunch, 20 minutes of upper body weights while on a conference call… Whatever your preference and however you can fit it in, physical activity while at work will help you think better.

“Schedule a daily ‘no screen time’ period when you get home from work or school. This means no computers, video games or T.V. during a set time everyday. A two to three hour period works best and encourages face-to-face social interaction (necessary for stress management) and gives your eyes a needed break from staring at a monitor.”

About Chantal Donnelly

Chantal Donnelly, MPT is a faculty member and research advisor at Mount St. Mary’s College in Los Angeles. She is the host of two rehabilitation DVDs: “Strong Knees” (Gaiam) and “Pain Free At Work” (Body Insight Inc.). She has been featured in various magazines including Woman’s World and Woman’s Day Magazine. Chantal designed the Pain Free At Work program in order to give people a healthy solution to repetitive strain injuries, back pain and neck pain so common in the workplace. 

For more information on health and wellness in the workplace, computer rest break programs or back to school resolution tips, please visit www.bodyinsight.com or contact Chantal Donnelly at [email protected] or by phone 213.215.6778.

Click here to see all recent news from this company

WINCHESTER, CA–(Marketwire – August 26, 2010) – Minutes after her father — a veteran of WWII — left to fight in the Korean War, Sandi Kriebel was born. “I was raised in a patriotic home. One of my brothers served in Vietnam and the other was in the Navy. We flew the American flag every day,” says Kriebel.

These days Kriebel applies that patriotism by working with hospitalized veterans distributing HHV-provided therapeutic arts & crafts kits at the Baltimore VA Medical Center, a position funded by Help Hospitalized Veterans (HHV). What makes her story touching is the fact that her son, a veteran of the Persian Gulf War, is seriously ill. “There are reminders of the pain he endures every day. I want to make sure all veterans, particularly those in VA hospitals and nursing homes, know they are not forgotten,” she adds.

Kriebel enjoys her work, witnessing the benefits of the craft kits every day. “When I approach a veteran to try something new, the initial reaction is oftentimes reluctance.” With encouragement, however, Kriebel says reluctance gives way to curiosity, then finally — willingness to try a project. “I’ve seen fear replaced with hope and despair replaced with enjoyment. As veterans work on their craft kits, levels of confidence and self-esteem increase,” says Kriebel.

In addition, a breakthrough moment was observed by a therapist on the mental health unit who was having difficulty getting patients to open up during group sessions. The therapist noticed that, while working on HHV’s leather craft items, a couple of the patients were talking to each other. Therapists decided to incorporate arts & crafts into regular group therapy. “You’d be amazed at the positive difference craft kits have made,” Kriebel added.

Since 1971, HHV has donated over 25 million therapeutic arts & crafts kits to our nation’s VA and military hospitals at no charge. For more information on HHV’s variety of programs and services — all of which are made possible through the generous support of donors throughout the United States — visit www.hhv.org.

Documents and/or Photos available for this release:
PDF_of_release

To view supporting documents and/or photos, go to www.enr-corp.com/pressroom and enter Release ID: 268310

FRIENDSWOOD, TX–(Marketwire – August 26, 2010) –  TrinityCare Senior Living, Inc. (OTCBB: TCSR), which develops, manages and owns faith-based senior living facilities, today announced the execution of an agreement with SeaBridge Freight, Inc., a Delaware company, which provides container-on-barge transport service between Port Brownsville, Texas and Tampa Bay, Florida.

“This agreement will create a change in focus for our public company, and a change we believe will be beneficial to our shareholders,” stated Donald W. Sapaugh, Chairman and Chief Executive Officer of TrinityCare Senior Living, Inc. “SeaBridge Freight, is a leader as a ‘Marine Highway,’ with revenues increasing each quarter this year. The company has excellent leadership and is poised to expand rapidly over the next year.”

This reorganization agreement has been approved by a majority of the shareholders of both companies, and further information will be available shortly.

About TrinityCare Senior Living, Inc.

TrinityCare Senior Living (“TrinityCare”) develops, owns, and manages quality senior living facilities that focus on enriching the faith of the residents and providing state-of-the-art independent living, assisted living, memory care and adult day care services in a single location. The Company partners with local churches and developers for each facility and offers a wide range of both community and personal services to residents. TrinityCare is a rapidly growing company with three successful facilities currently operating in Texas and Tennessee. Near-term expansion plans target the Southeastern part of the United States. For more information please visit www.trinitycare.com.

TrinityCare is headquartered in Friendswood, Texas (Houston metropolitan area) and its common stock trades on the OTC Bulletin Board under the symbol “TCSR.”

Forward-Looking Statements

The information in this news release includes certain forward-looking statements that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including statements related to the future financial performance of the Company. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Factors that could cause results to differ include, but are not limited to, successful execution of growth strategies, product development and acceptance, the impact of competitive services and pricing, general economic conditions, and other risks and uncertainties described in the Company’s periodic filings with the Securities and Exchange Commission.

IRVING, TX–(Marketwire – August 26, 2010) –  Seven hospitals in North Carolina, all members of VHA Inc., the national health care network, formed the Southern Atlantic Health Care Alliance, known as SAHA, purchasing coalition in 2007. Within the past two years, they have saved $2.8 million by aggregating their purchasing volume and achieving greater savings than they could have realized individually, while retaining their ability to make independent decisions about product purchases as hospitals adopt tactics that help them do more with reduced resources. 

“Almost daily, our member hospitals tell us that current conditions are forcing them to stretch their budgets without impinging upon patient care,” said Scott Downing, executive vice president of Supply Chain Management at VHA. “Purchasing coalitions create opportunities for savings on clinical commodities that hospitals use every day as well as more specialized products, resulting in significant savings while fostering peer-to-peer interaction and knowledge sharing.”

Working with VHA to focus on supply chain improvement activities, SAHA purchasing coalition acts as a single entity to drive savings and supply chain efficiency that reduce supply expenses. On average, members of VHA Supply Networks save 8% to 12% annually through network contracts.

Demonstrating the benefits of aggregation, collaboration, commitment and teamwork, SAHA members anticipate significant savings while preserving patient safety. For example, they created a prototype, with member-approved new features for some existing patient footwear. Because members agreed to aggregate their purchasing volumes and the supplier, Encompass, agreed to make the changes and lower the cost, this standardization initiative will reduce costs and decrease the number of inventory stock keeping units, or SKUs, for hospitals that discontinue their use of hard-soled slippers. 

“The Moses Cone Health System values the SAHA membership because we’ve realized more than $500,000 in savings since joining the network,” says Susan Aquino-Smith, SAHA’s chairman of the Joint Implementation Team and Contract Administrator for The Moses Cone Health System in Greensboro, NC. “We are working on several initiatives and believe that these savings will grow as SAHA continues to mature.” 

About VHA — VHA Inc., based in Irving, Texas, is a national network of not-for-profit health care organizations that work together to drive maximum savings in the supply chain arena, set new levels of clinical performance and identify and implement best practices to improve operational efficiency and clinical outcomes. In 2009, VHA delivered record savings and value of $1.47 billion to members. Formed in 1977, through its 16 regional offices, VHA serves more than 1,400 hospitals and more than 28,000+ non-acute care providers nationwide. VHA was ranked by Modern Healthcare as the 7th best place to work in health care in 2009.

IRVINE, CA–(Marketwire – August 26, 2010) –  A partnership between the Cystinosis Research Foundation and the Cystinosis Foundation along with a collaboration of 12 advocate foundations from around the world has launched the first global cystinosis patient registry. The registry’s goal is to connect patients with researchers and others developing potential new treatments and a cure for the metabolic and fatal disorder that afflicts about 2,000 persons, mostly children, worldwide.

The purpose of the Cure Cystinosis International Registry is to identify people with cystinosis worldwide and collect their medical histories and information. This information will allow clinicians, researchers and pharmaceutical companies to accelerate novel treatments and a cure for cystinosis.

“The cystinosis community has experienced exciting scientific advancements to treat and cure cystinosis. Currently there is a proliferation of research activity, breakthroughs and hope. The CCIR is a central hub of information and will be used as a resource for the research community and could prove vital to advances in the care and treatment for those with cystinosis,” said Nancy Stack, President of the Cystinosis Research Foundation.

The CCIR is the only registry created specifically for individuals with cystinosis and will contain current information regarding cystinosis clinical trials and studies. All patient information is de-identified (anonymous) and held in a secure data base accessible only by the CCIR curator. Information that could identify participants and their family members will not be shared without their expressed written approval. Participants will also be able to view aggregate data allowing them to view how they fit within the larger cystinosis community.

The registry was formed following discussions which began in 2009 among leaders in the cystinosis community who saw the need to establish a new and comprehensive resource to connect and serve the needs of the entire cystinosis community. The CCIR’s organizers come from family foundations around the world and the cystinosis academic and scientific communities. These groups are focused on the need to accelerate the research process in the quest to find the cure for cystinosis.

In patients with cystinosis, the amino acid cystine accumulates in the tissue due to the inability of the body to transport cystine out of one of the compartments of the cell. Cystinosis is a metabolic disease that slowly destroys every organ in the body, including the liver, kidneys, eyes, muscles, thyroid and brain. There is a medicine that prolongs the children’s lives, but there is no cure. Most cystinosis sufferers succumb to the disease or its complications by age 40.

CCIR officials say recruitment for clinical trials can be a lengthy process, especially for a rare disease like cystinosis. Participation in this registry will help speed up the recruitment process and facilitate and expedite clinical trials, officials said.

Plans are to offer the website in French, Italian and Spanish following the launch.

One of the major features of the registry is a professional/researcher portal that will allow the scientific and pharmaceutical communities to request access to de-identified patient information. Those seeking patient information have to meet stringent requirements governing patient medical data, including patient approval. Each request will be reviewed by the CCIR curator and operations board.

Twelve other cystinosis foundations have joined as advocates of the CCIR. They are: the Cystinosis Awareness & Research Effort in Canada; the Australian Cystinosis Support Group; Cystinosis France, Cystinosis Foundation UK, Cystinosis Ireland, The Cystinosis Foundation, New Jersey Chapter; Cystinosis Support Group South Africa, 24 Hours for Hank; Hope For Holt; Jenna & Patrick’s Foundation Of Hope, Joshua’s Journey of Hope and Tina’s Hope for a Cure.

For more information about Cure Cystinosis International Registry and the Cystinosis Research Foundation of Irvine, Calif., contact Zoe Solsby at (949) 223-7610 or visit www.cystinosisregistry.org or www.cystinosisresearch.org.

Click here to see all recent news from this company

ALEXANDRIA, VA–(Marketwire – August 26, 2010) –  This year, thousands of people in communities across the country will join the movement to Stop Diabetes® by participating in the American Diabetes Association’s Step Out: Walk to Fight Diabetes event. Step Out is a fundraising walk that takes place in more than 140 cities to raise awareness about diabetes and to raise much needed funds to help change the future of this growing epidemic that is taking a physical, emotional and financial toll on our country.

Step Out: Walk to Fight Diabetes is a family event for those who want to become involved in the community and help change the future of diabetes. Participants can walk as an individual or create a team and walk with friends, family, and co-workers.

Do you want to show what it is like to live with diabetes? The American Diabetes Association is also looking for Red Striders. A Red Strider is a person with diabetes who has a passion to stop diabetes and is willing to put a face on this disease by helping others understand what it takes to live with — and fight — this serious disease.

“On the day of Step Out, it is very important to recognize all of the people with diabetes,” said Christine Schaeberle, founder of one of the first Red Strider programs in Colorado. “By wearing red hats that signify that we are living with diabetes, we are able to recognize people with diabetes who are taking steps to stop diabetes.”

Join Christine and other Red Striders in the movement to Stop Diabetes as they ‘Step Out’ this year wearing their Red Strider red hats.

“The Red Strider program really opened my eyes to the fact that I am not alone and I am joined by so many other people who are living with diabetes. For people who participate in Step Out and don’t have diabetes themselves, this is a way for them to see the many faces of diabetes and reinforce the fact that diabetes affects people of all ages and ethnicities. These are the faces that encourage me to walk, and I am inspired to do all that I can do to fight this disease each and every day. I am encouraged to share my story with the hope that other people will join me in raising money to stop diabetes,” added Schaeberle.

Today, there are nearly 24 million children and adults in the United States who have diabetes. While nearly 18 million people have been diagnosed, there are 5.7 million people who don’t even know that they have the disease. If present trends continue, 1 in 3 Americans, and 1 in 2 minorities, will face a future with diabetes. To date, the American Diabetes Association has raised and donated more than $450 million for diabetes research.

National sponsors of Step Out: Walk to Fight Diabetes include Equal® Sweetener, Pure Via™ All Natural Zero Calorie Sweetener, Cary’s® Sugar Free Syrup and Walmart. Be a part of the cure and start raising money today. To register, volunteer or find out more information, please visit diabetes.org/stepout or call 1-888-DIABETES. Together we can stop diabetes. One step at a time.

About the American Diabetes Association
The American Diabetes Association is leading the fight to stop diabetes and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure, and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, its mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information, please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit www.diabetes.org. Information from both these sources is available in English and Spanish.

id=”nav_links”>

MUNDELEIN, IL–(Marketwire – August 26, 2010) –  Medline Industries, Inc., the nation’s largest privately held manufacturer and distributor of healthcare supplies, announced today the signing of a cost management prime vendor agreement with Northeast Alabama Regional Medical Center based in Anniston, Alabama. The five-year agreement is anticipated to deliver significant savings for the hospital over the term of the contract.

Under the agreement, Northeast Alabama Regional Medical Center will receive a broad array of Medline brand medical and surgical products, including surgical procedure trays, patient care products, disposable protective gowns, exam gloves and bandages. The hospital can also leverage other Medline clinical and educational evidence-based programs that were carefully designed to affect clinical outcomes, drive cost savings and improve patient satisfaction. 

Northeast Alabama Regional Medical Center will benefit from significant cost savings through the delivery of Medline manufactured products shipped directly from Medline’s distribution center located in Atlanta, GA.

Medline will also deliver cost savings by reducing distribution fees on other national brand products and product standardization. In addition, Medline will provide enhanced reporting capabilities and offer comprehensive product utilization, education and practical solutions to help the facility control costs and improve patient care. 

About East Jefferson General Hospital 
East Jefferson General has grown over the past three decades to become a medical landmark with the addition of medical office buildings, the Yenni Pavilion for outpatient cancer treatment, and the Domino Pavilion, which houses Same Day Surgery, outpatient laboratory and outpatient radiology services. Most recently, the Wellness Center, a 38,000 square foot, state-of-the-art fitness facility, was added to the hospital’s main campus.

East Jefferson General Hospital has grown with the East Bank community, offering the clinical expertise and cutting edge technology our community expects and deserves. Today, the hospital remains publicly owned and not-for-profit. It is a service district hospital governed by a 10-member volunteer Board of Directors appointed by the Jefferson Parish Council and the Parish President. The hospital is accredited by the Joint Commission on Accreditation of Healthcare Organizations. In 2002, East Jefferson General became Louisiana’s first Nurse Magnet Hospital. This honor is bestowed by the American Nurses Credentialing Center on select hospitals that demonstrate excellence in patient care and provide a superior environment for professional nurses.

About Medline Industries, Inc.
Medline, the nation’s largest privately held manufacturer and distributor of healthcare products, manufactures and distributes more than 100,000 products to hospitals, extended care facilities, surgery centers, home care dealers and agencies and other markets. Headquartered in Mundelein, IL, Medline has more than 800 dedicated sales representatives nationwide to support its broad product line and cost management services. 

Over the past five years, Medline has been the fastest growing distributor of medical and surgical supplies in the U.S., serving as the primary distributor to over 250 major hospitals and health care systems. As a leading distributor, Medline offers a comprehensive array of consulting and management services encompassing the supply chain and logistics, utilization and standardization, business tools and enhanced reporting capabilities, and on-staff clinicians.

Medline has a growing network of 34 distribution centers around the country, as well as an expanding, dedicated transportation fleet with over 180 vehicles in a variety of sizes to fit customers’ specific delivery needs. The fleet is equipped with the latest navigation devices for enhanced order tracking and communication. For more information on Medline, visit our Web site, www.medline.com.

SAN FRANCISCO, CA–(Marketwire – August 26, 2010) –  As children return to school, parents naturally consider how to help their children learn and succeed. Good vision and eye health are key to students’ ability to do well in the classroom, on the playground, in sports, and when studying at home. September is Children’s Eye Health and Safety month, and the American Academy of Ophthalmology encourages families to make sure students receive vision screening and learn eye health and safety practices. Also, it’s important for parents of children with learning disabilities to know how vision does — and does not — play a role.

Mary Lou Collins, M.D., a pediatric ophthalmologist in the Baltimore, Maryland area, said Quinn Kirby’s story illustrates how screening can make a big difference to a child’s future. Quinn is a bright, lively little girl whom Dr. Collins initially saw at age four.

The first hint that Quinn might have a vision problem was picked up in her pediatrician’s office. In a preliminary screening Quinn couldn’t name the pictures or letters — and she expressed a lot of frustration about that, since she knew her alphabet. Dr. Doran and Quinn’s mom, Kris, agreed on sending her to Dr. Collins for a comprehensive exam.

“We found that Quinn’s vision was 20/30 in her right eye and 8/200 in the left, compared with 20/20 normal vision,” Dr. Collins said. “Quinn’s stronger eye was doing most of the work, and her other eye was becoming weaker as a result, a condition called amblyopia. Also, Quinn’s weaker eye was slightly turned inward (one variation of a condition called strabismus), but this was too subtle to be noticed, except in an exam.”

Her parents take excellent care of their kids’ health, and so were stunned by the news. Dr. Collins told them not to blame themselves as such vision problems are nearly impossible to detect — especially in young children — except through vision screening by a school nurse, pediatrician or other qualified health provider. When a potential problem is revealed, a comprehensive eye exam by an ophthalmologist is the best way to determine whether vision correction or other treatment is needed.

Parents may have questions on how the eyes and vision interact with learning disabilities in children. These disabilities result from the brain’s misinterpretation of images received and relayed by the eyes, rather than from structural or functional eye problems. That’s why learning disabilities are not treatable by eye exercises or vision therapy. If disabilities are suspected, students need testing, followed as appropriate by in-depth neurological exams and treatment. And whether or not learning disabilities are suspected, all students need vision screening to check eye health and visual acuity.

Kris, who teaches third grade, said some of her students’ learning struggles might have been avoided if they had vision screening and treatment when they entered kindergarten, or as soon as vision or learning problems were suspected.

“I’d encourage all parents to make sure your children get screened at school, at your pediatrician’s office, or through another health service,” Kris said. “My husband and I are grateful that Quinn’s problem was discovered and treated early. She’s now almost 5 1/2, with 20/25 vision in her right eye and 20/30 in the left. She loves being able to do what ever her big brother does and enjoys reading with us.”

Her treatment included glasses — at first with very thick lenses — but Kris says Quinn liked choosing the pink and purple frames and didn’t mind wearing them. The eye patch treatment was a different story: after three months of persuasion, Quinn agreed to wear the patch over her stronger eye for about eight hours daily so that her weaker eye took on the work of seeing and developed more normally. “Actually, she insisted all of us wear patches along with her. Quinn and my husband in their daisy eye patches were famous at our local market!” Kris added.

For more on children’s eye health and safety at home, school and during sports, visit:
http://www.geteyesmart.org/eyesmart/resources/children/index.cfm

About the American Academy of Ophthalmology
American Academy Ophthalmology is the world’s largest association of eye physicians and surgeons — Eye M.D.s — with more than 29,000 members worldwide. Eye health care is provided by the three “O’s” — opticians, optometrists and ophthalmologists. It is the ophthalmologist, or Eye M.D., who can treat it all: eye diseases and injuries, and perform eye surgery. To find an Eye M.D. in your area, visit the Academy’s Web site at www.aao.org.

ROSWELL, GA–(Marketwire – August 26, 2010) –  Economic globalization brings increased international business travel, and as a result, greater exposure to communicable illnesses.

The H1N1 pandemic that began last year in Mexico forced many companies to face this reality, and new threats are emerging continuously, with illnesses such as Yellow Fever, Hepatitis A & B, Malaria and Japanese Encephalitis confronting today’s business travelers.

The key to mitigating these threats is Passport Health (www.passporthealthusa.com), a leading provider of travel health information and immunizations for international travelers, major corporations, universities and other international organizations, and a Charter Sponsor of the recently launched PREACTION EMERGENCY RESPONSE ALLIANCE™.

The PREACTION ALLIANCE™ (www.preaction.com) is a first-of-its-type private network offering business continuity and disaster-response capabilities through a low monthly-fee, membership-based organization. By becoming a Charter Sponsor, Passport Health has provided its network of franchisees — which comprise more than 170 locations nationwide — access to a free annual membership in the PREACTION ALLIANCE. Thereafter, Member benefits can be retained for less than $1 a day.

“Passport Health is committed to the health and well-being of all employees and our Vaccine Specialists are mission-ready to respond quickly to PREACTION ALLIANCE Members’ needs, including disaster relief and emergency preparedness,” said Fran Lessans, Passport Health CEO.

“The question about pandemics is not if, but when they will happen. We just saw the impact that the H1N1 pandemic had on corporate productivity,” Lessans added. “All businesses should have a pandemic plan in place and have a plan to deliver antivirals to employees if necessary. Passport Health’s presence in the PREACTION ALLIANCE assures that vaccines are available to Members and that they can be administered in short notice.”

The PREACTION ALLIANCE was developed by Firestorm® (www.firestorm.com), a national leader in crisis management, threat assessment/risk analysis, and business continuity. Other Charter Sponsors include W.W. Grainger Inc., the leading supplier of maintenance, repair and operations products.

“The ability to travel the world is one of the great aspects of modern society. Unfortunately, introduction to unusual places, people, and cuisine is often accompanied by exposure to disease threats for which your body is ill-prepared,” said Dr. Don Donahue, Firestorm’s Director of Healthcare Response. “Overseas trips — for business or pleasure — should be preceded by a travel medicine consultation. Vaccination and prophylaxis are critical requirements in many corners of the globe.”

BAY HARBOR, FL–(Marketwire – August 26, 2010) –  SmartMetric, Inc. (OTCBB: SMME) announced today that its fingerprint activated Biometric Data Card can be now used to provide the highest level of both security and portability for a person’s medical history and full medical records.

Colin Hendrick, President and CEO, stated, “Once again our research and development team has pioneered another exciting breakthrough in our Biometric Data Card. We believe that nothing like this exists anywhere in the world today. We are currently in negotiations with several worldwide corporate entities regarding the rollout and commercialization of our breakthrough products. We will be updating our shareholders as soon as possible on the status of these talks, as well as our previously announced legal actions against Visa and MasterCard.”

Unlike other portable solutions, the SmartMetric Data Card can store Gigabytes of medical information including full EKGs, complete CT and MRI digital images, and similar data making up an individual person’s complete medical records. Storage of digital images, in particular, requires significant digital storage capacities. Unlike other systems that are severely limited in the amount of digital data that can be held in a portable solution, the SmartMetric Data Card is in fact a powerful digital computer with significant memory capacity sitting inside a Data Card the size of a standard Health Insurance Card. Most importantly, the SmartMetric solution provides the highest level of portable security for the patients information in that it can only be accessed after the patient touches the surface sensor on the Health Card triggering the Card to scan the persons fingerprint and matching it with their fingerprint pre-stored inside the card. Only after a finger print verification internally in the card is the data able to be accessed or viewed by a Doctor, Hospital or even an EMT’s computer.

About SmartMetric, Inc.

SmartMetric, Inc. has developed a portable biometric identity and transaction card capable of storing a wide variety of personal information while protecting you against identity theft and fraud. It is one of the most advanced portable identity authentication solutions in the world today. The card contains a biometric fingerprint scanner and reader which only you can unlock and is smaller and thinner than a credit card. The SmartMetric card is ideal for a wide range of consumers, including Personal, Government and Corporate.

For more information please visit us at www.smartmetric.com

Safe Harbor Statement

Certain of the above statements contained in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements are within the meaning of that term in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those indicated in the forward-looking statements as a result of various factors.

Click here to see all recent news from this company

TUSTIN, CA–(Marketwire – August 26, 2010) – Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) announced today target market details for the domestic and international commercialization of its Onko-Sure® in vitro diagnostic (IVD) cancer test. 

RPC received USFDA for its Onko-Sure® IVD cancer test approximately 24 months ago, which marked the point at which RPC could begin commercialization. Since that time a considerable amount of work has gone into creating a domestic & international distribution network, plus the highly effort of validating RPC’s USFDA approved Onko-Sure® test kits with oncologists, gastroenterologist and lab directors. RPC has added various needed validation tools that include the first edition of RPC’s 2010 Onko-Sure® Reference Guide for physicians, oncologists, clinicians, consumers and patients, (“ODR”) designed to significantly gain sales traction for Onko-Sure® in North America and other international markets. The Company is also working on additional clinical trials and inclusion in industry publications to determine the standard of care for cancer diagnosis and targeting additional validation tools, which are anticipated to be in place by year-end. The Company is now in a position to begin making significant headway in commercializing Onko-Sure® in target market.

According to Mr. Douglas MacLellan, Chairman and CEO of RPC, “RPC has focused 18 months of dedicated, diligent work related to product validation, and we expect the Company will demonstrate significantly improved sales results during the second half of FY2010. Given the timing of our US FDA approval and commercialization work, we are akin to a start-up Company. That said, we expect meaningful sales to begin over the next two quarters. We understand there is tremendous market pressure and encourage the investing community to look to the long-term success of RPC, especially given the current economic environment and the very competitive and sophisticated market we are operating in.”

FY2010/ FY2011 Onko-Sure® Commercialization Plan
As RPC executes its domestic and international Onko-Sure® sales plan, the Company is focusing on 4 key target markets, that include:

• US FDA approved use and sales of Onko-Sure® as a CRC Monitoring Test in the U.S. & eventually Canada;
• US FDA approved use and sales of Onko-Sure® as a CRC Monitoring Test in various international markets;
• Use and sales of Onko-Sure® as a general cancer screening test (predominately outside the US, currently in Taiwan and Korea); and,
• Health Canada approved use and sales of Onko-Sure® as a lung cancer screening and monitoring test.

Target Market Segment Details:

• US FDA approved use as a CRC Monitoring Test Market in the US & Canada: This market represents a US$200 million per year market at the wholesale level, and is growing at a 10% annual growth rate. The competing test for Onko-Sure® is the Carcinoembryonic Antigen (CEA) — a test that typically only identifies cancer its latest stages when the probability of treating the disease is lowest. Onko-Sure® has been clinically shown to identify cancer in its earliest stages, and these studies also indicate Onko-Sure® to be a superior test to CEA. To capitalize on this, we are implementing an aggressive commercialization strategy in the US specifically targeted towards physicians, oncologists, clinicians, consumers, patients and reference labs that show demand for the test.

• US FDA Approved use as a CRC Monitoring Test in International Markets: This market represents a US$250 million per year market at the wholesale level, and is also growing at a 10% annual growth rate. We expect sales of Onko-Sure® in North America will create new market share in the International CRC monitoring market by FY2011.

• Government-backed General Cancer Screening Test (predominately outside the US): Government backed general cancer screening represents a potential US$1 billion per year market that is currently in its infancy. International recognition and demand for government-backed general cancer screening has only just begun. U.S. adoption of government back general cancer screening for high risk populations is expected to be commonplace by 2015. Based on RPC market analysis, we anticipate driving solid adoption and sales of Onko-Sure® in high risk populations specifically in India and Colombia by the fourth quarter 2010, and Brazil by the second quarter of 2011. We are actively targeting other countries and expect sales to ramp as RPC’s initial commercialization program in the above markets demonstrates results. Additionally, through our US-based CLIA lab partner, we have initiated product sales for Onko-Sure® that is being used as a general cancer screen in the US and Canada and we are selling Onko-Sure® as a general cancer screen in Korea and Taiwan. In order for RPC to gain up to US$1 billion in Onko-Sure sales from government-backed general cancer screening initiatives (“GCSI”), which would be focused on “patients with a high risk of developing cancer,” RPC will need to sell approximately 1,488,095 kits annually.

• Health Canada Approved use as a Lung Cancer Screening & Monitoring Test: This represents a US$50 million per year market, also currently in an infancy stage. More Canadians are diagnosed with lung cancer than any other cancer type, with mortality from lung cancer higher than breast, colorectal and prostate cancer combined. In 2010 alone, 1 in 12 Canadians are expected to develop lung cancer. Smoking causes most lung cancers. That said, approximately 50% of patients diagnosed have never smoked (15%) or are former smokers (35%). Most lung cancers are diagnosed in late stages, due in part to lack of effective screening procedures, this is a primary factor that leads us to believe Onko-Sure® will become an important and high demand test for cancer screening. Lung cancer patients and their family members are often stigmatized by a widespread prejudice about smoking, and many feel isolated and hesitant to tell others about their diagnosis. Lung cancer receives little public or media attention. This is due, in part, to a small community of survivors to bring a voice and attention to lung cancer issues. We are seeking Canadian government support for a lung cancer screening program to high risk segments of the population.

Global Cancer Statistics & Onko-Sure®
The latest World Health Organization (“WHO”) statistics indicate there are approximately 7.4 million cancer deaths worldwide annually. RPC’s goal is to test approximately 70 million “high risk factor” patients per year with the goal of identifying cancer in approximately 10% of this high risk factor population. According to the WHO, the annual global cost for cancer is approximately US$1 Trillion. By implementing GCSI, and catching early stage cancer, the savings with a low cost test such as Onko-Sure™ could be at least 30% or approximately US$330 billion per year, to government health agencies.

For additional information on RPC and its portfolio of cancer products visit the Company’s corporate website at www.Radient-Pharma.com. For Investor Relations information contact Kristine Szarkowitz at [email protected] or 1.206.310.5323.

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is an integrated pharmaceutical company devoted to the research, development, manufacturing, and marketing of in-vitro diagnostic products.

Forward Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company’s operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

References:

• Lung Cancer Canada, lungcancercanada.ca.
• World Health Organization (WHO) Cancer Fact Sheet No. 297, February 2009
• “Cancer costs the world nearly $1 trillion”, By Aaron Smith, CNNMoney.com staff writer, August 17, 2010.

Click here to see all recent news from this company

LOS ANGELES, CA–(Marketwire – August 26, 2010) – MMRGlobal, Inc. (OTCBB: MMRF) (www.mmrglobal.com) is a sponsor of The Gulf is Back,  a one-hour TV special on the CW Network airing this Friday, August 27, 2010, at 8:00 p.m. ET. The Company believes the sponsorship of the special tribute, hosted by David Hasselhoff and featuring musical performances by Lonestar, Ricky Skaggs, Taylor Hicks and Brian McKnight, will help call attention to the importance of having a MyMedicalRecords Personal Health Record account (www.mmrvideos.com) or MyEsafeDepositBox online safe (www.myesafevideos.com) in the event of a disaster or emergency at home or anywhere in the world.

Robert H. Lorsch, MMRGlobal Chairman and Chief Executive Officer, said, “We are proud to be a sponsor of Associated Television International’s network television special The Gulf is Back. People experiencing a personal or business loss need access to the important documents necessary to rebuild their lives. Our products offer the reliability and resiliency needed to recover more quickly from any emergency or disaster. With MyMedicalRecords, individuals and families can have direct access to their most important documents, including insurance policies, deeds of trust, wills, birth certificates and advance directives in addition to their medical records. Everything is located in one secure, convenient location accessible from any Internet device anywhere in the world.”

Viewers responding to the MyMedicalRecords TV spots on The Gulf is Back will be greeted with the same onscreen technology used for the Daytime Emmy Awards last June. However, in addition to fulfilling requests for information, consumers who sign up for a free trial account can participate in the MMRGlobal $25 cash refund program applied to the viewer’s next check-up or doctor visit.

MMRGlobal’s advertising campaigns can be previewed at www.mmrontv.com. 

About MMRGlobal, Inc.
MMR Global, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. (“MMR”), provides secure and easy-to-use online Personal Health Records (“PHRs”) and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, and professional organizations and affinity groups. MyMedicalRecords enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. The MyMedicalRecords Personal Health Record is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user’s account. The Company’s professional offering, MMRPro, is designed to give physicians’ offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time through an integrated patient portal. MMR is an Independent Software Vendor Partner with Kodak to deliver an integrated turnkey EMR solution for healthcare professionals. MMR is also an integrated service provider on Google Health. To learn more about MMR Global, Inc. and its products, visit www.mymedicalrecords.com and view the videos at www.mmrtheater.com.

Forward-Looking Statements
Any statements contained in this press release that refer to future events or other non-historical matters are forward-looking statements. MMRGlobal, Inc. disclaims any intent or obligation to revise or update any forward-looking statements. These forward-looking statements are based on MMRGlobal, Inc.’s reasonable expectations as of the date of this press release and are subject to risks and uncertainties that could cause actual results to differ materially from current expectations. The information discussed in this release is subject to various risks and uncertainties related to changes in MMRGlobal, Inc.’s business prospects, results of operations or financial condition, government regulation, television programming changes, and such other risks and uncertainties as detailed from time to time in MMRGlobal, Inc.’s public filings with the U.S. Securities and Exchange Commission.

Click here to see all recent news from this company

BOCA RATON, FL–(Marketwire – August 26, 2010) –  David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced that abstracts of three studies involving its PD2i^® nonlinear algorithm have been accepted for presentation during the Poster Session of the 2010 Heart-Brain Summit. Vicor Technologies is a biotechnology company focused on the development of innovative, non-invasive medical devices using its patented, proprietary PD2i^® nonlinear algorithm and software. Vicor is currently in the process of commercializing diagnostics that accurately risk stratify specific target populations for future pathological events including cardiac death resulting from arrhythmia or pump failure, and autonomic nervous system dysfunction, and trauma victims in need of lifesaving intervention.

“We’re honored to have three abstracts selected for presentation before this prestigious group, especially during the distinguished Poster Session. We believe the results achieved by the PD2i^® in each of these studies suggest the prospect of incorporating the PD2i^® nonlinear algorithm into a noninvasive diagnostic that will significantly contribute to the identification and treatment of at-risk patients. We hope that having the opportunity to share these results with those active in the field of heart-brain medicine worldwide will further opportunities to advance study of the PD2i^® as a noninvasive diagnostic to identify at-risk populations and further our commercialization efforts for the PD2i^®,” stated Mr. Fater.

Dr. James E. Skinner, Vicor Vice President and Director of Grant Research, will present the following abstracts at the 2010 Heart-Brain Summit, which will be held at the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, September 23-24. The Poster Session is on September 23, from 5:00 to 7:00pm.

Short-Term Heart Rate Complexity Determined by the PD2i^® Algorithm is Reduced in Patients with Type 1 Diabetes Melitus — The objective of this study was to test the ability of PD2i^® to discriminate between young DM patients without neuropathy and age- and gender-matched controls. Seventeen DM patients with known autonomic dysfunction and 17 age- and gender-matched controls were studied. The same R-R interval data (3,200 heartbeats per subject) were analyzed (blinded) to determine the PD2i^® values. The study revealed that the PD2i^® was able to detect ANS dysfunction with p = 0.0006.

Prognostic Significance of PD2i^® in Heart Failure Patients — The goal of this effort was to determine the PD2i^®‘s ability to predict cardiac events in chronic heart failure patients. The study population was a group of chronic heart failure patients, who had been studied for 44 months, on average, with total mortality as primary endpoint and cardiac mortality, sudden cardiac death, and heart failure death as secondary endpoints. The PD2i^® was computed based on 20-minute supine high-resolution Holter recording and was categorized as positive (PD2i® less than or equal to 1.4) or negative (pD2i® greater than 1.4) based on pre-specified criteria. Of the 651 chronic heart failure patients studied, 537 had successful PD2i^® analyses resulting in 144 (27%) patients showing positive results and 393 (73%) negative results. After adjustment for clinical covariates PD2i^®, was found predictive for total mortality (HR=1.55; p=0.026). Predictive value of PD2i^® was observed in heart failure patients with left ventricular ejection fraction less than or equal to 35% (HR=1.95; p=0.004) whereas not in patients with greater than 35% (HR=0.87; p=0.716); p for interaction 0.072. Further analyses revealed that among patients with ejection fraction less than or equal to 35%, PD2i^® was also predictive for cardiac death and for heart failure death.

Mild Hypovolemia and PD2i^® — The goal of this pilot study was to test the ability of the PD2i^® to identify acute hypovolemia in blood donors as a preliminary step toward ascertaining whether it could be a useful noninvasive diagnostic for detecting blood loss from internal bleeding. Study subjects were volunteers who presented for a standard single unit whole blood donation. A 15-minute ECG recording was made pre-donation and the recording was then continued during the donation period and a rest afterwards. Eighteen subjects participated with a mean age of 48+/-18 years. Three were on beta blockers, 2 on antidepressants, and 1 had diabetes. At baseline the minimum PD2i^® had a mean of 2.6+/-0.8 dimensions, whereas after donation it fell to 1.8+/-0.5 dimensions (p=0.0011). The minimum PD2i^® was found to be a sensitive metric for the detection of mild blood loss, as seen in the controlled environment of donation of a whole unit of blood. Thus, PD2i^® may serve as a marker for mild hemorrhage in hospital (e.g., surgery) and trauma environments. In addition, given PD2i^®‘s association with autonomic activity, these results suggest significant sympathetic activation with even standard blood donation, suggesting that PD2i^® can be used to track a patient’s autonomic response to insult.

The Heart-Brain Summit, now in its fifth year, is the annual event of The Society for Heart Brain Medicine. More than 200 physicians, researchers, scientists, and industry professionals from around the world attended the 4^th Annual Heart-Brain Summit in 2009.

The Society for Heart Brain Medicine was officially established as a 501(c) (3) organization in June of 2008, with the purpose of:

• educating clinicians and scientists about the physiology, pathophysiology, and medical aspects of heart-brain interactions;
• educating the public about these aspects; and
• promoting and fostering research into heart-brain relationships.

The Society for Heart-Brain Medicine provides a forum for researchers and clinicians from different disciplines, both clinical and laboratory, to present, discuss, and evaluate data, and promotes the study of heart-brain medicine as a discipline in its own right. Additional information about the Society for Heart-Brain Medicine is available at www.heartbrain.org.

About Vicor Technologies, Inc.
Vicor Technologies is focused on commercializing innovative non-invasive diagnostics employing its patented, proprietary point correlation dimension algorithm (PD2i^®). The PD2i^® nonlinear algorithm is a deterministic, nonlinear measure of electrophysiological potentials that predicts future pathological events with a high degree of accuracy in target populations.

The PD2i Analyzer™, which has FDA 510(k) marketing clearance, measures heart rate variability. Physicians performing diagnostic tests with the PD2i Analyzer™ are able to receive reimbursement under existing CPT codes. The PD2i VS™ (Vital Sign), in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research (http://www.usaisr.amedd.army.mil/), risk stratifies combat and civilian trauma victims. The PD2i CA™ (Cardiac Analyzer), in various clinical trials, identifies patients at elevated risk of cardiac death resulting from arrhythmia or pump failure.

Vicor anticipates developing additional applications utilizing the PD2i^® nonlinear algorithm to enable early detection and risk stratification for a variety of other disorders and diseases. Additional information is available at www.vicortech.com.

Disclaimer
The appearance of name-brand institutions or products in this media release does not constitute endorsement by the U.S. Army Medical Research and Materiel Command, the Department of the Army, Department of Defense, the U.S. Government, or the AABB of the information, products or services contained therein.

Caution Regarding Forward-Looking Statements
Forward-looking statements in this press release are based on current plans and expectations that are subject to uncertainties and risks, which could cause our future results to differ materially. The following factors, among others, could cause our actual results to differ: our ability to generate revenues from the sale of the PD2i Analyzer™; our ability to obtain FDA approval of our 510(k) submission to secure a claim for the PD2i CA™(Cardiac Analyzer) for risk stratifying congestive heart failure patients at elevated risk of cardiac mortality and our ability to obtain marketing clearance from the FDA for the PD2i VS™ (Vital Sign) for military and civilian applications; our ability to continue to receive financing sufficient to continue operations and complete critical clinical trials; our ability to continue as a going concern; our ability to successfully develop products based on our technologies; our ability to obtain and maintain adequate levels of third-party reimbursement for our products; the impact of competitive products and pricing; our ability to receive regulatory approval for our products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for our technologies; the ability of third-party manufacturers to manufacture our products; our ability to retain the services of our key personnel; our ability to market and sell our products successfully; our ability to protect our intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and we assume no obligation to update forward-looking statements or the reasons why actual results could differ.

Click here to see all recent news from this company

BUENA PARK, CA–(Marketwire – August 26, 2010) –  SOHM, Inc. (PINKSHEETS: SHMN), a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories, today announced that it has posted a 1,000 percent year-over-year increase in revenue for the second quarter ending June 30, 2010. Due to successive record quarters and the company’s unprecedented corporate revenue growth the Company expects continued consumer adoption of its private label generic pharmaceutical products. Revenues for the three months ended June 30, 2010 increased over 1,000% to $339,545 compared to $33,599 in the second quarter of 2009. Revenue growth was fueled by expansion of current and new clients and from pilot distribution projects to full production deployments.

Shailesh Shah, Vice President for Corporate Strategy at SOHM, Inc., stated, “Our ability to generate record revenue growth and accelerated consumer adoption rates for our generic pharmaceutical products is a direct reflection of our sales and marketing team’s dedication. We continue to demonstrate our ability to penetrate and lead in our chosen emerging markets. Most significantly, SOHM has grown and matured its generic drug manufacturing operations allowing for the scalability of resources and product production necessary to support a growing worldwide customer base.”

About SOHM, Inc.
SOHM, Inc. is a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories. Global headquarters are located in North America with manufacturing sites in India. Generic pharmaceuticals are exported globally with a focus on distribution in emerging markets in Africa, Latin America, and Southeast Asia. www.sohm.com

Safe Harbor Statement

This press release contains statements, which may constitute “forward-looking statements” within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of SOHM, Inc., and members of their management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

HOUSTON, TX–(Marketwire – August 25, 2010) –  Over the next three days, the Discovery Channel will begin airing a special episode of Health Heroes focused on dental innovations, including a segment on clear aligner therapy. The episode educates viewers about clear aligner therapy, a popular teeth-straightening alternative to metal braces, and also explores how orthodontic manufacturers such as ClearCorrect are making the procedure simpler and more affordable to the public. 

The episode premieres on both the East and West Coast at 7 am on Thursday, August 26, 2010 on the Discover Channel. It will re-air on Dish Network Channel 225 on Friday, August 27, 2010 at 10 pm EDT and on the Discovery Channel via DirectTV on Saturday, August 28, 2010 at 10 pm EDT.

Clear aligner therapy is an orthodontic treatment involving a series of clear, removable aligners that gradually move teeth to improve aesthetics and bite function. The technique, often referred to as “invisible braces,” is becoming increasingly popular with the public and a key growth area for dentists looking to add services.

The Health Heroes episode features dental industry innovators, including ClearCorrect founder Willis Pumphrey, DDS, and how he, along with input from other dentists, worked to create a more patient and doctor-friendly alternative to more costly clear aligner choices on the market.

In the clear aligner process, ClearCorrect receives the patient’s records from their general dentist or orthodontist and creates exact 3D models of the teeth. Working with a doctor, ClearCorrect then maps out a complete treatment plan of gradual adjustment, then manufacturers and delivers the clear aligners used in the procedure. 

For doctors interested in learning more about clear aligner therapy, ClearCorrect will be at two upcoming dental conventions. It will be at the California Dental Association (CDA) convention in San Francisco, CA on September 9-11, 2010 at Booth # 736 and at the American Dental Association (ADA) convention in Orlando, FL on October 9-11, 2010 at Booth #1244.

For more info, call 888-331-3323 toll free; visit www.clearcorrect.com; or write to ClearCorrect, Inc. at 5200 Mitchelldale St., Suite F-26, Houston TX 77092.

NASHVILLE, TN–(Marketwire – August 25, 2010) – Vanguard Health Systems, Inc. (Vanguard)
today announced results for the fourth quarter and fiscal year ended June
30, 2010.

Total revenues for the quarter ended June 30, 2010 were $858.4 million, an
increase of $31.9 million or 3.9% from the prior year quarter. Patient
service revenues increased $17.4 million from the prior year quarter.
Health plan premium revenues increased $14.5 million from the prior year
quarter. The increase in patient service revenues was attributable to a
3.3% increase in adjusted discharges offset by a 0.2% decrease in patient
revenue per adjusted discharge during the current year quarter compared to
the prior year quarter. Absent the implementation of an insured discount
policy in our Phoenix and San Antonio hospitals effective July 1, 2009,
similar to the program implemented in our two Illinois hospitals on April
1, 2009, and a change to the Medicaid pending policy at all of our
hospitals, patient revenue per adjusted discharge would have increased 3.2%
during the current year quarter compared to the prior year quarter. The
increase in health plan premium revenues was primarily attributable to a
17.1% increase in average membership in Phoenix Health Plan (PHP) during
the current year quarter compared to the prior year quarter. Economic
conditions in Arizona continue to increase the number of individuals
eligible for coverage under the Arizona Health Care Cost Containment System
(AHCCCS) and thus expand PHP’s membership.

Vanguard reported income from continuing operations of $3.4 million for the
current year quarter compared to $2.1 million during the prior year
quarter. During the current year quarter, Vanguard’s net income
attributable to Vanguard Health Systems, Inc. stockholders was $2.8 million
compared to $1.8 million during the prior year quarter. Many quarter over
quarter comparisons of individual cost and expense items, particularly for
health plan claims expense and the provision for doubtful accounts, as a
percentage of total revenues during the current year quarter were impacted
by the significant growth in health plan premium revenues and the uninsured
discount and Medicaid pending policy changes. A table describing the impact
of adjustments to certain expenses and revenues and related ratios for our
acute care services segment and to certain statistical measures is included
in this release in the attached Supplemental Operating Measures Adjusted
for Comparative Analysis.

Adjusted EBITDA for the current year quarter was $82.9 million, an 11.3%
increase compared to the prior year quarter. A reconciliation of Adjusted
EBITDA to net income (loss) attributable to Vanguard Health Systems, Inc.
stockholders as determined in accordance with generally accepted accounting
principles for the quarters ended June 30, 2009 and 2010 is included in the
attached supplemental financial information.

The consolidated operating results for the current year quarter reflect a
1.8% increase in discharges and a 3.3% increase in adjusted discharges
compared to the prior year quarter. Emergency room visits increased 1.0%,
while inpatient surgeries and outpatient surgeries decreased 3.0% and 2.2%,
respectively, during the current year quarter compared to the prior year
quarter. General economic weakness in the United States economy continues
to impact demand for elective surgical procedures.

Total revenues for the year ended June 30, 2010 were $3,376.9 million, an
increase of $191.5 million or 6.0% from the prior year. Patient service
revenues and health plan premium revenues increased $29.8 million and
$161.7 million, respectively, from the prior year. Total revenues during
the current year were positively impacted by a 2.4% increase in adjusted
discharges but were negatively impacted by a 1.1% decrease in patient
revenue per adjusted discharge compared to the prior year. Absent the
previously discussed uninsured discount and Medicaid pending policy
changes, patient revenue per adjusted discharge would have increased 2.8%
during the current year compared to the prior year. Health plan premium
revenues increased 23.8% during the current year primarily due to the
significant enrollment increase associated with PHP’s new contract with
AHCCCS that went into effect on October 1, 2008.

Vanguard reported a loss from continuing operations of $44.6 million during
the current year compared to income from continuing operations of $32.1
million during the prior year. Net loss attributable to Vanguard Health
Systems, Inc. stockholders for the current year was $49.2 million compared
to net income attributable to Vanguard Health Systems, Inc. stockholders of
$28.6 million during the prior year. Each of these current year measures
was negatively impacted by the goodwill impairment loss related to our
Illinois hospitals recognized in December 2009 and by debt extinguishment
costs incurred to complete a refinancing of our indebtedness in January
2010. Many year over year comparisons of individual cost and expense items
as a percentage of total revenues, particularly for health plan claims
expense and the provision for doubtful accounts, were impacted by the
significant growth in health plan premium revenues and the uninsured
discount and Medicaid pending policy changes previously discussed. The
Supplemental Operating Measures Adjusted for Comparative Analysis table
included elsewhere in this release sets forth the impact of the uninsured
discount and Medicaid pending policy changes to certain expenses and
revenues and related ratios for our acute care services segment and to
certain statistical measures. Health plan claims expense as a percentage of
health plan premium revenues increased to 79.3% during the current year
compared to 77.5% during the prior year primarily as a result of changes to
capitation and supplemental payment rates, enrollee medical costs and
enrollee demographic mix under PHP’s new contract with AHCCCS that went
into effect on October 1, 2008.

Adjusted EBITDA was $326.6 million for the current year, an increase of
$23.9 million or 7.9% from the prior year. A reconciliation of Adjusted
EBITDA to net income (loss) attributable to Vanguard Health Systems, Inc.
stockholders as determined in accordance with generally accepted accounting
principles for the years ended June 30, 2009 and 2010 is included in the
attached supplemental financial information.

Cash flows from operating activities were $315.2 million for the current
year, an increase of $2.1 million from the prior year. Current year
operating cash flows were negatively impacted by AHCCCS’ deferral of the
June 2010 capitation and supplemental payments to PHP of approximately
$62.0 million until July 2010. Current year operating cash flows were
positively impacted by an improvement in net days revenue in accounts
receivable from 45 days at June 30, 2009 to 41 days at June 30, 2010. Cash
flows from operating activities were also positively impacted by the timing
of payments of accounts payable during the current year compared to the
prior year. Vanguard’s cash and cash equivalents balance was $257.6 million
at June 30, 2010 compared to $308.2 million at June 30, 2009.

On June 10, 2010, Vanguard entered into a definitive agreement to purchase
Detroit Medical Center (DMC), which owns and operates eight hospitals in
and around Detroit, Michigan with 1,734 licensed beds. Under the purchase
agreement, Vanguard will acquire all of DMC’s assets (other than donor
restricted and certain other assets) and assume all of its liabilities
(other than its outstanding bonds and other certain liabilities) for $417.0
million in cash, substantially all of which will be used to repay all such
non-assumed debt. The acquisition is pending review and approval by the
Michigan Attorney General. Detailed information regarding the purchase
price, assets acquired, liabilities assumed and future commitments related
to the DMC purchase are set forth in Vanguard’s Form 8-K filed with the
Securities and Exchange Commission on June 15, 2010. If approval is
obtained, Vanguard expects the DMC transaction to close during its second
quarter of fiscal 2011.

On July 14, 2010, certain of Vanguard’s subsidiaries issued $225.0 million
aggregate principal amount of 8% Senior Notes due 2018 (the Add-On Notes)
utilizing the same indenture governing the $950.0 million 8% Senior Notes
previously issued in January 2010. The Add-On Notes were issued at an
offering price of 96.250% plus accrued interest from January 29, 2010. The
proceeds from the issuance of the Add-On Notes will be used to fund a
portion of the DMC purchase price if such acquisition is approved by the
Michigan Attorney General or else used for general corporate purposes
including other potential acquisitions. Additional information regarding
the Add-On Notes is set forth in Vanguard’s Form 8-K filed with the
Securities and Exchange Commission on July 19, 2010.

On August 1, 2010, Vanguard completed the purchase of Westlake Hospital and
West Suburban Medical Center in the western suburbs of Chicago, Illinois
from Resurrection Health Care. As part of the purchase, Vanguard acquired
certain assets and assumed certain liabilities of these hospitals for a
total cash purchase price of approximately $45.0 million. These hospitals
have a combined 459 licensed beds and are each located within 10 miles of
Vanguard’s MacNeal Hospital. Additional information related to this
acquisition is set forth in Vanguard’s Form 8-K filed with the Securities
and Exchange Commission on August 4, 2010.

Vanguard will host a conference call for investors at 11:00 am EDT on
August 26, 2010. All interested investors are invited to access a live
audio broadcast of the call, via webcast. The live webcast can be accessed
on the home page of Vanguard’s Web site at www.vanguardhealth.com by
clicking on “Fourth Quarter Webcast” or at
http://visualwebcaster.com/event.asp?id=71303. If you are unable to
participate during the live webcast, the call will be available on a replay
basis on Vanguard’s Web site www.vanguardhealth.com. To access the replay,
click on the Investor Relations of www.vanguardhealth.com. The replay will
be available via this link for one year.

Vanguard owns and operates 17 acute care hospitals and complementary
facilities and services in Chicago, Illinois; Phoenix, Arizona; San
Antonio, Texas; and Massachusetts. Vanguard’s strategy is to develop
locally branded, comprehensive healthcare delivery networks in urban
markets. Vanguard will pursue acquisitions where there are opportunities to
partner with leading delivery systems in new urban markets or to increase
its presence in existing markets. Upon acquiring a facility or network of
facilities, Vanguard implements strategic and operational improvement
initiatives including expanding services, strengthening relationships with
physicians and managed care organizations, recruiting new physicians and
upgrading information systems and other capital equipment. These strategies
improve quality and network coverage in a cost effective and accessible
manner for the communities Vanguard serves.

This press release contains forward-looking statements within the meaning
of the federal securities laws, which are intended to be covered by the
safe harbors created thereby. These forward-looking statements include all
statements that are not historical statements of fact and those statements
regarding Vanguard’s intent, belief or expectations. Do not rely on any
forward-looking statements as such statements are subject to numerous
factors, risks and uncertainties that could cause Vanguard’s actual
outcomes, results, performance or achievements to be materially different
from those projected. These factors, risks and uncertainties include, among
others, Vanguard’s high degree of leverage and interest rate risk;
Vanguard’s ability to incur substantially more debt; operating and
financial restrictions in Vanguard’s debt agreements; Vanguard’s ability to
successfully implement its business strategies; Vanguard’s ability to
successfully integrate any future acquisitions; conflicts of interest that
may arise as a result of Vanguard’s control by a small number of
stockholders; the highly competitive nature of the healthcare business;
governmental regulation of the industry including Medicare and Medicaid
reimbursement levels; changes in Federal, state or local regulation
affecting the healthcare industry; the currently unknown effect on us of
the major federal healthcare reforms enacted by Congress in March 2010 or
other potential additional federal or state healthcare reforms; pressures
to contain costs by managed care organizations and other insurers and
Vanguard’s ability to negotiate acceptable terms with these third party
payers; the ability to attract and retain qualified management and
personnel, including physicians and nurses; claims and legal actions
relating to professional liabilities or other matters; the impacts of a
prolonged economic recession and tightened credit and capital markets on
Vanguard’s results of operations, financial position and cash flows
including its ability to successfully service its debt and remain in
compliance with debt covenants under its senior secured credit agreement;
Vanguard’s exposure to the increased amounts of and collection risks
associated with uninsured accounts and the co-pay and deductible portions
of insured accounts; Vanguard’s ability to maintain or increase patient
membership and control costs of its managed healthcare plans; the
availability and terms of capital to fund the expansion of Vanguard’s
business; the geographic concentration of Vanguard’s operations; the
technological and pharmaceutical improvements that increase the cost of
providing healthcare services or reduce the demand for such services; the
timeliness of reimbursement payments received under government programs;
the potential adverse impact of known and unknown government
investigations; and those factors, risks and uncertainties detailed in
Vanguard’s filings from time to time with the Securities and Exchange
Commission, including, among others, Vanguard’s Annual Reports on Form 10-K
and its Quarterly Reports on Form 10-Q.

Although Vanguard believes that the assumptions underlying the
forward-looking statements contained in this press release are reasonable,
any of these assumptions could prove to be inaccurate, and, therefore,
there can be no assurance that the forward-looking statements included in
this press release will prove to be accurate. In light of the significant
uncertainties inherent in the forward-looking statements included herein,
you should not regard the inclusion of such information as a representation
by Vanguard that its objectives and plans anticipated by the
forward-looking statements will occur or be achieved, or if any of them do,
what impact they will have on Vanguard’s results of operations and
financial condition. Vanguard undertakes no obligation to publicly release
any revisions to any forward-looking statements contained herein to reflect
events and circumstances occurring after the date hereof or to reflect the
occurrence of unanticipated events.

                          VANGUARD HEALTH SYSTEMS
        Condensed Consolidated Statements of Operations (Unaudited)
                              (In millions)


                                              Quarter ended June 30,
                                        ----------------------------------
                                              2009
                                          (as adjusted)         2010
                                        ----------------  ----------------
Patient service revenues                $ 629.3     76.1% $ 646.7     75.3%
Premium revenues                          197.2     23.9    211.7     24.7
                                        -------  -------  -------  -------
   Total revenues                         826.5    100.0    858.4    100.0
Costs and expenses:
   Salaries and benefits (includes
    stock compensation of $1.0 and $0.7,
    respectively)                         314.9     38.1    333.6     38.9
   Health plan claims expense             154.9     18.7    165.9     19.3
   Supplies                               116.1     14.0    116.7     13.6
   Provision for doubtful accounts         55.3      6.7     39.5      4.6
   Purchased services                      41.5      5.0     44.5      5.2
   Non-income taxes                        12.6      1.5     14.1      1.6
   Rents and leases                        10.8      1.3     11.0      1.3
   Other operating expenses                46.9      5.7     50.9      5.9
   Depreciation and amortization           34.2      4.1     37.7      4.4
   Interest, net                           27.0      3.3     30.8      3.6
   Debt extinguishment costs                  -        -      0.3        -
   Impairment loss                          6.2      0.8        -        -
   Other                                    0.7      0.1      5.6      0.7
                                        -------  -------  -------  -------
      Total costs and expenses            821.1     99.3    850.6     99.1
                                        -------  -------  -------  -------
Income from continuing operations
 before income taxes                        5.4      0.7      7.8      0.9
Income tax expense                         (3.3)    (0.4)    (4.4)    (0.5)
                                        -------  -------  -------  -------
Income from continuing operations           2.1      0.3      3.4      0.4
Income from discontinued operations,
 net of taxes                               0.6      0.1      0.2        -
                                        -------  -------  -------  -------
Net income                                  2.7      0.3      3.6      0.4
Less: Net income attributable to
 non-controlling interests                 (0.9)    (0.1)    (0.8)    (0.1)
                                        -------  -------  -------  -------
Net income attributable to Vanguard
 Health Systems, Inc. stockholders      $   1.8      0.2% $   2.8      0.3%
                                        =======  =======  =======  =======




                      VANGUARD HEALTH SYSTEMS, INC.
        Condensed Consolidated Statements of Operations (Unaudited)
                              (In millions)


                                            Year ended June 30,
                                ------------------------------------------
                                        2009                  2010
                                --------------------  --------------------
Patient service revenues        $ 2,507.4       78.7% $ 2,537.2      75.1%
Premium revenues                    678.0       21.3      839.7      24.9
                                ---------  ---------  ---------  --------
   Total revenues                 3,185.4      100.0    3,376.9     100.0
Costs and expenses:
   Salaries and benefits
    (includes stock
    compensation
    of $4.4 and $4.2,
    respectively)                 1,233.8       38.7    1,296.2      38.4
   Health plan claims expense       525.6       16.5      665.8      19.7
   Supplies                         455.5       14.3      456.1      13.5
   Provision for doubtful
    accounts                        210.3        6.6      152.5       4.5
   Purchased services               163.8        5.1      179.5       5.3
   Non-income taxes                  52.2        1.6       52.9       1.6
   Rents and leases                  42.6        1.3       43.8       1.3
   Other operating expenses         203.3        6.4      207.7       6.2
   Depreciation and
    amortization                    128.9        4.0      139.6       4.1
   Interest, net                    111.6        3.5      115.5       3.4
   Debt extinguishment costs            -          -       73.5       2.2
   Impairment loss                    6.2        0.2       43.1       1.3
   Other                              2.7        0.1        9.1       0.3
                                ---------  ---------  ---------  --------
      Total costs and expenses    3,136.5       98.5    3,435.3     101.7
                                ---------  ---------  ---------  --------
Income (loss) from continuing
 operations before income taxes      48.9        1.5      (58.4)     (1.7)
Income tax benefit (expense)        (16.8)      (0.5)      13.8       0.4
                                ---------  ---------  ---------  --------
Income (loss) from continuing
 operations                          32.1        1.0      (44.6)     (1.3)
Loss from discontinued
 operations, net of taxes            (0.3)      (0.0)      (1.7)     (0.1)
                                ---------  ---------  ---------  --------
Net income (loss)                    31.8        1.0      (46.3)     (1.4)
Less: Net income attributable
 to non-controlling interests        (3.2)      (0.1)      (2.9)     (0.1)
                                ---------  ---------  ---------  --------
Net income (loss) attributable
 to Vanguard Health Systems, Inc.
 stockholders                   $    28.6        0.9% $   (49.2)     (1.5)%
                                =========  =========  =========  ========




                      VANGUARD HEALTH SYSTEMS, INC.
              Supplemental Financial Information (Unaudited)
  Reconciliation of Adjusted EBITDA to Net Income (Loss) Attributable to
                Vanguard Health Systems, Inc. Stockholders
                              (In millions)


                                          Quarter Ended      Year Ended
                                             June 30,          June 30,
                                        ----------------  ----------------
                                          2009     2010     2009     2010
                                        -------  -------  -------  -------
Net income (loss) attributable to
 Vanguard Health Systems, Inc.
 stockholders                           $   1.8  $   2.8  $  28.6  $ (49.2)
Interest, net                              27.0     30.8    111.6    115.5
Income tax expense (benefit)                3.3      4.4     16.8    (13.8)
Depreciation and amortization              34.2     37.7    128.9    139.6
Non-controlling interests                   0.9      0.8      3.2      2.9
Loss (gain) on disposal of assets          (0.2)     1.4     (2.3)     1.8
Equity method income                       (0.4)    (0.1)    (0.8)    (0.9)
Stock compensation                          1.0      0.7      4.4      4.2
Monitoring fees and expenses                1.3      1.2      5.2      5.1
Realized loss on investments                  -        -      0.6        -
Impairment loss                             6.2        -      6.2     43.1
Acquisition related expenses                  -      3.1        -      3.1
Debt extinguishment costs                     -      0.3        -     73.5
Discontinued operations, net of taxes      (0.6)    (0.2)     0.3      1.7
                                        -------  -------  -------  -------
    Adjusted EBITDA (1)                 $  74.5  $  82.9  $ 302.7  $ 326.6
                                        =======  =======  =======  =======


(1) Adjusted EBITDA is defined as income before interest expense (net of
    interest income), income taxes, depreciation and amortization,
    non-controlling interests, gain or loss on disposal of assets, equity
    method income, stock compensation, monitoring fees and expenses,
    realized holding loss on investments, acquisition related expenses,
    debt extinguishment costs, impairment loss and discontinued operations,
    net of taxes. Adjusted EBITDA is not intended as a substitute for net
    income (loss) attributable to Vanguard Health Systems, Inc.
    stockholders, operating cash flows or other cash flow data determined
    in accordance with accounting principles generally accepted in the
    United States. Due to varying methods of calculation, Adjusted EBITDA
    as presented may not be comparable to similarly titled measures of
    other companies.




                      VANGUARD HEALTH SYSTEMS, INC.
                        Consolidated Balance Sheets
                              (In millions)


                                                      June 30,   June 30,
ASSETS                                                  2009       2010
                                                      ---------  ---------
Current assets:
  Cash and cash equivalents                           $   308.2  $   257.6
  Restricted cash                                           1.9        2.3
  Accounts receivable, net of allowance for doubtful
   accounts of approximately $121.5 and $75.6 at
   June 30, 2009 and June 30, 2010, respectively          275.3      270.4
  Inventories                                              48.3       49.6
  Deferred tax assets                                      29.6       21.9
  Prepaid expenses and other current assets                68.4      119.2
                                                      ---------  ---------
    Total current assets                                  731.7      721.0
Property, plant and equipment, net of accumulated
 depreciation                                           1,174.1    1,203.8
Goodwill                                                  692.1      649.1
Intangible assets, net of accumulated amortization         54.6       66.0
Deferred tax assets, noncurrent                            38.0       50.0
Investments in auction rate securities                     21.6       19.8
Other assets                                               19.0       19.9
                                                      ---------  ---------
    Total assets                                      $ 2,731.1  $ 2,729.6
                                                      =========  =========

LIABILITIES AND  EQUITY
Current liabilities:
  Accounts payable                                    $   127.9  $   194.8
  Accrued salaries and benefits                           133.9      144.9
  Accrued health plan claims and settlements              117.6      149.8
  Accrued interest                                         13.2       41.4
  Other accrued expenses and current liabilities           79.5       76.9
  Current maturities of long-term debt                      8.0        8.2
                                                      ---------  ---------
    Total current liabilities                             480.1      616.0
Professional and general liability and workers
 compensation reserves                                     76.7       83.6
Other liabilities                                          34.9       31.6
Long-term debt, less current maturities                 1,543.6    1,743.8
Commitments and contingencies
Equity:
  Vanguard Health Systems, Inc. stockholders' equity:
   Common stock                                               -          -
   Additional paid-in capital                             651.3      354.9
   Accumulated other comprehensive loss                    (6.8)      (2.5)
   Retained deficit                                       (56.7)    (105.9)
                                                      ---------  ---------
    Total Vanguard Health Systems, Inc. stockholders'
     equity                                               587.8      246.5
  Non-controlling interests                                 8.0        8.1
                                                      ---------  ---------
    Total equity                                          595.8      254.6
                                                      ---------  ---------
    Total liabilities and equity                      $ 2,731.1  $ 2,729.6
                                                      =========  =========




                         VANGUARD HEALTH SYSTEMS, INC.
                     Consolidated Statements of Cash Flows
                                 (In millions)


                                                            Year Ended
                                                             June 30,
                                                        ------------------
                                                          2009      2010
                                                        --------  --------
Operating activities:

Net income (loss)                                       $   31.8  $  (46.3)
Adjustments to reconcile net income (loss) to net cash
 provided by operating activities:
  Loss from discontinued operations                          0.3       1.7
  Depreciation and amortization                            128.9     139.6
  Provision for doubtful accounts                          210.3     152.5
  Amortization of loan costs and accretion of principal
   on notes                                                 27.2      11.7
  Loss (gain) on disposal of assets                         (2.3)      1.8
  Stock compensation                                         4.4       4.2
  Deferred income taxes                                      6.4      (8.5)
  Impairment loss                                            6.2      43.1
  Realized holding loss on investments                       0.6         -
  Acquisition related expenses                                 -       3.1
  Debt extinguishment costs                                    -      73.5
  Changes in operating assets and liabilities:
   Accounts receivable                                    (185.6)   (148.3)
   Inventories                                               1.0      (1.3)
   Prepaid expenses and other current assets               (12.7)    (80.5)
   Accounts payable                                        (27.5)     67.1
   Accrued expenses and other liabilities                  122.7     102.8
                                                        --------  --------
Net cash provided by operating activities - continuing
 operations                                                311.7     316.2
Net cash provided by (used in) operating activities -
 discontinued operations                                     1.4      (1.0)
                                                        --------  --------
Net cash provided by operating activities                  313.1     315.2

Investing activities:
Acquisitions and related expenses                           (4.4)     (4.6)
Capital expenditures                                      (132.0)   (155.9)
Proceeds from asset dispositions                             4.9       2.0
Sales of auction rate securities                               -       1.8
Other                                                       (2.0)      0.3
                                                        --------  --------
Net cash used in investing activities - continuing
 operations                                               (133.5)   (156.4)
Net cash used in investing activities - discontinued
 operations                                                 (0.1)     (0.1)
                                                        --------  --------
Net cash used in investing activities                     (133.6)   (156.5)

Financing activities:
Payments of long-term debt                                  (7.8) (1,557.4)
Proceeds from debt borrowings                                  -   1,751.3
Payments of refinancing costs and fees                         -     (93.6)
Repurchases of stock and stock options                      (0.2)   (300.6)
Payments related to derivative instrument with
 financing element                                             -      (6.2)
Distributions paid to non-controlling interests and
 other                                                      (4.9)     (2.8)
                                                        --------  --------
Net cash used in financing activities                      (12.9)   (209.3)
                                                        --------  --------
Net increase (decrease) in cash and cash equivalents       166.6     (50.6)
Cash and cash equivalents, beginning of year               141.6     308.2
                                                        --------  --------
Cash and cash equivalents, end of year                  $  308.2  $  257.6
                                                        ========  ========




                      VANGUARD HEALTH SYSTEMS, INC.
                      Segment Information (Unaudited)
                              (In millions)


                                Three months ended June 30, 2009
                      ----------------------------------------------------
                       Acute
                       Care     % of     Health   % of    Elimin-  Consol-
                     Services Revenues   Plans  Revenues  ations   idated
                      -------  ------   -------- -------  -------  -------
Patient service
 revenues(1)          $ 638.3   100.0%  $      -       -% $  (9.0) $ 629.3
Premium revenues            -       -      197.2   100.0        -    197.2
                      -------  ------   -------- -------  -------  -------
   Total revenues       638.3   100.0      197.2   100.0     (9.0)   826.5

Salaries and benefits
 (excludes stock
 compensation)          306.0    47.9        7.9     4.0        -    313.9
Health plan claims
 expense                    -       -      163.9    83.1     (9.0)   154.9
Supplies                116.0    18.2        0.1     0.1        -    116.1
Provision for
 doubtful
 accounts                55.3     8.7          -       -        -     55.3
Other operating
 expenses               102.2    16.0        9.6     4.9        -    111.8
                      -------  ------   -------- -------  -------  -------
   Total operating
    expenses            579.5    90.8      181.5    92.0     (9.0)   752.0
                      -------  ------   -------- -------  -------  -------
   Segment EBITDA(2)     58.8     9.2       15.7     8.0        -     74.5
Less:
 Interest, net           26.8     4.2        0.2     0.1        -     27.0
 Depreciation and
  amortization           33.1     5.2        1.1     0.6        -     34.2
 Equity method income    (0.4)   (0.1)         -       -        -     (0.4)
 Stock compensation       1.0     0.2          -       -        -      1.0
 Gain on disposal of
  assets                 (0.2)   (0.0)         -       -        -     (0.2)
 Monitoring fees and
  expenses                1.3     0.2          -       -        -      1.3
Impairment loss           6.2     1.0          -       -        -      6.2
                      -------  ------   -------- -------  -------  -------
 Income (loss) from
  continuing operations
  before income taxes $  (9.0)   (1.4)% $   14.4     7.3% $     -  $   5.4
                      =======  ======   ======== =======  =======  =======


(1) Vanguard eliminates in consolidation those patient service revenues
    earned by its healthcare facilities attributable to services provided
    to enrollees in its owned health plans and eliminates the corresponding
    medical claims expenses incurred by the health plans for those
    services.

(2) Segment EBITDA is defined as income (loss) from continuing operations
    before income taxes less interest expense (net of interest income),
    depreciation and amortization, equity method income, stock
    compensation, gain or loss on disposal of assets, realized holding
    losses on investments, monitoring fees and expenses, acquisition
    related expenses, debt extinguishment costs and impairment losses.
    Management uses Segment EBITDA to measure performance for Vanguard's
    segments and to develop strategic objectives and operating plans for
    those segments. Segment EBITDA eliminates the uneven effect of non-cash
    depreciation of tangible assets and amortization of intangible assets,
    much of which results from acquisitions accounted for under the
    purchase method of accounting. Segment EBITDA also eliminates the
    effects of changes in interest rates which management believes relate
    to general trends in global capital markets, but are not necessarily
    indicative of the operating performance of Vanguard's segments.
    Management believes that Segment EBITDA provides useful information
    about the financial performance of Vanguard's segments to investors,
    lenders, financial analysts and rating agencies. Additionally,
    management believes that investors and lenders view Segment EBITDA as
    an important factor in making investment decisions and assessing the
    value of Vanguard. Segment EBITDA is not a substitute for net income
    (loss), operating cash flows or other cash flow statement data
    determined in accordance with accounting principles generally accepted
    in the United States. Segment EBITDA, as presented, may not be
    comparable to similar  measures of other companies.




                      VANGUARD HEALTH SYSTEMS, INC.
                      Segment Information (Unaudited)
                              (In millions)


                               Three months ended June 30, 2010
                  --------------------------------------------------------
                   Acute
                    Care      % of    Health     % of   Elimina-  Consoli-
                  Services  Revenues   Plans   Revenues  tions     dated
                  --------  -------   -------  -------  --------  --------
Patient service
 revenues(1)      $  657.8    100.0%  $     -        -% $  (11.1) $  646.7
Premium revenues         -        -     211.7    100.0         -     211.7
                  --------  -------   -------  -------  --------  --------
 Total revenues      657.8    100.0     211.7    100.0     (11.1)    858.4

Salaries and
 benefits
 (excludes stock
 compensation)       324.0     49.3       8.9      4.2         -     332.9
Health plan
 claims expense          -        -     177.0     83.6     (11.1)    165.9
Supplies             116.7     17.7         -        -         -     116.7
Provision for
 doubtful
 accounts             39.5      6.0         -        -         -      39.5
Other operating
 expenses            110.8     16.8       9.7      4.6         -     120.5
                  --------  -------   -------  -------  --------  --------
  Total operating
   expenses          591.0     89.8     195.6     92.4     (11.1)    775.5
                  --------  -------   -------  -------  --------  --------
  Segment EBITDA(2)   66.8     10.2      16.1      7.6         -      82.9
Less:
 Interest, net        31.2      4.7      (0.4)    (0.2)        -      30.8
 Depreciation and
  amortization        36.6      5.6       1.1      0.5         -      37.7
 Equity method
  income              (0.1)    (0.0)        -        -         -      (0.1)
 Stock compensation    0.7      0.1         -        -         -       0.7
 Loss on disposal
  of assets            1.4      0.2         -        -         -       1.4
 Monitoring fees
  and expenses         1.2      0.2         -        -         -       1.2
 Acquisition
  related expenses     3.1      0.5         -        -         -       3.1
 Debt
  extinguishment
  costs                0.3        -         -        -         -       0.3
                  --------  -------   -------  -------  --------  --------
  Income (loss)
   from continuing
   operations
   before income
   taxes          $   (7.6)    (1.2)% $  15.4      7.3% $      -  $    7.8
                  ========  =======   =======  =======  ========  ========


(1) Vanguard eliminates in consolidation those patient service revenues
    earned by its healthcare facilities attributable to services provided
    to enrollees in its owned health plans and eliminates the
    corresponding medical claims expenses incurred by the health plans for
    those services.

(2) Segment EBITDA is defined as income (loss) from continuing operations
    before income taxes less interest expense (net of interest income),
    depreciation and amortization, equity method income, stock
    compensation, gain or loss on disposal of assets, realized holding
    losses on investments, monitoring fees and expenses, acquisition
    related expenses, debt extinguishment costs and impairment losses.
    Management uses Segment EBITDA to measure performance for Vanguard's
    segments and to develop strategic objectives and operating plans for
    those segments. Segment EBITDA eliminates the uneven effect of
    non-cash depreciation of tangible assets and amortization of
    intangible assets, much of which results from acquisitions accounted
    for under the purchase method of accounting. Segment EBITDA also
    eliminates the effects of changes in interest rates which management
    believes relate to general trends in global capital markets, but are
    not necessarily indicative of the operating performance of Vanguard's
    segments. Management believes that Segment EBITDA provides useful
    information about the financial performance of Vanguard's segments to
    investors, lenders, financial analysts and rating agencies.
    Additionally, management believes that investors and lenders view
    Segment EBITDA as an important factor in making investment decisions
    and assessing the value of Vanguard. Segment EBITDA is not a
    substitute for net income (loss), operating cash flows or other cash
    flow statement data determined in accordance with accounting
    principles generally accepted in the United States. Segment EBITDA,
    as presented, may not be comparable to similar
    measures of other companies.




                      VANGUARD HEALTH SYSTEMS, INC.
                      Segment Information (Unaudited)
                              (In millions)


                                  Year ended June 30, 2009
                  --------------------------------------------------------
                    Acute
                    Care      % of    Health    % of    Elimina-  Consoli-
                  Services  Revenues  Plans   Revenues    tions     dated
                  --------  --------  ------  --------  --------  --------
Patient service
 revenues(1)      $2,541.4     100.0% $    -         -% $  (34.0) $2,507.4
Premium revenues         -         -   678.0     100.0         -     678.0
                  --------  --------  ------  --------  --------  --------
  Total revenues   2,541.4     100.0   678.0     100.0     (34.0)  3,185.4

Salaries and
 benefits
 (excludes stock
 compensation)     1,198.8      47.2    30.6       4.5         -   1,229.4
Health plan
 claims expense          -         -   559.6      82.5     (34.0)    525.6
Supplies             455.2      17.9     0.3         -         -     455.5
Provision for
 doubtful
 accounts            210.3       8.3       -         -         -     210.3
Other operating
 expenses            425.5      16.7    36.4       5.4         -     461.9
                  --------  --------  ------  --------  --------  --------
  Total operating
   expenses        2,289.8      90.1   626.9      92.5     (34.0)  2,882.7
                  --------  --------  ------  --------  --------  --------
  Segment EBITDA(2)  251.6       9.9    51.1       7.5         -     302.7
Less:
 Interest, net       112.2       4.4    (0.6)     (0.1)        -     111.6
 Depreciation and
  amortization       124.8       4.9     4.1       0.6         -     128.9
 Equity method
  income              (0.8)     (0.0)      -         -         -      (0.8)
 Stock
  compensation         4.4       0.2       -         -         -       4.4
 Gain on disposal
  of assets           (2.3)     (0.1)      -         -         -      (2.3)
 Monitoring fees
  and expenses         5.2       0.2       -         -         -       5.2
 Realized holding
  loss on
  investments          0.6         -       -         -         -       0.6
 Impairment loss       6.2       0.2       -         -         -       6.2
                  --------  --------  ------  --------  --------  --------
  Income from
   continuing
   operations
   before income
   taxes          $    1.3       0.1% $ 47.6       7.0% $      -  $   48.9
                  ========  ========  ======  ========  ========  ========


(1) Vanguard eliminates in consolidation those patient service revenues
    earned by its healthcare facilities attributable to services provided
    to enrollees in its owned health plans and eliminates the
    corresponding medical claims expenses incurred by the health plans for
    those services

(2) Segment EBITDA is defined as income (loss) from continuing operations
    before income taxes less interest expense (net of interest income),
    depreciation and amortization, equity method income, stock
    compensation, gain or loss on disposal of assets, realized holding
    losses on investments, monitoring fees and expenses, acquisition
    related expenses, debt extinguishment costs and impairment losses.
    Management uses Segment EBITDA to measure performance for Vanguard's
    segments and to develop strategic objectives and operating plans for
    those segments. Segment EBITDA eliminates the uneven effect of
    non-cash depreciation of tangible assets and amortization of
    intangible assets, much of which results from acquisitions accounted
    for under the purchase method of accounting. Segment EBITDA also
    eliminates the effects of changes in interest rates which management
    believes relate to general trends in global capital markets, but are
    not necessarily indicative of the operating performance of Vanguard's
    segments. Management believes that Segment EBITDA provides useful
    information about the financial performance of Vanguard's segments to
    investors, lenders, financial analysts and rating agencies.
    Additionally, management believes that investors and lenders view
    Segment EBITDA as an important factor in making investment decisions
    and assessing the value of Vanguard. Segment EBITDA is not a
    substitute for net income (loss), operating cash flows or other cash
    flow statement data determined in accordance with accounting
    principles generally accepted in the United States. Segment EBITDA,
    as presented, may not be comparable to similar measures of other
    companies.




                      VANGUARD HEALTH SYSTEMS, INC.
                      Segment Information (Unaudited)
                              (In millions)


                                  Year ended June 30, 2010
                  --------------------------------------------------------
                    Acute
                    Care      % of    Health     % of   Elimina-  Consoli-
                  Services  Revenues   Plans   Revenues  tions     dated
                  --------  -------   -------  -------  --------  --------
Patient service
 revenues(1)      $2,580.0    100.0 % $     -        -% $  (42.8) $2,537.2
Premium revenues         -        -     839.7    100.0         -     839.7
                  --------  -------   -------  -------  --------  --------
  Total revenues   2,580.0    100.0     839.7    100.0     (42.8)  3,376.9

Salaries and
 benefits
 (excludes stock
 compensation)     1,257.9     48.8      34.1      4.1         -   1,292.0
Health plan
 claims expense          -        -     708.6     84.4     (42.8)    665.8
Supplies             456.0     17.7       0.1        -         -     456.1
Provision for
 doubtful
 accounts            152.5      5.9         -        -         -     152.5
Other operating
 expenses            447.0     17.3      36.9      4.4         -     483.9
                  --------  -------   -------  -------  --------  --------
  Total operating
   expenses        2,313.4     89.7     779.7     92.9     (42.8)  3,050.3
                  --------  -------   -------  -------  --------  --------
  Segment EBITDA(2)  266.6     10.3      60.0      7.1         -     326.6
Less:
 Interest, net       116.5      4.5      (1.0)    (0.1)        -     115.5
 Depreciation and
  amortization       135.2      5.2       4.4      0.5         -     139.6
 Equity method
  income              (0.9)    (0.0)        -        -         -      (0.9)
 Stock
  compensation         4.2      0.2         -        -         -       4.2
 Loss on disposal
  of assets            1.8      0.1         -        -         -       1.8
 Monitoring fees
  and expenses         5.1      0.2         -        -         -       5.1
 Acquisition
  related expenses     3.1      0.1         -        -         -       3.1
 Debt
  extinguishment
  costs               73.5      2.8         -        -         -      73.5
 Impairment loss      43.1      1.7         -        -         -      43.1
                  --------  -------   -------  -------  --------  --------
  Income (loss)
   from
   continuing
   operations
   before income
   taxes          $ (115.0)    (4.5)% $  56.6      6.7% $      -  $  (58.4)
                  ========  =======   =======  =======  ========  ========


(1) Vanguard eliminates in consolidation those patient service revenues
    earned by its healthcare facilities attributable to services provided
    to enrollees in its owned health plans and eliminates the corresponding
    medical claims expenses incurred by the health plans for  those
services.

(2) Segment EBITDA is defined as income (loss) from continuing operations
    before income taxes less interest expense (net of interest income),
    depreciation and amortization, equity method income, stock
    compensation, gain or loss on disposal of assets, realized holding
    losses on investments, monitoring fees and expenses, acquisition
    related expenses, debt extinguishment costs and impairment losses.
    Management uses Segment EBITDA to measure performance for Vanguard's
    segments and to develop strategic objectives and operating plans for
    those segments. Segment EBITDA eliminates the uneven effect of non-cash
    depreciation of tangible assets and amortization of intangible assets,
    much of which results from acquisitions accounted for under the
    purchase method of accounting. Segment EBITDA also eliminates the
    effects of changes in interest rates which management believes relate
    to general trends in global capital markets, but are not necessarily
    indicative of the operating performance of Vanguard's segments.
    Management believes that Segment EBITDA provides useful information
    about the financial performance of Vanguard's segments to investors,
    lenders, financial analysts and rating agencies. Additionally,
    management believes that investors and lenders view Segment EBITDA as
    an important factor in making investment decisions and assessing the
    value of Vanguard. Segment EBITDA is not a substitute for net income
    (loss), operating cash flows or other cash flow statement data
    determined in accordance with accounting principles generally accepted
    in the United States. Segment EBITDA, as presented, may not be
    comparable to similar measures of other companies.




                      VANGUARD HEALTH SYSTEMS, INC.
                      Selected Operating Statistics
                                (Unaudited)

                                                Three months ended
                                                     June 30,
                                                 ----------------
                                                   2009     2010   % Change
                                                 -------  -------  -------
Number of hospitals at end of period                  15       15
Licensed beds at end of period                     4,135    4,135
Discharges                                        41,400   42,159      1.8%
Adjusted discharges                               73,210   75,620      3.3
Adjusted discharges - hospitals                   69,258   71,657      3.5
Average length of stay                              4.18     4.09     (2.2)
Patient days                                     173,022  172,388     (0.4)
Adjusted patient days                            305,966  309,209      1.1
Adjusted patient days - hospitals                289,447  293,003      1.2
Patient revenue per adjusted discharge           $ 8,422  $ 8,407     (0.2)
Patient revenue per adjusted discharge -
 hospitals                                       $ 8,850  $ 8,560     (3.3)
Inpatient surgeries                                9,530    9,244     (3.0)
Outpatient surgeries                              19,521   19,084     (2.2)
Emergency room visits                            158,936  160,523      1.0%

Charity care and uninsured discounts as a
 percent of acute care segment revenues
 (prior to these discounts)(1)                       4.9%    10.8%

Provision for doubtful accounts as a percent of
 acute care services segment revenues (prior to
 charity and uninsured discounts)(1)                 8.2%     5.4%

Net patient revenue payer mix:
   Medicare                                         24.8%    25.0%
   Medicaid                                          7.7      7.6
   Managed Medicare                                 14.7     14.7
   Managed Medicaid                                  9.1      9.3
   Managed care                                     34.0     35.2
   Commercial                                        0.9      1.0
   Self pay                                          8.8      7.2
                                                 -------  -------
      Total                                        100.0%   100.0%
                                                 =======  =======

Discharges by payer:
   Medicare                                         26.7%    27.8%
   Medicaid(1)                                       9.7      9.3
   Managed Medicare                                 16.5     16.3
   Managed Medicaid                                 14.3     15.2
   Managed care                                     28.3     26.4
   Commercial                                        0.4      0.4
   Self pay(1)                                       4.1      4.6
                                                 -------  -------
      Total                                        100.0%   100.0%
                                                 =======  =======


(1) See Supplemental Operating Measures Adjusted For Comparative Analysis
    for the impact to the ratio of charity and uninsured discounts as a
    percent of acute care services segment revenues, the ratio of
    provision for doubtful accounts as a percent of acute care services
    segment revenues and Medicaid and self pay discharges of the change
    in our Medicaid pending policy during the three months ended June
    30, 2010.




                      VANGUARD HEALTH SYSTEMS, INC.
                      Selected Operating Statistics
                          (Unaudited) (continued)


                                            Year ended June 30,
                                           --------------------
                                             2009       2010     % Change
                                           ---------  ---------  ---------
Number of hospitals at end of period              15         15
Licensed beds at end of period                 4,135      4,135
Discharges                                   167,880    168,370        0.3%
Adjusted discharges                          288,807    295,702        2.4
Adjusted discharges - hospitals              274,767    280,437        2.1
Average length of stay                          4.23       4.17       (1.4)
Patient days                                 709,952    701,265       (1.2)
Adjusted patient days                      1,221,345  1,231,604        0.8
Adjusted patient days - hospitals          1,161,967  1,168,027        0.5
Patient revenue per adjusted discharge     $   8,503  $   8,408       (1.1)
Patient revenue per adjusted discharge -
 hospitals                                 $   8,623  $   8,516       (1.2)
Inpatient surgeries                           37,970     37,320       (1.7)
Outpatient surgeries                          76,378     75,969       (0.5)
Emergency room visits                        605,729    626,237        3.4%

Charity care and uninsured discounts as a
 percent of acute care services segment
 revenues (prior to these discounts)             3.9%      10.5%

Provision for doubtful accounts as a
 percent of acute care services segment
 revenues (prior to charity and uninsured
 discounts)(1)                                   8.0%       5.3%

Net patient revenue payer mix:
   Medicare                                     25.3%      25.5%
   Medicaid                                      7.9        7.4
   Managed Medicare                             14.1       14.8
   Managed Medicaid                              8.8        9.5
   Managed care                                 34.7       34.9
   Commercial                                    0.9        1.1
   Self pay                                      8.3        6.8
                                           ---------  ---------
      Total                                    100.0%     100.0%
                                           =========  =========

Discharges by payer:
   Medicare                                     27.1%      27.5%
   Medicaid (1)                                 10.2        8.8
   Managed Medicare                             16.0       16.3
   Managed Medicaid                             13.8       15.3
   Managed care                                 29.2       26.8
   Commercial                                    0.3        0.4
   Self pay (1)                                  3.4        4.9
                                           ---------  ---------
      Total                                    100.0%     100.0%
                                           =========  =========

(1) See Supplemental Operating Measures Adjusted For Comparative Analysis
    for the impact to the ratio of charity and uninsured discounts as a
    percent of acute care services segment revenues, the ratio of provision
    for doubtful accounts as a percent of acute care services segment
    revenues and Medicaid and self pay discharges of the change in our
    Medicaid pending policy during the year ended June 30, 2010.




                      VANGUARD HEALTH SYSTEMS, INC.
    Supplemental Operating Measures Adjusted for Comparative Analysis
                 For the three months ended June 30, 2010
          (dollars in millions, except for statistical measures)
                                (Unaudited)


                         Impact of Policy           % of Segment Revenues
                             Changes                ----------------------
                 GAAP-   ----------------  Non-GAAP           Non-GAAP
                 basis  Uninsured Medicaid adjusted  GAAP    adjusted(4)
                 amounts discounts pending amounts   basis  --------------
                   (1)      (2)      (3)     (4)     2010    2009    2010
                 ------- --------  ------  -------  ------  ------  ------
Acute care
 services
 segment:
 Total
  revenues(5)    $ 657.8 $   33.5  $ (4.7) $ 686.6   100.0%  100.0%  100.0%
 Salaries and
  benefits(8)    $ 324.7 $      -  $    -  $ 324.7    49.4    47.6    47.3
 Supplies        $ 116.7 $      -  $    -  $ 116.7    17.7    18.0    17.0
 Provision for
  doubtful
  accounts       $  39.5 $   33.5  $ (3.6) $  69.4     6.0     9.6    10.1
 Other operating
  expenses       $ 110.8 $      -  $    -  $ 110.8    16.8    15.8    16.1
 Total operating
  expenses       $ 591.7 $   33.5  $ (3.6) $ 621.6    90.0%   91.0 %  90.5%


                                                    % of Segment Revenues
                                                     Prior to Charity and
                         Impact of Policy            Uninsured Discounts
                             Changes                ----------------------
                 GAAP-   ----------------  Non-GAAP           Non-GAAP
                 basis  Uninsured Medicaid adjusted  GAAP    adjusted(4)
                 amounts discounts pending amounts   basis  --------------
                   (1)      (2)      (3)     (4)     2010     2009   2010
                 ------- --------  ------  -------  ------  ------  ------
Uncompensated
 care(6)         $ 117.8 $  (21.2) $ (3.6) $  93.0    16.0%   12.4%   13.1%
Total revenues,
 prior
 to charity(7)   $ 681.3 $   33.5  $ (4.7) $ 710.1


                  2010                           2010
              Statistical   2010      2010   Statistical   2009    Current
Vanguard        Measure   Uninsured Medicaid   Measure   Measure    year
consolidated:      as     discounts  pending      as        as    change as
               reported      (2)       (3)    adjusted  adjusted  adjusted
                -------   --------   ------    -------   -------   ------
Patient revenue
 per total
 adjusted
 discharge      $ 8,407   $    443   $  (62)   $ 8,788   $ 8,516      3.2%
Self-pay
 discharges       1,942          -     (600)     1,342     1,526    (12.1)%
Medicaid
 discharges       3,910          -      600      4,510     4,197      7.5%




                      VANGUARD HEALTH SYSTEMS, INC.
    Supplemental Operating Measures Adjusted for Comparative Analysis
                     For the year ended June 30, 2010
          (dollars in millions, except for statistical measures)
                                (Unaudited)


                         Impact of Policy           % of Segment Revenues
                             Changes               -----------------------
                 GAAP-   ---------------   Non-GAAP           Non-GAAP
                 basis  Uninsured Medicaid adjusted GAAP    adjusted(4)
                 amounts discounts pending amounts  basis  ---------------
                   (1)      (2)      (3)     (4)    2010    2009     2010
                 -------- ------  ------  -------- ------  -----   -------
Acute care
 services
 segment:
 Total
  revenues(5)    $2,580.0 $128.7  $(22.9) $2,685.8  100.0% 100.0%    100.0%
 Salaries and
  benefits(8)    $1,262.1 $    -  $    -  $1,262.1   48.9   47.2      47.0
 Supplies        $  456.0 $    -  $    -  $  456.0   17.7   17.9      17.0
 Provision for
  doubtful
  accounts       $  152.5 $128.7  $(22.3) $  258.9    5.9    8.5       9.6
 Other operating
  expenses       $  447.0 $    -  $    -  $  447.0   17.3   16.7      16.6
 Total operating
  expenses       $2,317.6 $128.7  $(22.3) $2,424.0   89.8%  90.3%     90.3%


                                                    % of Segment Revenues
                                                     Prior to Charity and
                         Impact of Policy            Uninsured Discounts
                             Changes                ----------------------
                 GAAP-   ----------------  Non-GAAP           Non-GAAP
                 basis  Uninsured Medicaid adjusted  GAAP    adjusted(4)
                 amounts   dis-   pending  amounts  basis  ---------------
                   (1)   counts(2)  (3)     (4)      2010   2009     2010
                 -------- ------  ------  --------  -----  -----    ------
Uncompensated
 care(6)         $  455.9 $(87.0) $(22.3) $  346.6   15.8%  11.6%     12.5%

Total revenues,
 prior to
 charity(7)      $2,667.7 $128.7  $(22.9) $2,773.5


                  2010                           2010
              Statistical   2010      2010   Statistical   2009    Current
Vanguard        Measure   Uninsured Medicaid   Measure   Measure    year
consolidated:      as     discounts  pending      as        as    change as
               reported      (2)       (3)    adjusted  adjusted  adjusted
                -------   --------   ------    -------   -------   ------
Patient revenue
 per total
 adjusted
 discharge      $ 8,408   $    435   $  (79)   $ 8,764   $ 8,527      2.8%
Self-pay
 discharges       8,168          -   (2,717)     5,451     5,483     (0.6)%
Medicaid
 discharges      14,867          -    2,717     17,584    17,235      2.0%


(1) Amounts reflected in or components of amounts reflected in the
    segment information tables included in this release. These amounts
    are based upon revenues or expenses determined in accordance with
    accounting principles generally accepted in the United States.

(2) Includes the impact of the uninsured discount policy implemented
    for Vanguard's Illinois hospitals effective April 1, 2009 and for
    it Phoenix and San Antonio hospitals effective July 1, 2009. Under
    this policy, Vanguard applies an uninsured discount (calculated as
    a standard percentage of gross revenues) at the time of patient
    billing and includes the discount as a reduction of revenues. This
    uninsured discount program applies to patients receiving hospital
    services who have no insurance coverage and do not otherwise meet
    Vanguard's charity care guidelines. Vanguard recorded a total of
    $11.7 million and $54.7 million of uninsured discounts relates to
    its acute care services segment during the three months ended June
    30, 2009 and 2010, respectively. Of these amounts $7.6 million and
    $33.5 million for the three months ended June 30, 2009 and 2010,
    respectively, related to non-Medicaid pending accounts that reduced
    revenues as a result of implementing this policy. Vanguard recorded
    a total of $11.7 million and $215.7 million of uninsured discounts
    related to its acute care services segment during the years ended
    June 30, 2009 and 2010, respectively. Of these amounts, $7.6 million
    and $128.7 million for the years ended June 30, 2009 and 2010,
    respectively, related to non-Medicaid pending accounts that reduced
    revenues as a result of implementing this policy.

(3) Includes the impact of Vanguard's policy change for accounts pending
    Medicaid qualification. Prior to the implementation of its new
    uninsured discount policy, Vanguard classified accounts pending
    Medicaid qualification as Medicaid revenues (and Medicaid discharges)
    and recorded a contractual discount for these accounts based upon
    the average Medicaid reimbursement rate for each specific state until
    qualification was confirmed. Vanguard implemented a new Medicaid
    pending policy for all of its hospitals whereby Medicaid pending
    accounts are classified as self-pay revenues (and self-pay discharges)
    with an uninsured discount applied. The balance of these accounts is
    subject to Vanguard's allowance for doubtful accounts policy. For
    those accounts that subsequently qualify for Medicaid coverage, the
    uninsured discount is reversed and the account is reclassified to
    Medicaid revenues (and Medicaid discharges) with the appropriate
    contractual discount applied. The difference between the
    state-specific Medicaid contractual discounts under the previous
    policy and the uninsured discount percentage applied to Medicaid
    pending accounts under the new policy increased total revenues by
    $0.7 million, $4.7 million, $0.7 million and $22.9 million for the
    three months ended June 30, 2009 and 2010 and the years ended June
    30, 2009 and 2010, respectively. The provision for doubtful accounts
    recorded for Medicaid pending accounts, after the uninsured discounts
    were applied, were $1.0 million, $3.6 million, $1.0 million and $22.3
    million for the three months ended June 30, 2009 and 2010 and the
    years ended June 30, 2009 and 2010, respectively.

(4) Revenues, certain expenses and those expenses as a percentage of
    revenues for the acute care services segment for the three months and
    year ended June 30, 2010 have been adjusted to allow for comparative
    measurement on a basis consistent with the three months and year ended
    June 30, 2009 (before implementation of the majority of the uninsured
    discount policy or the change to the Medicaid pending policy).
    Management believes these non-GAAP measures will provide investors,
    analysts and general users of this financial information an effective
    means to compare the operating results of Vanguard's acute care
    services segment for the current year periods to those of the prior
    year periods. However, these non-GAAP operating measures are not
    meant to replace GAAP-basis revenues, expenses or expenses as a
    percentage of revenues as operating performance indicators for the
    acute care services segment.

(5) Total revenues for the acute care services segment represent revenues
    prior to the elimination in consolidation of revenues earned by
    Vanguard's hospitals for services provided to enrollees in Vanguard's
    owned health plans.

(6) Uncompensated care is defined as the sum of uninsured discounts,
    charity deductions and the provision for doubtful accounts.

(7) Represents total revenues for the acute care services segment plus
    charity deductions.

(8) Includes stock compensation.

MOUNTAINSIDE, NJ–(Marketwire – August 25, 2010) –  PROTEONOMIX, INC. (OTCBB: PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that Mr. Michael Cohen, Chairman and CEO, is scheduling a multi-city European road trip to create additional awareness of the Proteonomix, Inc. investment opportunity to institutional investors. 

Scheduled for early October, Mr. Cohen will discuss with sophisticated investors the recent contract to establish a joint venture with a group of investors that will establish a new stem cell treatment and research facility in the United Arab Emirates (U.A.E.). In addition, Mr. Cohen will discuss the opportunity to set up additional joint ventures in other countries using the U.A.E. arrangement as a model.

The recent contract calls for the joint venture partner to invest $5 million on or before September 10, 2010 in a Joint Venture company, XGEN Medical LLC. (“XGen”), a Nevis Island limited liability company. For additional details about the joint venture agreement, please refer to the August 17, 2010 press release.

“Proteonomix has made great strides recently,” stated Mr. Cohen, “and we have been contacted by several European entities that have requested additional information about our proprietary stem cell activities. In recognition of the interest in Europe and the potential for additional joint venture agreements in various European countries, we recognize that it is propitious to meet with a number of the European institutional investors both to educate them on the intrinsic value of Proteonomix shares and garner interest in strategic relationships.”

About Proteonomix, Inc.:

Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. is a wholly owned subsidiary of Proteonomix that has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging line of skin care products. StromaCel, Inc.’s goal is the development therapeutic modalities for the treatment of Cardiovascular Disease (CVD). StromaCel, Inc. is pursuing the licensing of other technologies for therapeutic use. National Stem Cell, Inc. is Proteonomix’s operating subsidiary. The Sperm Bank of New York, Inc. is a fully operational tissue bank. Proteonomix Regenerative Translational Medicine Institute, Inc. (“PRTMI”) intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies. Please also visit http://www.proteonomix.com/, http://www.proteoderm.com/, http://www.otcqb.com/ and http://www.sec.gov/.

Forward-looking statements

Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that statements made in this press release constitute forward-looking statements and makes no guarantee of future performance. Actual results or developments may differ materially from projections. More specifically, the investment may never occur negating the agreement, product performance and/or side effects may necessitate termination of the joint venture, the implementation of the agreement may not succeed and inadequate or no business may develop causing the failure of the joint venture and there are inherent risks in foreign operations, particularly those in the Mideast. Forward-looking statements are based on estimates and opinions of management at the time statements are made.

Click here to see all recent news from this company

PHOENIX, AZ–(Marketwire – August 25, 2010) –  Remuda Ranch Programs for Eating and Anxiety Disorders reports in the past five years, self-injury, particularly cutting oneself, is becoming more prevalent among eating disorder patients. 

“Approximately 40 to 50 percent of our patients have either reported a history of self-injury or are presently engaging in these behaviors,” said Dena Cabrera, PsyD, psychologist and national speaker at Remuda Ranch. “This number seems to be consistent for the past five years. Studies have shown that adolescents engaging in self-injury behavior were more likely to have an eating disorder.”

Cutting may be increasing in our culture because young women today are struggling with identity issues and dealing with challenging problems. They feel they have to go to extremes to show others that they are suffering. Often, they are suffering from depression. In a visual culture, cutting may be a voice to get needs met. Self-injury may represent that struggle visually while physiologically and emotionally numbing the pain.

Based on studies and direct patient reports, Dr. Cabrera lists the following as additional reasons for self-injury:

• Stimulation: Escaping dissociative experience through an intentional gesture to feel one’s body, thereby using self-injury as a self-grounding technique.
• Emotional Release: Self-imposed when feeling guilt, shame, weakness, anger or punishment.
• Relaxation: A pleasure response to the warmth of the blood and to the physical sensation of pain.
• Distraction: Inducing dissociation or a trance-like state to avoid attending to an emotional trigger, issue, subject or suicidal thoughts.
• Social Attention: Obtaining self-affirmation by showing oneself and others one’s strength and achieving protection through the response of others.
• Alteration: Altering one’s body to make it unattractive to others through scarring.

At Remuda Ranch, Dialectical Behavior Therapy is used to teach patients skills to replace the self-harm behavior whether that behavior is an eating disorder, cutting, or both.

“We provide structure to the patient’s environment to motivate, reinforce and individualize appropriate skills needed for recovery,” adds Dr. Cabrera. “We also help remove negative behaviors as well as establish plans in case of relapse.”

“If someone you know is practicing self-injury it’s important to get help immediately,” said Dr. Cabrera. “Cutting is not like biting your nails, it can be very dangerous. Further, it perpetuates low self worth and esteem. It becomes a vicious cycle.”

About Remuda Ranch Programs for Eating and Anxiety Disorders
Remuda Ranch offers inpatient and residential programs for individuals of all faiths suffering from eating or anxiety disorders. Each patient is treated by a multi-disciplinary team including a psychiatric and a primary care provider, registered dietitian, master’s level therapist, psychologist and registered nurse. The professional staff equips each patient with the right tools to live a healthy, productive life. For more information, call
1-800-445-1900 or visit www.remudaranch.com.

Click here to see all recent news from this company

LEXINGTON, MA–(Marketwire – August 25, 2010) –  Imprivata^®, Inc., the company that simplifies and secures user access, today announced the formation of its Healthcare Advisory Board. This board draws upon real-world perspectives of industry leaders to address healthcare IT challenges and trends as the company develops innovative and practical solutions that solve the unique challenges facing the healthcare industry. Chaired by Barry P. Chaiken, MD, MPH, FHIMSS, chief medical officer of Imprivata, the Healthcare Advisory Board is comprised of Imprivata customers and industry experts, including:

• Michael Westcott, MD, CMIO, Alegent Health
• Denis Le Beuf, Chief Information Security Officer, Centre Hospitalier de l’Universite de Montreal
• Tarun Ghosh, CIO, Fremont-Rideout Health Group
• John Fernandez, CEO, Massachusetts Eye and Ear Infirmary
• Michael Krouse, Senior Vice President and CIO, OhioHealth
• Ted Lewis, President, Parkview Adventist Medical Center
• Deborah Peel, MD, Founder and Chair, Patient Privacy Rights

Through open sharing of experiences, dialogue about trends and regulatory influences and thoughtful debate, this new Healthcare Advisory Board is the latest example of Imprivata’s commitment to helping hospitals improve clinician workflow, enforce patient privacy and deploy transparent security.

“Today’s healthcare organizations face constant change, new regulatory mandates and a unique working environment that demands quick access to information but tight security on patient data,” said Dr. Michael Westcott, CMIO of Alegent Health, the largest healthcare system in Nebraska. The not-for-profit, faith based health care provider, which is 9,000 employees strong, has been an Imprivata customer since 2006. “One of the primary goals of the Healthcare Advisory Board is to share our experiences, study our similarities and differences, develop creative solutions to the challenges we face as an industry, and help Imprivata develop practical solutions that make a difference in hospitals around the world,” Dr. Westcott explained.

The Healthcare Advisory Board held its first meeting in Boston in June 2010 and will meet again in December. While topics for discussion at the first meeting were broad, there were clear commonalities among this varied group of healthcare organizations. Among the topics were:

• The impacts of the Healthcare Information Portability and Privacy (HIPAA) and Health Information Technology for Economic and Clinical Health (HITECH) Acts
• The role of access management in the implementation and “Meaningful Use” of EMRs
• Health information exchanges (HIEs) and the accompanying Beacon Grants (in ARRA)
• SSO and Strong Authentication enhancements for improved workflow
• Privacy and security
• Compliance demonstration, auditing and reporting
• Enterprise-wide business intelligence
• SaaS/cloud computing

“With the Healthcare Advisory Board, we have built a community of trusted, experienced and motivated members that are dedicated to triage industry priorities and provide fresh perspectives from C-level leaders,” said Barry P. Chaiken, MD, MPH, FHIMSS, chief medical officer of Imprivata. “I am very proud to be working with this diverse group of industry insiders and influencers to solve the problems of tomorrow — fast EMR access, patient privacy, security — today.”

Built upon a foundation of deep healthcare industry experience, Imprivata strives to make patient data easily accessible throughout clinical workflows, empowering physicians, nurses and other clinicians with fast EMR access, while enforcing stringent patient privacy policies through transparent security across healthcare information systems. Today Imprivatas’ Global Healthcare Division, has more than 550 healthcare customers and one million-plus healthcare users worldwide. 

“Imprivata long ago established a firm commitment to the healthcare industry, which has in turn fueled our rapid growth in recent years,” said Omar Hussain, president and CEO of Imprivata. “We have a history of not asking our customers what products they need, but rather spending time understanding what their problems and concerns are. It is in this mindset that we’re excited to tap into some of the healthcare industry’s brightest minds to spark vibrant discussion and help shape what solutions Imprivata brings to market over the long term.”

About Imprivata
Imprivata is the leading independent vendor focused on simplifying and securing user access. By strengthening user authentication, streamlining application access and simplifying compliance reporting across multiple computing environments, customers can align security with user workflows and realize substantial productivity gains while lowering IT costs.

Imprivata has received numerous product awards and top review ratings from leading industry publications and analysts. Headquartered in Lexington, Mass., Imprivata partners with over 200 resellers, and serves the access security needs of more than 1,000 customers around the world. For more information, please visit www.imprivata.com.

RSS Feed to Imprivata News: http://feeds.feedburner.com/ImprivataNews

Follow Imprivata on Twitter: https://twitter.com/Imprivata

id=”nav_links”>

DALLAS, TX–(Marketwire – August 25, 2010) –  Metiscan, Inc. (PINKSHEETS: MTIZ), the parent company of a portfolio of enterprises with operations in healthcare, healthcare IT, mobile technology and employment services, today announces results for its second quarter ending June 30, 2010. During the three months ended June 30, 2010, revenues were up 47% and cost of revenues were reduced 25% compared to the three months ended June 30, 2009. Additionally, for the first half of 2010, the Company had positive income from operations of $184,464 and would have had positive net income of approximately $140,000, if not for a one-time write-off of uncollectable notes of approximately $350,000 in the first quarter of 2010.

Interested parties may access MTIZ’s recent 10-Q from the SEC website at www.SEC.gov.

During the three months ended June 30, 2010 the Company’s revenues were $514,862 as compared to $349,423 during the three months ended June 30, 2009. This increase of $165,439, or 47%, is primarily the result of the Company’s operation of Schuylkill Open MRI, Inc. and FirstView EHR, Inc.

The Company’s cost of revenues during the three months ended June 30, 2010 were $140,333 as compared to $181,066 during the three months ended June 30, 2009. Cost of revenues as a percentage of revenues were 27% during the three months ended June 30, 2010 as compared to 52% during the three months ended June 30, 2009. This decrease of $40,733 or 25% is a result of the increased revenues with the Company’s change in operational focus.

During the six months ended June 30, 2010 the Company’s revenues were $1,413,490 as compared to $1,219,379 during the six months ended June 30, 2009, an increase of $194,111, or 16%. Additionally, for the first half of 2010, the Company demonstrated positive income from operations of $184,464 and would have had positive net income of approximately $140,000, if not for a one-time write-off of uncollectable notes of approximately $350,000 in Q1 of 2010.

Furthermore, during the second quarter ended June 30, 2010, 58,500,000 shares of common stock were issued of which 30,000,000 restricted shares were issued related to a settlement agreement, and 28,500,000 free trading shares were issued to Big Apple Equities, LLC for investor relations services. Therefore, the issuance of these shares increased the Company’s issued shares by approximately 2.5%.

As previously announced, Metiscan will be hosting a nationwide teleconference on Wednesday, September 1, 2010 at 4:15 PM (Eastern Daylight Time) to update the financial community on points of interest that affect Metiscan and its shareholders. Space is limited on the call-in lines for this national teleconference, therefore in order to participate please call 407-389-5900 and ask for investor relations to make a reservation. If you have a particular question for the Company’s officers, please email questions in advance to [email protected].

About Metiscan, Inc.

Metiscan, Inc. (Metiscan) (PINKSHEETS: MTIZ) is the parent company of a portfolio of enterprises with operations in healthcare, healthcare IT, mobile technology and employment services. Metiscan manages all aspects of its subsidiaries and is currently pursuing acquisitions that complement its subsidiaries’ operations. Metiscan’s subsidiaries include FirstView EHR, Inc., Taptopia, Inc., Schuylkill Open MRI, Inc., Shoreline Employment Services, Inc. For more information visit www.metiscan.com

Safe Harbor Statement: Certain of the statements made in this press release constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause Metiscan’s actual results to be materially different from the historical results or from any future results expressed or implied by such forward-looking statements. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms “believes,” “belief,” “intends,” “anticipates” or “plans” to be uncertain and forward-looking. The Company does not intend to update any of the forward-looking statements after the date of this release to conform these statements to actual results or to changes in its expectations, except as may be required by law. 

Click here to see all recent news from this company

SAN FRANCISCO, CA–(Marketwire – August 25, 2010) –  WCG, a global communications company offering integrated creative, interactive and marketing communications services primarily to healthcare clients, today announced it won seven Awards of Excellence from the Communicator Awards, a leading international awards program honoring creative excellence in communications. The Award of Excellence is the highest honor in the competition, given to those entries that demonstrate “best in the field.”

The Communicator Awards are judged by the International Academy of the Visual Arts, a select and invitation-only group of leading professionals representing the best in media, communications, advertising, creative and marketing. Now in its 16th year, the awards competition had more than 9,000 entries from agencies of all sizes.

“This achievement is the result of our laser focus on putting creativity at the core of all we do so that we deliver the most impactful messaging — conceptually, visually and strategically,” said WCG’s Chief Creative Officer Paulo Simas. “I believe the strong combination of creative and strategy is foundational to a company’s success because creativity is innovation. And nothing catapults an organization like true innovation.”

WCG won the following Awards of Excellence:

• Perlegen — MammaPLUS ( logo)
• PEAK Surgical — PlasmaBlade ( packaging)
• Omnicell — ASHP Omnicell Apparel ( apparel)
• Viveve — Start the Conversation ( campaign)
• Elan — Elan Excellence ( pharmaceuticals)
• Medtronic — The 360 Suite ( biotechnology)
• Medtronic — Find the AAAnswers ( social responsibility)

About WCG

WCG is led by Chairman & CEO Jim Weiss, who was named to PRWeek’s Power List for 2010. The company also recently earned the distinction of North American Agency of the Year by the Holmes Report.

WCG’s mission is to create the positive future of communications by focusing on the corporate, product marketing and communications needs of the world’s leading companies.

Serving clients from offices in San Francisco, New York, Chicago, Washington, D.C., Austin and London, WCG’s seasoned professionals specialize in branding, design, digital, interactive, social and traditional marketing, corporate and product PR, media, investor and advocacy relations, clinical trial recruitment and grassroots direct-to-patient communications campaigns.

For more information, please visit www.wcgworld.com.

KANKAKEE, IL–(Marketwire – August 25, 2010) – Riverside Medical Center, a leading provider in the Chicago south suburbs hospital network, now offers a new way to stay connected to loved ones and friends during their stay in the hospital.

Under Riverside’s website features, located at www.RiversideMC.net, loved ones logging in online can simply click on the red email a patient button to get started. From there, friends and relatives can send an electronic message to a patient being treated within the Riverside Illinois healthcare system. Messages will be delivered by a Riverside volunteer Monday through Friday during business hours (8 a.m. to 5 p.m.). This service is offered as a courtesy to all Riverside patients and their families.

Additional Riverside online features include bill payment, nursery and scheduling. Patients and loved ones can also shop, check maternity registration, browse the news room and look for upcoming events at Riverside.

In an effort to provide more efficient service, Riverside Medical Center volunteers will deliver all email messages Monday – Friday during normal business hours at Riverside’s Kankakee hospital facilities. Delays in delivery may occur during weekends and holidays. Riverside Medical Center will make every effort to deliver your message promptly but cannot guarantee delivery. If a patient has been discharged or has opted to stay anonymous during their stay at Riverside Medical Center, message will be discarded.

This e-mail service should not be used for any confidential communication and is solely for the purpose of sending encouragement to patients in the hospital. Emails containing information of a personal nature or ones including any medical or diagnostic information should not be sent via this method. 

All messages will be read and printed by Riverside Medical Center volunteers. Inappropriate messages, including business solicitations or messages containing offensive or obscene language, etc. will be discarded at the discretion of the volunteers.

Unfortunately, the e-mail service can only receive and deliver messages at this time. The system cannot send a response from the patient or provide outgoing e-mail services for patients.

To learn more about the patient e-mail service, or for more information about other quality services offered by Riverside Medical Center, visit www.RiversideMC.net or call (815) 933-1671.

Click here to see all recent news from this company

BRENTWOOD, MO–(Marketwire – August 24, 2010) –  Scrubs & Beyond is proud to introduce a new line of medical scrubs exclusive to their already amazing selection. The David After Dentist (DAD) scrubs were inspired from the video seen online of David after a visit to his dentist. This video became so popular it was nominated for a Webby Award in the category of Best Viral Video. With scrub tops, scrubs pants and a scrub jacket to choose from, you can outfit yourself with your favorite DAD scrubs.

Most of us have seen the video where David is in the back seat of his Dad’s car, completely out of it after having a tooth pulled. During the video he can be seen asking “is this real life?”, which is the saying that DAD has chosen to run with. Scrubs & Beyond has placed the DAD logo and the saying on their new line of scrubs. David After Dentist unisex cargo scrub pants are a classic fit with drawstring waist and cargo pocket with cell phone slot. DAD unisex scrub tops feature a chest pocket with a pencil slot and stethoscope loop. This top comes in sizes up to 5X. If you are looking for a top with great value and quality construction, this one is for you.

In addition to the scrub pants and scrub top, Scrubs & Beyond also has a scrub jacket featured in the DAD lineup. Featuring two patch pockets, one cell phone pocket and knit cuffs, you are sure to love this jacket. With a snap front cardigan design and round neck, this is one of the best scrub jackets you can find. The DAD scrubs are made with the kind of quality that Scrubs & Beyond demands in their products. 

The best thing about these scrubs is that they come in a variety of thirty-two colors. Chocolate, new eggplant, dandelion, Malibu blue, aloe, shocking pink and orchid are just a few of the popular colors. Whatever color you want, you are sure to find it with that many colors to choose from. Scrubs & Beyond and David After Dentist make a great pairing with this new line of scrubs. Check out for yourself just how great this combination can be by visiting www.ScrubsandBeyond.com and buying a pair today!

Click here to see all recent news from this company

GLEN ELLEN, CA–(Marketwire – August 24, 2010) –  The DAISY Foundation is encouraging nurses seeking to impact and improve treatment of patients with auto-immune diseases and cancer to apply for a research or evidence-based practice project grant awarded by the foundation. The Fall deadline to submit a letter of intent for the J. Patrick Barnes Research Grant is September 3, 2010.

The foundation offers two types of research grants: research grants of up to $5,000 for projects that involve clinical research studies that directly benefit patients and/or families; and evidence-based practice grants of up to $2,000 that use patient-focused data to study and develop improved nursing practices. 

For the first time this year, successful applicants will also be allowed to apply for subsequent funding to share their findings at professional conferences. This funding will provide grantees with up to $2,000 for expenses and fees for attending or presenting at a professional conference. 

The DAISY Foundation provides these grants to support registered nurses who continually evaluate their practice, seek answers to clinical questions in an effort to improve their practice, and change their practice based on evidence and evaluation of that change. 

The DAISY Foundation encourages nurses who have research/EBP experience, as well as those who do not have experience to apply. Additional information and the grant applications are available at www.DAISYfoundation.org. 

The DAISY Foundation was established in 1999 by the family of J. Patrick Barnes, who died from complications of Idiopathic Thrombocytopenic Purpura (ITP) at the age of 33. Having been touched by the remarkable care, clinical skills and compassion demonstrated by nurses during Patrick’s illness, the Barnes family established the Foundation to recognize and support exceptional nurses around the country. The Foundation has three primary programs: the DAISY Award for Extraordinary Nurses, which recognizes the outstanding daily work of nurses in more than 650 hospitals throughout the United States, the J. Patrick Barnes Research Grant, and the newly introduced DAISY Faculty Award program. 

Click here to see all recent news from this company

ALEXANDRIA, VA–(Marketwire – August 24, 2010) –  The American Diabetes Association is extremely disappointed by the federal district court decision yesterday blocking the federal government from funding research involving embryonic stem cells. 

President Obama’s Executive Order in March of 2009 assisted advancement of stem cell research by lifting existing restrictions on the use of embryonic stem cells, while maintaining strict ethical guidelines. Even prior to that Order, federal funding of stem cell research was permitted on a limited number of previously-existing stem cell lines.

“This is a major setback for medical research, in particular, research towards a cure for diabetes,” said Richard Bergenstal, MD, President, Medicine & Science, American Diabetes Association. “This decision stands as a roadblock to research that has shown great promise in finding a cure for diabetes and treating its complications.”

Stem cell research has the potential to save and significantly improve the lives of the nearly 24 million Americans with diabetes who face its many complications including heart disease, amputation and blindness. The American Diabetes Association has extensively advocated for stem cell research, which holds the promise of accelerating medical advancements in many fields. “We will work with other concerned organizations to find a way to remove this barrier to scientific progress,” said Bergenstal.

The American Diabetes Association is leading the fight to stop diabetes and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, our mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit www.diabetes.org. Information from both these sources is available in English and Spanish.

id=”nav_links”>

CHICAGO, IL–(Marketwire – August 24, 2010) –  As the back-to-school season approaches, students and parents shouldn’t forget about health insurance after budgeting for tuition, books, and other school costs. Students who face a temporary gap in coverage or don’t have any health insurance should explore their options in the individual market.

Though health reform will allow full-time students to stay on their parents plan until age 26, this won’t go into effect for millions until next year, leaving many students without coverage.

Students facing a gap in coverage. For students who are just going to face a gap in coverage for a few months, they should look into purchasing a short term health insurance policy. Short term plans are very inexpensive and cover emergency visits.

Students without health insurance. There are many students who will be going to college this fall and are required by their university to purchase health insurance. While many schools offer coverage, it is usually best and cheaper to purchase an individual health insurance policy from an insurance company.

As for cost, individual policies tend to be cheaper because young adults are in good health. An individual plan also offers more comprehensive doctor and hospital networks — university plans frequently have a strict list of covered health care providers.

Another great benefit of individual health plans for students is portability. Even after graduation, an individual health insurance policy can be kept throughout their early professional career.

“Students in need of health coverage can use GoHealthInsurance.com to quickly compare plans from different companies easily with our Quote Engine,” said Michael Mahoney, Director of Consumer Markets at GoHealthInsurance.com. “It’s never a good idea to go without coverage, and students will be surprised at how affordable health insurance can be.”

About GoHealthInsurance

GoHealthInsurance.com makes buying health insurance simple. GoHealthInsurance explains health coverage options in plain English, provides free health insurance quotes, connects shoppers with local agents, and helps consumers choose plans that meet their health and budget needs.

Click here to see all recent news from this company

VANCOUVER, BRITISH COLUMBIA–(Marketwire – Aug. 24, 2010) – ALDA Pharmaceuticals Corp. (TSX VENTURE:APH)(OTCQB:APCSF) (“ALDA” or “the Company”) is monitoring reports of new “Superbugs” that are highly resistant to nearly all antibiotics, including penicillin-like antibiotics that possess broad spectrum antibacterial properties and are typically used as a last resort. The new strains of antibiotic-resistant E. coli and Klebsiella were created when genetic material that codes for an antibiotic-digesting enzyme was incorporated from other species. Such genetic “swapping” is common among bacteria and is a major cause of antibiotic resistance. Although primarily observed in Pakistan, India and the UK, similar infections have been reported in US, Canada, Australia and the Netherlands and international researchers are concerned that these new strains could become a major global health problem.

To reduce the spread of these bacteria, health authorities are recommending proper hand hygiene and disinfection procedures. Dr. Terrance Owen, President & CEO comments, “Using effective hand sanitizers and disinfectant products is an important step in keeping one’s environment safe. ALDA’s products contain 70% ethanol and benzalkonium chloride which have both proven to be very effective against E. coli and other resistant bacteria, such as MRSA. Although the threatened H1N1 pandemic did not materialize, it certainly made people aware of the need for products that can reduce the transmission of infectious diseases. The lessons learned may prove to be very useful as we face ever-increasing numbers of Superbugs.”

About ALDA Pharmaceuticals Corp.

ALDA is focused on the development of infection-control therapeutics derived from its patented T³6^® technology. The company trades on the TSX Venture Exchange under the symbol APH and on the OTCQB under the symbol APCSF. The Company was the Official Supplier to the Vancouver 2010 Olympic Winter Games and the Vancouver 2010 Paralympic Winter Games and is the Official Supplier to the Canadian Olympic Committee, the 2010 Canadian Olympic Team and the 2012 Canadian Olympic Team for antiseptic hand sanitizer, disinfectant and disinfectant cleaning products. The Company was also selected as one of the TSX Venture 50 companies in the Technology and Life Sciences sector for 2010.

Terrance G. Owen, Ph.D., MBA, President & CEO

ALDA Pharmaceuticals Corp.

The Units, common shares, warrants and the common shares issuable upon exercise of the warrants have not been registered under the United States Securities Act of 1933 (the “Act”) and may not be offered or sold absent registration under the Act or an applicable exemption from the registration requirements thereof. This news release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction or an exemption therefrom.

Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves ALDA’s expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. ALDA generally uses words such as “outlook”, “will”, “could”, “would”, “might”, “remains”, “to be”, “plans”, “believes”, “may”, “expects”, “intends”, “anticipates”, “estimate”, “future”, “plan”, “positioned”, “potential”, “project”, “remain”, “scheduled”, “set to”, “subject to”, “upcoming”, and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to ALDA as of the date of this release, and ALDA assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of ALDA and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.

TAMPA, FL–(Marketwire – August 24, 2010) – Sage North America today announced that products developed by its Healthcare Division are now part of the award-winning Sage Partner Advantage program. The Sage Healthcare Division provides electronic health records (EHR) and practice management software and services to approximately 80,000 physicians in North America. Sage business partners choosing to represent healthcare solutions now have access to a vast array of proven, successful resources and programs that will ultimately result in better overall customer service and satisfaction.

“The Sage Partner Advantage program is critical to Sage’s success as we continuously enhance service for small and midsized healthcare practices,” said Lee Horner, Senior Vice President of Sales at Sage Healthcare Division. “This strategy will enable us to grow our market share and increase our partners’ ability to deliver products and services to meet accelerated demand, and expand our go-to-market strategy.”

Sage’s business partner channel services millions of businesses across North America. By adding the Sage Healthcare Division product portfolio to the Sage Partner Advantage program, Sage business partners can more aggressively address the needs of healthcare providers with products and services to enhance their practices. The first Sage business partner to offer healthcare products under the Sage Partner Advantage program is EHR & EMR Software Solutions, LLC, a division of Alliance Solutions Group of Brandon, FL (ASG). ASG currently represents Sage Timberline Office, Sage Master Builder and Sage FAS product lines and will now offer the Sage Intergy line of products.

“Sage’s Partner Advantage program has helped ASG in every way; from business planning and development to consulting services to improving our overall customer experience,” said Mike Griffith, Managing Member at ASG. “We’re very anxious to apply the elements of the program to capitalize on new market opportunities in Healthcare.”

The launch of the Healthcare Division’s channel program is the latest addition to the award-winning Sage Partner Advantage program, which is consistently rated a 5-Star program by EverythingChannel. The program is designed to help channel partners realize greater overall business success through extensive training in sales, consulting, business leadership and product expertise; hiring assistance; direct financial support and marketing assistance programs.

According to IDC Health Insights(1), (2), Sage Healthcare Division products that include Sage Intergy and Sage Intergy EHR are recognized as leaders in the market for small, midsized and large healthcare practices for ownership confidence and fit to market needs.

“Adding Sage healthcare solutions to the Sage Partner Advantage program shows our continued commitment to our current clients, and all practices we strive to serve,” said Betty Otter-Nickerson, President of Sage Healthcare Division. “This program enables our business partners to build on the personal support Sage currently offers its healthcare clients at the practice level and will encourage an even more robust, high level of service for our clients.”

Sage channel partners will service the ambulatory healthcare market.

For more information about the Sage Partner Advantage healthcare channel network or to find out how to join, please contact [email protected] or call 866-693-7067, press option 1.

About Sage North America
Sage North America is part of The Sage Group plc, a leading global supplier of business management software and services. Sage North America employs 4,000 people and supports 3.1 million small and midsized business customers including approximately 80,000 physicians. The Sage Group plc, formed in 1981, was floated on the London Stock Exchange in 1989 and now employs 13,100 people and supports 6.2 million customers worldwide. For more information, please visit the website at www.sagenorthamerica.com.

© 2010 Sage Software, Inc. All rights reserved. Sage, Sage Software, Sage logos and the Sage product and service names mentioned herein are registered trademarks or trademarks of Sage Software, Inc. or its affiliated entities. All other trademarks are the property of their respective owners.

1. “Vendor Assessment: The Industry Short List of Electronic Health and Medical Records for Small and Midsize Ambulatory Practices,” Document # HI220502, November 2009. 

2. “Vendor Assessment: The Industry Short List of Electronic Health and Medical Records for Large Ambulatory Practices,” Document # HI220600, November 2009.

TORONTO, ONTARIO–(Marketwire – Aug. 24, 2010) – Proponents of for-profit private health care claim our public health care system is “unsustainable,” but the facts show that these claims are driven far more by ideology than real data. Canadian Doctors for Medicare’s briefing note, Health Care Sustainability, explains the issues underlying the debate about health care sustainability, and how physicians in Canada can work together to control health care costs and to improve our health care system for the benefit of all Canadians.

Canadian Doctors for Medicare (CDM) is a national, membership-based organization that believes in Canada’s publicly-funded health care system. The organization’s mission is to provide a voice for Canadian doctors who want to strengthen and improve Canada’s universal publicly-funded health care system in a way that benefits all Canadians. 

TUSTIN, CA–(Marketwire – August 24, 2010) –  Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) announced today broad availability of its 2010 Onko-Sure® Reference Guide for the Company’s USFDA-approved Onko-Sure® in vitro diagnostic (IVD) cancer test kit.

The 2010 Onko-Sure® Reference Guide is a commercially published compilation of Radient Pharmaceuticals general information and clinical studies on the Company’s Onko-Sure® IVD cancer test kit. Designed to provide oncologists, physicians and clinicians with the most current and important information for Onko-Sure®, the guide also serves as a comprehensive reference for other health care professionals, consumers and patients.

In addition to general Company information and Onko-Sure® clinical study data, RPC’s 2010 Onko-Sure® Reference Guide provides a comprehensive list of key references, resources and other published materials users can consult to better understand the medical utilities of Onko-Sure®, how healthcare providers and patients can use the test and the science behind Onko-Sure®. 

RPC’s Onko-Sure® IVD cancer test is a simple, non-invasive, patent-pending and regulatory-approved in vitro diagnostic (IVD) test used for the detection, screening, and monitoring of various types of cancer. The test enables physicians and healthcare professionals to effectively monitor and/or detect certain types of cancers by measuring the accumulation of Fibrin and Fibrinogen Degradation Products (FDP) in the blood. FDP levels rise dramatically with the progression of cancer. Onko-Sure® is approved by the US FDA for the monitoring of colorectal cancer and by Health Canada as a lung cancer detection and monitoring test. 

According to Mr. Douglas MacLellan, Chairman and CEO of Radient Pharmaceuticals, “The 2010 Onko-Sure® Reference Guide is an invaluable resource for both members of the healthcare community and patients alike, and we believe it will serve as an important educational tool that will drive broad-based adoption and use of RPC’s Onko-Sure® IVD cancer test for the diagnosis, treatment and monitoring of cancer.”

RPC’s 2010 Onko-Sure® Reference Guide is available in both print and on-line versions. Print versions can be ordered by contacting Radient Pharmaceuticals at 1-714-505-4461 or via e-mail [email protected]; and online versions are available for download by visiting the Radient Pharmaceuticals corporate website at www.Radient-Pharma.com or RPC’s Onko-Sure®-dedicated website located at www.onko-sure.com.

RPC Contact Information:
For additional information on Radient Pharmaceuticals, ADI and its portfolio of products visit the Company’s corporate website at www.Radient-Pharma.com. For information specifically related to Onko-Sure® visit www.onko-sure.com. For Investor Relations information contact Kristine Szarkowitz at [email protected] or 1.206.310.5323.

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is dedicated to saving lives and money for patients and global healthcare systems through the deployment of our Onko-Sure™ In Vitro Diagnostic cancer test. Our focus is on the discovery, development and commercialization of unique high-value diagnostic tests that help physicians answer important clinical questions related to early disease detection; treatment strategy; and the monitoring of disease progression, prognosis, and diagnosis to ultimately improve outcomes for patients. Radient Pharmaceutical’s current Onko-Sure™ cancer test is used to guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, perform additional testing, or assist in the selection of therapy. To learn more about our company, people and potentially life-saving cancer test, visit www.radient-pharma.com. 

Forward-Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company’s operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Click here to see all recent news from this company

HOUSTON, TX–(Marketwire – August 24, 2010) –  Bederra Corporation (PINKSHEETS: BEDA), a Houston, Texas-based, diversified medical services provider, discusses recent events in detail below.

The company released its June 30, 2010 quarterly financials. As mentioned in the Management Discussion part of the filings, the financials of its recent acquisition, Texas Mobile Health (TMH), were included. The company has not been able to achieve the level of sales it had anticipated due to the overall unemployment situation causing loss of insurance benefits and therefore lower patient visits to doctors. Also, the recently passed Healthcare Legislation has caused many physicians, particularly in Texas, to opt out of Medicare therefore causing TMH to lose several doctor clients. In addition to all of this, Medicare has cut back reimbursements by 30-40%.

TMH is exploring other areas of diagnostic testing services to increase sales and these areas will be discussed in future releases.

The company reported that it had received a subpoena from the SEC. The subpoena requests certain information concerning the recently reported short selling activities in the company’s common stock and historical stock issuances. Management is fully cooperating with the Commission and will provide it information that management has compiled including weekly DTC Securities Positions Reports, its most recent NOBO list, registered shareholder list, reports and information from Buyins.net and spreadsheets prepared by management together with records requested of the company’s former transfer agent. Management also reiterated that it intends to maintain its Pink Sheets Current Information status as the company’s minimum level of transparency and disclosure as it continues to grow its business internally and through acquisitions.

As previously stated, the company’s long-term goal is to become a fully reporting company and has begun this process by achieving Pink Sheet Current Status.

About Bederra Corp.
http://www.bederra.com
Bederra Corporation provides multiple modality diagnostic medical imaging services to the greater Houston area and the world famous Texas Medical Center. The Company’s business strategy is to continue to expand its current operations and seek out additional acquisitions that will complement its core offerings.

Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company’s expectations with regard to the future impact on the company’s results from new products and services in development, including any planned acquisitions, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The results anticipated by any or all of these forward-looking statements might not occur. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company’s plans or expectations.

LOS ANGELES, CA–(Marketwire – August 24, 2010) –  MMRGlobal, Inc. (OTCBB: MMRF) (www.mmrglobal.com) through its subsidiary, MyMedicalRecords, Inc. (www.mymedicalrecords.com), a leading provider of Personal Health Records (PHR) technology and professional document management and imaging systems, today announced the signing of a distribution agreement with Image Access Corporation, Kodak’s largest reseller of document imaging products and services. Image Access, in business for over 20 years, will sell the MMRPro electronic document management solution to hospitals, alternate care facilities and physician practices and clinics (www.mmrprovideos.com).

Robert H. Lorsch, Chairman and CEO of MMRGlobal, commented, “We are excited about Image Access joining our growing list of resellers in support of the deployment of MMRPro. Image Access through its offering of MMRPro enables its customers to take the first step toward meaningful use.”

MMRGlobal also recently announced its move to new corporate headquarters, expanding its office space by more than 300%. The offices are located in the Associated Television International building (www.associatedtelevision.com), the Company’s strategic media and advertising partner, at 4401 Wilshire Blvd. 2nd Floor, Los Angeles, California 90010. The move will enable MMRGlobal to house development resources from its technology partner, Nihilent in India. The two companies are working together in support of MMRGlobal’s worldwide expansion of its products and services, including China.

About MMRGlobal, Inc.

MMR Global, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. (“MMR”), provides secure and easy-to-use online Personal Health Records (“PHRs”) and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, and professional organizations and affinity groups. MyMedicalRecords enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. The MyMedicalRecords Personal Health Record is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user’s account. The Company’s professional offering, MMRPro, is designed to give physicians’ offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time through an integrated patient portal. MMR is an Independent Software Vendor Partner with Kodak to deliver an integrated turnkey EMR solution for healthcare professionals. MMR is also an integrated service provider on Google Health. To learn more about MMR Global, Inc. and its products, visit www.mymedicalrecords.com and view the videos at www.mmrtheater.com.

Forward-Looking Statements
Any statements contained in this press release that refer to future events or other non-historical matters are forward-looking statements, and some can be identified by the use of words (and their derivations) such as “need,” “possibility,” “offer,” “development,” “if,” “negotiate,” “when,” “begun,” “believe,” “achieve,” “will,” “estimate,” “expect,” “maintain,” “plan,” and “continue,” or the negative of these words. MMRGlobal, Inc. disclaims any intent or obligation to revise or update any forward-looking statements. These forward-looking statements are based on MMRGlobal, Inc.’s reasonable expectations as of the date of this press release and are subject to risks and uncertainties that could cause actual results to differ materially from current expectations. The information discussed in this release is subject to various risks and uncertainties related to changes in MMRGlobal, Inc.’s business prospects, results of operations or financial condition, government regulation and initiatives, uncertainties associated with doing business internationally across borders and territories, and such other risks and uncertainties as detailed from time to time in MMRGlobal, Inc.’s public filings with the U.S. Securities and Exchange Commission.

Click here to see all recent news from this company

MADISON, WI–(Marketwire – August 24, 2010) –  TomoTherapy Incorporated (NASDAQ: TOMO), maker of advanced, integrated radiation therapy solutions for cancer care, announced today that General Hospital of Guangzhou Military Command of PLA has purchased the first TomoTherapy^® radiation therapy system to be installed in Southern China. The TomoTherapy treatment system will enable the hospital to provide advanced cancer care to a wide variety of patients, including those with head and neck cancers.

“In this area of Southern China, we see a large number of patients who suffer from head and neck cancers. But our aging linear accelerator technology has limited our ability to treat these patients, forcing us to refer them to other cancer centers,” said Jian Liu, president of PLA Guangzhou Hospital, which treats more than 1 million patients annually. “The TomoTherapy platform will enable us to expand our care and deliver treatments for the most complicated cases very effectively and accurately with its integrated daily 3-D imaging.”

The TomoTherapy radiation therapy system allows clinicians to provide helical image-guided, intensity-modulated radiation therapy (IG-IMRT), which has been shown to offer better dosimetric distributions when compared to traditional IMRT treatments. PLA Guangzhou will use the TomoTherapy treatment system to address complex nasopharyngeal cancer cases, in which patients can suffer significant side effects. The daily megavoltage CT (MVCT) imaging offered by the TomoTherapy treatment system will allow clinicians at PLA Guangzhou General Hospital to better monitor changes to the parotid glands, and calculate the dosage they receive. In addition, the TomoTherapy system’s innovative adaptive planning capabilities enable clinicians to quickly and easily re-plan treatment so that the dosage received is optimized over the course of treatment.

“With its plan to focus its TomoTherapy treatments on complex head and neck cancers, we believe that PLA Guangzhou General Hospital will quickly become one of the premier locations for these types of treatments in Southern China,” said Fred Robertson, CEO of TomoTherapy. “We are happy to continue our strong relationship with our distributor TomoKnife to expand access to TomoTherapy technology for the benefit of clinicians and patients throughout China.”

About TomoTherapy Incorporated
TomoTherapy Incorporated develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy^® platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy’s suite of solutions include its flagship Hi·Art^® treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD^™ treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile^™ relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. TomoTherapy’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

Forward-Looking Statements
Statements in this release regarding future products or product capabilities, events, expectations and other similar matters, including but not limited to statements using the terms “may,” “should,” “suggests” or “indicates” constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements contained in this press release are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated, including but not limited to factors such as our ability to integrate acquired assets, ability to protect intellectual property, risks of interruption due to events beyond the company’s control, and the other risks listed from time to time in TomoTherapy’s filings with the U.S. Securities and Exchange Commission, which by this reference are incorporated herein. These forward-looking statements represent TomoTherapy’s judgments as of the date of this press release. TomoTherapy assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events or otherwise.

©2010 TomoTherapy Incorporated. All rights reserved. TomoTherapy, Tomo, TomoDirect, TQA, the TomoTherapy logo and Hi·Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated in the United States and other countries.

DALLAS, TX–(Marketwire – August 24, 2010) –  Too many men have suffered in silence for too long, according to Dr. Bill Johnson, Medical Director of Innovations Medical. He wants more men to “Loose the Moobs” by leveraging modern cosmetic procedures to solve a serious problem.

Male breast fat.

“Either more men are developing flabby pecs, or men are just taking better care of themselves now,” says Dr. Johnson. “We’ve seen the interest in male breast fat reduction jump dramatically in the last year.”

Johnson’s team of technicians at Innovations medical has seen a 300% increase in the demand for this procedure over the last 3 years. “These days, I see at least one ‘moob’ patient per week,” says Johnson. “All of them want liposuction to reduce their chest fat.”

Medically, it’s called gynecomastia, but most men refer to their enlarged breasts as “moobs.” Some Hollywood glitterati have been snapped with “moobs”: Jack Nicholson, Tom Cruise, even Arnold Schwarzenegger. There are numerous YouTube videos. But no one needs to put up with it, according to Johnson.

Causes can include obesity, hormones and kidney disease, but most of the determining factors are genetic.

“A decade ago, men didn’t seek out cosmetic procedures to address their appearance, but they do now,” says Dr. Johnson. “It’s simple and effective.” Dr. Johnson’s unique “moob” liposuction takes less than one hour, and the patient is awake the entire time. “A guy can come in, have the procedure, and be back at work the next day,” says Johnson. He combines two popular lipo technologies — Tickle Liposuction and SmartLipo. The combination allows for removal of excess fat and skin tightening in the chest area.

“I want more men to take better care of themselves,” says Dr. Johnson. “Get over the hesitation and loose the moobs!”

Innovations Medical is a full-service aesthetic medical practice with locations in Dallas, Fort Worth and Grapevine, Texas. Medical Director Bill Johnson, M.D., has been treating patients in North Texas since 1984. As the name implies, Innovations Medical was the first in North Texas to offer many leading-edge technologies, including SmartLipo, Vibro Liposuction and Acoustic Wave Therapy for cellulite. www.innovationsmedical.com

Click here to see all recent news from this company

LOUISVILLE, KY–(Marketwire – August 24, 2010) –  ZirMed®, a leading national provider of revenue cycle management solutions for healthcare providers, today announced the addition of a first-of-its-kind new self-sign up capability for Patient Notebook, ZirMed’s online electronic billing and patient medical account management solution. The self-sign up function allows patients to enroll themselves to receive and pay their medical bills electronically for multiple healthcare providers in a single convenient, secure location.

With the new self-sign up feature, patients not only enjoy the convenience and privacy of enrolling for the service from the comfort of their own home, but healthcare practices also benefit from the improved workflow, reduced paperwork and cost savings of having more patients enroll in electronic bill presentment.

“Self-subscription had been a major hurdle due to HIPAA regulations and logistical concerns, but we’ve been able to overcome these challenges to offer a new level of convenience and efficiency to both the provider and the patient,” said Jim Lacy, ZirMed CFO. “As healthcare evolves into a more consumer-driven industry, this new feature demonstrates our view of giving patients more transparency into the payment process. Our approach is a fundamental step in giving patients control over their healthcare information, both financial and clinical.”

The new self-enrollment feature allows patients to sign up online to receive billing statements and pay bills at www.patientnotebook.com. Prior to this capability, office staff had to ask patients to sign up and enroll at the office. With the self-sign up feature, the office has the flexibility to continue to enroll patients or direct them to Patient Notebook to sign themselves up for this service.

For more information about Patient Notebook visit www.zirmed.com or www.patientnotebook.com.

About ZirMed:
Founded in 1999, ZirMed is a nationally recognized leader in delivering revenue cycle management solutions to healthcare providers. ZirMed enables healthcare providers to leverage the power of technology to cure administrative burdens and increase cash flow. ZirMed solutions include eligibility verification, credit/debit card processing, check processing, claims management, coding compliancy and reimbursement management, electronic remittance advice, patient statements, patient e-commerce solutions, provider credentialing, and lock box services. ZirMed solutions are designed to complement provider workflow and to provide innovative, creative and flexible solutions for healthcare’s most pressing administrative challenges. For more information about ZirMed, visit www.zirmed.com/pr. 

PLANTATION, FL–(Marketwire – August 24, 2010) –  Transax International Limited (Transax) (OTCQB: TNSX), a network solutions company for healthcare providers and health insurance companies, today reported financial results for the first half of 2010 and second quarter ended June 30, 2010.

For the quarter ending June 30, 2010 Transax generated net revenues of $1,046,429 compared to $1,093,705 in net revenues during second quarter of 2009, a 4% decrease. The decrease in revenue is due to the loss of one minor contract during the second quarter 2010 partly offset by continued growth in real-time transactions and rollout of previously announced contracts. Transaction volume was 2.3 million for the second quarter of 2010 compared to 2.1 million in the same period during 2009.

Loss from operations in the second quarter of 2010 was $418,904 compared with a $243,988 loss during the same period in 2009. Net loss for the second quarter of 2010 was $975,480 compared with a net loss in the second quarter of 2009 of $3,442,588. The decrease in net loss is principally due to a decrease in non cash items related to derivative liabilities expenses.

For the quarter ending June 30, 2010, the Company incurred $1,465,333 in operating expenses compared to $1,337,693 during the same period in 2009. The increase in expenses was attributed to significant increases in cost of product support services together with general and administrative expense increases in complying the Company products to new government regulations in Brazil.

For the six months ended June 30, 2010 revenues increased by 1% to $2,069,261 from $2,046,023 during the same period in 2009. The loss of one customer during the period was partially offset by revenues from new customers during the period. The Company recorded an operational loss of $938,180 for the six months ending June 30, 2010 compared to operational loss of $561,171 for the six months ending June 30, 2009. Net loss for the first six months of 2010 was $1,367,493 compared to a net loss of $3,721,815 for the same period in 2009.

At the end of the second quarter 2009 the Company had over 20,150 solutions installed in Brazil including 3,125 Point of Sales (POS) Solutions, 16,350 operational WEB solutions and 1,870 Interactive Voice Response (IVR) solutions with the balance of PC and Server solutions installed in medical laboratories. During the six month period ending June 30, 2010 the company installed over 5,000 WEB solutions to medical provider locations to support future roll out and revenue growth.

In announcing the results Stephen Walters, President & CEO, stated, “Transaction volumes have increased steadily during 2010 recording a 11% annual increase. The company installed 1,250 solutions during July 2010 and recorded over 850,000 for the month of July 2010. Additional roll out of solutions to increase revenues and reduction in operating costs is the main target of the company for the second half of the year.”

About Transax International Limited

Transax International is an emerging network solutions provider for the healthcare sector. Utilizing its proprietary MedLink™ technology, Transax provides a service similar to credit card processing for the health insurance and providers industries. A transaction consists of: approving eligibility, authorization, auto-adjudication of the health claim and generating the claim payable files — provided instantaneously in “real time” — regardless of method of claim generation.

Transax’s solutions have been proven to significantly decrease health insurance claim expenditures and healthcare provider costs. Based in Plantation, Fl, Transax maintains a major operations office in Rio de Janeiro, Brazil, with approximately 45 staff and a Sales Office in Sao Paulo, Brazil. The Company has contracts in place with major health insurers in Brazil and currently undertakes approximately 800,000 transactions per month.

SAFE HARBOR STATEMENT: “THIS NEWS RELEASE MAY INCLUDE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED, WITH RESPECT TO ACHIEVING CORPORATE OBJECTIVES, DEVELOPING ADDITIONAL PROJECT INTERESTS, THE COMPANY’S ANALYSIS OF OPPORTUNITIES IN THE ACQUISITION AND DEVELOPMENT OF VARIOUS PROJECT INTERESTS AND CERTAIN OTHER MATTERS. THESE STATEMENTS ARE MADE UNDER THE ‘SAFE HARBOR’ PROVISIONS OF THE UNITED STATES PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 AND INVOLVE RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE IN THE FORWARD-LOOKING STATEMENTS CONTAINED HEREIN.”

MELVILLE, NY–(Marketwire – August 24, 2010) – FONAR Corporation (NASDAQ: FONR), the Inventor of MR Scanning™, announced the purchase of an UPRIGHT® Multi-Position™ MRI by a distinguished Board Certified radiologist in Florida. He is the owner operator of two multi-modality imaging centers equipped with MRIs.

“He was initially considering purchasing a 3 Tesla lie-down MRI,” said Raymond V. Damadian, M.D., president and founder of FONAR Corporation, “but decided instead to buy the FONAR UPRIGHT® Multi-Position™ MRI when he became aware of its many unique imaging capabilities.”

As he explained, “many of the physicians who send patients to our multi-modality medical imaging practices are surgeons who perform spine surgery. It is a very important specialty in medical practice since the second most common reason today, after the common cold, for visiting a doctor’s office is ‘back pain.’

“Each year, 40 to 60 percent of American adults suffer from chronic back pain. More than one million spine surgery procedures are performed annually, with medical costs to treat back pain approaching $24 billion per year. (http://nyp.org/news/hospital/spine-fusion-surgery.html).

“As of 2007, approximately 9 million of the 27.5 million MRIs performed each year in the U.S. are of the spine.

“Accordingly,” he said, “aware that the number one priority of all my referring spine surgeons is the best possible outcomes for their patients, I became convinced that the only technology capable of maximizing the surgical outcomes for my physician senders was to assure that they were able to see ALL of the pathology they had to address, not just part of it from a lie-down scanner in which the body weight has been removed.”

“The spine is a difficult region of anatomy for the surgeon,” he continued, “because as the principal weight-bearing structure of the body it shows its wear and tear degeneration early on. Consequently, degenerative changes of the spine are a normal concomitant of the aging process. This reality, however, from the surgeon’s perspective, can be confounding. Does he, for example, surgically address the degenerative loss of disc height and neural foramina narrowing at L1/2, the ‘spondy’ at L2/3, or the disc herniation at L4/5? It is evident that if a vertebral segment not responsible for the patient’s pain is subjected to surgery, the pain will not improve and there is even the risk that the patient’s clinical condition and pain could be made worse by carrying out surgery on the wrong segment.”

“Consequently,” he stated, “the key to a good surgical outcome is the success with which the degenerative changes responsible for the patient’s pain, are successfully separated from the degenerative changes that are not causing the patient’s pain, so that only those segments responsible for the patient’s pain are operated on.”

“Of all the commercially available MRI scanners,” he said, “the FONAR UPRIGHT® Multi-Position™ scanner is the only MRI that meets this need. What FONAR’s UPRIGHT® Multi-Position™ weight-bearing technology makes possible that no other scanner can accomplish is the ability for the radiologist to ask the patient to put himself in the position (standing, sitting, lateral bending, flexion, extension, rotation, etc.) that generates his pain, which no other scanner can do. A picture can then be taken with the patient in his actual pain generating position and then compared to a picture of the patient in an adjacent non-pain-generating position so that the correct pain generating anatomy can be unequivocally identified. This permits the surgeon to address only the anatomy segment generating the patient’s pain, and enables him to avoid surgery on segments not involved in pain generation. The ultimate result is excellent outcomes for the surgeons and their patients.

“A recumbent non-weight-bearing single-position MRI simply cannot meet this need. We see it as a critical need, if we are going to be successful in improving surgical outcomes for our patients.

“Also important to our surgeons is their ability to see their surgical results post-operatively, which the FONAR UPRIGHT® Multi-Position™ MRI can accomplish and the conventional MRI cannot. In the event of a less than optimal surgical outcome, or even an outcome that deteriorates over time, it is critical for the surgeon to be able to see post-operatively any hardware devices he may have implanted (e.g. artificial discs, pedicle screws, fusion rods, etc.) in order to address any surgical results that require further attention. Consequently, being able to clearly visualize installed implants in the post-operative spine is key for the surgeon to be able to address any further needs the patient might have.

“The FONAR scanner at 0.6 T meets this need of the surgeon since it is uniquely spared the magnetic susceptibility image artifacts that the 1.5 T and 3.0 T lie-down scanners generate. The implant artifacts obliterate the anatomy of the vertebral segments that are being imaged and make it impossible for the surgeon to discern the source of any persisting post-operative symptoms or pain that the patient might be experiencing.”

He also expressed the need to be able to provide the unique imaging capabilities provided by the FONAR UPRIGHT® scanner to distinguish his radiology practice from competing radiology centers. “The FONAR UPRIGHT® Multi-Position™ MRI is the quintessence of the technology for breaking existing referral patterns. By offering the unique capabilities of the FONAR UPRIGHT® MRI,” he stated, “and thereby distinguishing our radiology practice from competitors who market the same ‘me-too’ products, we would be bringing to our community a ‘Center of Excellence’ for imaging the spine. In so doing, we would be establishing for our community a COMPLETE radiology imaging service that could not be obtained elsewhere. Ultimately this would generate business for all of our imaging modalities. By offering a COMPLETE imaging service that includes all of FONAR’s new UPRIGHT® imaging technologies that are not available anywhere in our community, we would achieve ‘One Stop Shopping’ for our patients to address all of their imaging needs.”

“An example of one of the many unique imaging capabilities made possible by the FONAR UPRIGHT® Multi-Position™ fully weight-loaded imaging,” he continued, “is the ability to image, without x-ray, the 400,000 scoliosis patients that must be imaged UPRIGHT® 2 to 3 times per year to monitor their scoliosis treatment. The elimination of x-ray avoids the 70% increased incidence of breast cancer reported by the National Cancer Institute to be the result of the standard annual x-ray examinations of these patients (National Cancer Institute, www.cancer.gov and M. Morin Doody et al. Spine, 8/15/2000, Vol. 25, #16).

“Another example is the ability to scan small children and infants seated on their mother’s lap as they watch their favorite cartoon on the flat screen TV shipped with the system. This greatly reduces the number of children requiring anesthesia when MRI is needed and is a valuable feature of the FONAR UPRIGHT® that we will be bringing to our pediatric community.

“In addition, the ability to scan UPRIGHT® the large population of women suffering from the PFD (pelvic floor dysfunction) symptoms of cystitis, urinary incontinence and bowel dysfunction is another valuable benefit of the UPRIGHT® MRI. Because of the FONAR UPRIGHT® MRI, the cause of these dysfunctions can now be definitively shown on the MRI images and successfully treated surgically. These pelvic floor dysfunctions are the result of the cystic, vaginal, and rectal prolapses generated by the pelvic floor stresses of childbirth. They are readily visualized,” he said, “by the FONAR UPRIGHT® MRI but are not readily diagnosed by the gynecologist employing the conventional lie-down pelvic examination.”

“There are also now,” he stated, “a large number of patients suffering the consequences of automobile whiplash injuries (Brain Injury, July 2010; 24[7-8]:988) and the ‘fallen’ cerebellar tonsil syndrome (Chiari or CTE; cerebellar tonsil ectopia) that results. The ‘fallen’ cerebellar tonsils require UPRIGHT® imaging to be seen and cannot satisfactorily be visualized by a conventional lie-down MRI. It is another unique need met by the FONAR UPRIGHT® MRI capability.”

“In addition, there is now the power using FONAR’s new cerebro-spinal fluid (CSF) flow technology,” he said, “to create cinés of cerebro-spinal fluid flow, and in particular, to be able to create cinés of this CSF flow in the upright position so that the adequacy of CSF flow into the upright brain can be quantified and visualized. Imaging patients in the upright position assures there are no dynamic impairments to this vital cerebro-spinal function and enables their correction if it exists. With the recent increased incidence of automobile whiplash injuries (C.S.B. Galasko et al., J. Musc-Skel. Pain 2000, Vol. 8, No. 1-2, p. 15) and the cerebellar tonsillar ectopias (CTE) that result, it is critical to identify this pathology as soon as it occurs so it can be addressed before more dire consequences occur.”

“The ‘Thoracic Outlet Syndrome (TOS)’ is yet another symptom complex,” he further stated, “that can benefit from FONAR’s UPRIGHT® imaging technology. The ‘TOS’ patients can now be scanned upright in the FONAR UPRIGHT® Multi-Position™ MRI and placed in the positions that compress the brachial plexus and subclavian artery so that the pathologic anatomy causing the compressions can be visualized and specifically addressed surgically when necessary.

“There is also now the newly recognized Pelvic Congestion Syndrome (PCS) that needs the benefits of UPRIGHT® imaging. PCS is a symptom complex in women where pelvic pain arises secondary to venous congestion and pelvic varicosities. Prolonged standing, in particular, gives rise to the pain and has to be diagnostically distinguished from other causes of pelvic pain such as fibrosis and endometriosis. Placing the patient upright in the FONAR UPRIGHT® Multi-Position™ MRI can readily visualize the pain generating venous congestion and pelvic varicosities so that a definitive diagnosis can be achieved and treatment administered.

“Another valued application for the FONAR UPRIGHT® Multi-Position™ MRI scanner is its potential for evaluating the ‘runner’s knee’ syndrome, i.e. the Patella Femoral Pain Syndrome (PFPS). In the light of the current day practice of daily running exercise to achieve aerobic fitness, accurate diagnosis of the fully weight-loaded ‘runner’s knee’ in different degrees of flexion and extension, including single leg squats, is a growing need. The FONAR UPRIGHT® Multi-Position™ MRI makes possible the visualization of the cartilage contact surfaces of the knee, namely, the miniscal and articular cartilage surfaces that support the body’s weight and enable smooth motion of this dynamic weight-supporting structure. This enables the risks from any long-bone malalignments or patella tracking dysfunctions that give rise to ‘runner’s knee’ to be assessed and addressed before they result in a permanent debilitating osteoarthritis. University biomechanical specialists have recently been conducting research using the FONAR UPRIGHT® Multi-Position™ MRI to explore and better define the ‘runner’s knee’ condition and the ‘patellar tracking’ abnormalities that can aggravate it. The FONAR UPRIGHT® cinés of the fully weight-bearing knee make the multi-position dynamic visualization of ‘runner’s knee’ and the diagnostic analysis of it a reality.

“Particularly valuable to me as a radiologist,” he continued, “is FONAR’s new Correlated Slice Profile (CSP) technology. It takes the FONAR Multi-Position™ MRI technology to a new level. With FONAR’s Correlated Slice Profile (CSP) technology, each slice of a 15-slice multi-slice MRI scan of the spine appears on the radiologist’s screen (or film) adjacent to the images of the other positions of the same slice. By re-centering the slices prior to the image acquisition of a new position, the slices of each position scan remain correlated despite any shifts of the body axis that result from changes in body position. The radiologist can then view each slice of the scan in all 3 of its weight-bearing positions, neutral sit, flexion and extension, alongside the same slice from the recumbent position. This enables the radiologist to easily track a given pathology (e.g. a disc herniation or spondylolisthesis) through all of its four positions so the surgeon can be advised of the full range the patient’s spinal pathology (e.g. disc herniation, spondylolisthesis) traverses during the daily range of his/her body positions. By so doing, the surgeon sees the FULL EXTENT of the pathology he must address to get a good outcome.

“I agree with FONAR’s German customer who just ordered their 4^th FONAR UPRIGHT® MRI because of their business success with FONAR’s new technology (Press Release, FONAR Corporation, August 3, 2010). We agree with them that FONAR’s UPRIGHT® Multi-Position™ MRI is indeed setting a new MRI ‘standard of care’ for a wide range of medical applications.”

For investor and other information visit: www.fonar.com.

UPRIGHT® and STAND-UP® are registered trademarks and The Inventor of MR Scanning™, Full Range of Motion™, pMRI™, Dynamic™, Multi-Position™, True Flow™, The Proof is in the Picture™, Spondylography™ Spondylometry™ and Upright Radiology™ are trademarks of FONAR Corporation.

This release may include forward-looking statements from the company that may or may not materialize. Additional information on factors that could potentially affect the company’s financial results may be found in the company’s filings with the Securities and Exchange Commission.

CLARK, NJ–(Marketwire – August 24, 2010) –  HealthEd, a specialized agency focused on turning health education into positive outcomes, today announced the appointment of Raffaele Piemonte as chief technology officer (CTO). With the addition of Piemonte to the company’s executive team, HealthEd aims to position itself for further growth in this year’s fourth quarter and in 2011.

“We’re committed to improving people’s lives and helping our clients find new and engaging ways to do that,” said Roy Broadfoot, CEO and president of HealthEd. “Digital solutions will be critical to achieving that goal. Raffaele’s extensive experience in developing original applications, combined with his deep understanding of the integration of IT, business, and operational needs, perfectly aligns with the company’s mission of creating a healthier world.”

As CTO, Piemonte will be responsible for developing and executing HealthEd’s technology strategy and leading its technology team. Mr. Piemonte brings to the growing company a variety of IT expertise in several areas, including software architecture, identity management, project life cycle management, and business process optimization. Piemonte’s appointment signals the company’s commitment to making digital marketing integral to its growth and development.

Previously, Mr. Piemonte was with KPMG as director of application integration services. His prior experience includes CTO positions with IEG-Sponsordirect, Riverblade, and Ingredients.com.

Mr. Piemonte’s experience also includes presenting at numerous conferences and penning several articles for various tech journals as well as coauthoring “Developing Applications Using Outlook 2000, CDO, Exchange and Visual Basic,” a comprehensive reference guide for IT professionals for building program applications in collaboration with Microsoft platforms and tools.

About HealthEd
HealthEd is a specialized agency that uses education to help people develop the knowledge, skills, motivation, and confidence to manage important health decisions and activities and ultimately achieve better health outcomes. For more information about HealthEd and the services we offer, please visit http://www.HealthEd.com or contact Anita St. Clair, chief client development officer, at 908-389-2133.

Click here to see all recent news from this company

NIAGARA FALLS, ONTARIO–(Marketwire – Aug. 22, 2010) – Canadian doctors have applauded the Canadian Medical Association’s affirmation of the principle of universal access to health care regardless of ability to pay, but urge the CMA to ensure that future reform proposals are firmly based on the principle of equity. Canadian Doctors for Medicare’s assessment of the CMA’s Health Care Transformation policy document examines some of the CMA’s main proposals and offers some suggestions to Canadian physicians about how they can work together to help reform the health care system so that reforms benefit all Canadians.

Canadian Doctors for Medicare (CDM) is a national, membership-based organization that believes in Canada’s publicly-funded health care system. The organization’s mission is to provide a voice for Canadian doctors who want to strengthen and improve Canada’s universal publicly-funded health care system in a way that benefits all Canadians.

MUNDELEIN, IL–(Marketwire – August 20, 2010) –  Medline Industries, Inc., the company that produced the original Pink Glove Dance, is looking for breast cancer survivors in the New York City and surrounding areas who want to be part of the next Pink Glove Dance video. The original video has become an internet sensation, generating more than 11 million views on YouTube since its release last November. The video features healthcare workers at Providence St. Vincent Medical Center in Portland, Ore. dancing while wearing pink gloves. Medline, based in Mundelein, Ill., is the largest privately held manufacturer and distributor of healthcare supplies in the country.

When and where will it be?
Filming will take place Saturday, August 28 at 10:00 a.m. at The Broadway Plaza in Times Square between 42nd and 43rd streets.

What are the qualifications to participate?
Participants need to be breast cancer survivors and willing to dance wearing pink gloves. No special dancing skills required. A choreographer will be there to teach simple routines.

How long will it take?
Approximately two hours.

How do I sign up?
Details of the video shoot and registration can be found online at www.pinkglovedance.com.
Although participants can just show up on the day of the event, participants are encouraged to register online. 

Why is this video being made?
The first video was created to help spread the word about breast cancer awareness and the importance of the healthcare worker who takes care of breast cancer patients. It was so successful and generated so much positive attention that hospitals around the country inquired about participating in the next video. So the idea of a sequel was developed that not only included hospital workers but breast cancer survivors too. 

Why pink exam gloves?
As a way to extend Medline’s breast cancer awareness campaign, the company developed a pink glove called Generation Pink™. Gloves are also the first point of contact between the healthcare worker and the patient. And, the fact the glove is pink, Medline hoped would get people talking about breast cancer. When the gloves were launched in October, Medline committed to donating $1 of every case purchased to the National Breast Cancer Foundation to fund mammograms for individuals who cannot afford them. In the past five years, Medline has donated almost $500,000 to the National Breast Cancer Foundation. 

ALEXANDRIA, VA–(Marketwire – August 20, 2010) – All people with type 1 diabetes, and some with type 2, need to inject or pump insulin into their bodies to survive. Figuring out how much insulin is necessary requires frequent monitoring and can be difficult, even risky. According to Diabetes Forecast, the consumer magazine of the American Diabetes Association, one of the most hopeful trends in diabetes research is the quest to develop an artificial pancreas, a device that could make the lives of people with diabetes safer, healthier and easier — possibly within the next few years.

Despite its name, the artificial pancreas would not replace the entire biological organ. Instead, its goal is to mimic the pancreatic beta cells, which are destroyed by a malfunctioning immune system in type 1 diabetes or have stopped producing adequate insulin supply in type 2 diabetes. The artificial pancreas would consist of three components; the first two, an insulin pump and a continuous glucose monitor (CGM), are already used by many people with diabetes. It’s the third piece that acts like a glue between the two systems: an algorithm that will turn data from the CGM into instructions for the insulin pump. “Closing the loop” with an algorithm may allow for an automated system of insulin dosing, allowing the person wearing the device to spend less time on daily diabetes management.

So if we already have insulin pumps and CGMs and we can do some math, why isn’t the artificial pancreas already in place? The main reason is the math itself — and its ability to contribute to safety. While some versions of the algorithm are being developed based on decades of diabetes research and even account for the imperfections of mechanical systems, like delays in CGM measurements or insulin delivery, the line between the ideal blood glucose range and a dangerously low level is very narrow. In fact, Aaron Kowalski, PhD, who oversees the Artificial Pancreas Project at the Juvenile Diabetes Research Foundation, tells Diabetes Forecast that the ideal target for glucose levels is “right next to hypoglycemia, so there’s very little buffer.”

As the artificial pancreas concept evolves, it has taken research into new directions, including shut-off mechanisms for insulin pumps when glucose levels drop too low, pumps that deliver a second hormone in addition to insulin that would raise blood glucose, faster-acting insulins that could make the automated artificial pancreas work more effectively, and, of course, several different algorithms with different capabilities based on an individual’s routine. Getting an artificial pancreas approved for market in the United States is going to take a lot of research — but scientists are closer than they’ve ever been before. 

The artificial pancreas would not be a cure for diabetes. But it has tremendous potential to improve and save lives. And, perhaps, the best part? “An artificial pancreas is there all the time,” says Boris Kovatchev, PhD, who developed one of the algorithms for a U.S. study. “It can make decisions while a person sleeps.” In a not too distant future, people with diabetes may finally be able to rest easy.

The September issue of Diabetes Forecast also reports on how health care reform will affect people with diabetes and their families, including what to expect, and when. By the time the new law has fully taken effect, diabetes should no longer keep people from getting and keeping adequate health insurance coverage.

This issue also offers:

• Eyes on the Prize: Prevention is crucial in combating retinopathy
• Diabetes and Dementia: Does type 2 care also bolster brain function?
• Pump Up the Volume: How to eat more but lose weight

Diabetes Forecast has been America’s leading diabetes magazine for more than 60 years, offering the latest news on diabetes research and treatment to provide information, inspiration, and support to people with diabetes. 

The American Diabetes Association is leading the fight to stop diabetes and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure, and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, its mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information, please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit www.diabetes.org. Information from both these sources is available in English and Spanish.

id=”nav_links”>

NEW YORK, NY–(Marketwire – August 20, 2010) –  The cost-savings associated with early disease detection and clinicians’ demand for better, more accurate diagnostic tools are key drivers for a predicted 5.8% yearly increase in the market for molecular imaging devices. According to a new report by healthcare market research publisher Kalorama Information, this market is expected to reach $6.6 billion by 2014.

Differing from traditional diagnostic tools, molecular imaging devices use biomarkers, which produce finer images that display molecular changes, allowing physicians to pinpoint diseases. Devices include nuclear medicine based PET, which renders metabolic information, and SPECT, which produces anatomical images. These devices are well known for their ability to detect the molecular basis of diseases, including neurological and cardiovascular based diseases. In tumors, they detect chemical signatures that provide an early warning. In addition, advances in these devices have recently helped to identify vulnerable plaque in at-risk cardiac patients. Kalorama notes that combining new molecular contrast agents with traditional diagnostic tools, such us Ultrasound, MRI and CT has enabled physicians to capture specific molecular pathways to track the progress of treatment. 

While rapid advances in molecular imaging devices are pushing growth, physicians are even quicker to demand better products with:

• minimal invasiveness,
• rapid imaging processing time,
• low imaging cost,
• low radiation dose, and
• optimal resolution and contrast.

“Meeting the growing demand for a better molecular imaging device is a big driver for companies seeking to break into this market,” says Bruce Carlson, publisher of Kalorama Information. “The market could even grow further if physicians’ demands are met and we see a rise in patient confidence, as this could translate into more individuals opting in for these services.”

The adoption of molecular imaging equipment is not exclusive to physicians, according to Kalorama. Pharmaceutical and biotechnology companies are also utilizing molecular imaging equipment, as it allows them to test drug candidates in vivo for mechanisms, disposition and efficacy. The big players, such as Siemens, GE Healthcare, Phillips, and Toshiba are teaming up with contrast media companies to develop the next generation of molecular imaging equipment.

Kalorama Information’s report, “Molecular Imaging Markets (Market Intelligence Analysis of Market Opportunities in Molecular Imaging),” contains more information on market forecasts, company profiles, and trends in the molecular imaging market. The report is available at:
http://www.kaloramainformation.com/redirect.asp?progid=79480&productid=2613825.

About Kalorama Information
Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter (http://www.twitter.com/KaloramaInfo) and LinkedIn (http://www.linkedin.com/groups?gid=2177845&trk=hb_side_g).

CLIFTON, NJ–(Marketwire – August 20, 2010) – Electronic Control Security, Inc. (OTCBB: EKCS) (ECSI), a global leader in perimeter security systems, today announced receipt of orders totaling $1.1 million for security upgrades at several U.S. Air Force bases and nuclear power stations to meet updated force protection and NRC requirements. In addition, proposals have been submitted for other U.S. Air Force base and nuclear power station upgrades scheduled for fiscal 2011 and 2012.

“These security upgrades have been in the planning stage since 2008 following the terror attacks against our domestic assets in 2001. All branches of government including the nuclear facilities are upgrading and hardening our facilities at an accelerated pace. The NRC has always been one step ahead of potential terrorist threats, and the Department of Defense has increased its efforts in hardening its facilities as well,” commented Arthur Barchenko, President and CEO of ECSI. “Our business is about assisting in the development of security solutions to prevent infiltration of high-value assets and to guard against potential terrorist penetration. We are very proud to be part of this on-going security and anti-terrorism process to help protect the nation’s sensitive and high-visibility sites.” 

These security upgrades include the design and installation of multi-layer security systems including ECSI’s Infrared Perimeter Intrusion Detection (IPID®) system, Fiber Optic Intelligence Detection System (FOIDS®), Intelligent Video Motion Detection (IVMD®) and infrared pan-tilt-zoom camera technology.

About ECSI
ECSI is a global leader in perimeter security and a quality provider to the Department of Defense, Department of Energy, nuclear power stations, and other large commercial-industrial complexes. The Company designs, manufactures and markets physical electronic security systems for high-profile, high-threat environments utilizing risk assessment and analysis to determine and address the security needs of its customers. Teaming agreements with major system integrators enable ECSI to support the installation and aftermarket of its products in the U.S. and overseas. ECSI is located at 790 Bloomfield Avenue, Bldg. C-1, Clifton, NJ 07012. Tel: 973-574-8555; Fax: 973-574-8562. For more information on ECSI and its customers, please visit http://www.ecsiinternational.com.

ECSI INTERNATIONAL, INC. SAFE HARBOR STATEMENT: This press release contains forward-looking statements that involve substantial uncertainties and risks. These forward-looking statements are based upon our current expectations, estimates and projections about our business and our industry and reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including but not limited to changes in economic conditions generally and in our industry specifically, changes in security technology, receipt and timing of collections from purchase orders, legislative or regulatory changes that affect us, the availability of working capital, changes in costs and the availability of goods and services, the introduction of competing products, changes in our operating strategy or development plans, sufficiency of cash reserves and the risks and uncertainties discussed under the heading “RISK FACTORS” in Item 1 of our Annual Report on Form 10-K for the fiscal year ended June 30, 2009 and in our other filings with the Securities and Exchange Commission. We undertake no obligation to revise or update any forward-looking statement for any reason.

JOHANNESBURG, SOUTH AFRICA–(Marketwire – August 20, 2010) – www.wallstreetequityresearch.com gives shareholders valuable insight on REIT – healthcare facilities stocks Nationwide Health Properties Inc. (NYSE: NHP) and HCP Inc. (NYSE: HCP). Sign up today at www.wallstreetequityresearch.com to receive free research reports on these equities.

Investors in the REIT healthcare facility sector are hoping that an aging population of baby boomers and recent healthcare reform will translate to solid bottom lines for companies in the sector. Recent increases in occupancy at senior care facilities are reflective of a population drifting into old age.

www.wallstreetequityresearch.com is a specialized website where investors can have specific access to free reports REIT – healthcare facilities industry; traders looking for analyst opinions on Nationwide Health Properties Inc., HCP Inc. and other companies in this industry are welcomed to sign up for a free one year membership at http://www.wallstreetequityresearch.com/.

While interest expenses have put a damper on some companies’ earnings, the sector remains positive about the future as the population continues to age and the number of senior care facilities remains comparatively low. Companies are looking to partnerships and mergers to acquire more real estate, including medical office buildings and nursing care projects.

The increased buying activity, especially in medical office buildings, is due in part to the security of the investment. Generally speaking, medical office buildings provide positive returns over long periods of time. This coupled with the potential influx of customers has made medical office buildings attractive to many REIT healthcare companies. Visit us at http://www.wallstreetequityresearch.com/ to understand the catalysts and forces driving or affecting the REIT – healthcare facilities industry in today’s economic environment.

Early this month, Nationwide Health Properties Inc. posted its financial results with revenue surging 13% whilst HCP Inc. saw its revenue increase to $303 million. Traders can have complimentary access to today’s complete research reports on HCP Inc. and Nationwide Health Properties Inc. by signing up at http://wallstreetequityresearch.com/August202010HCPInc.(HCP)200810.php or http://wallstreetequityresearch.com/August202010NationwideHealthPropertiesInc.(NHP)200810.php. 

About Wall Street Equity Research: 
Wall Street Equity Research looks to bring simplicity and highly sophisticated research to an ever-changing investing environment. Wall Street Equity Research has been partnering with a number of North American and Emerging Economies analysts to bring you the best of both continents in terms of market analysis and analytical opinions. 

SUN VALLEY, CA–(Marketwire – August 20, 2010) –  XTend Medical Corporation (PINKSHEETS: XMDC), a company that specializes in delivering life-changing medical technology to healthcare organizations globally, received confirmation that the Delaware Chancery Court has scheduled a mediation of the lawsuit that XTend commenced against U&I Bio-Tech Korea, U&I Bio-Tech California, Mr. Sam Lee, and Mr. Eric Shin. Through the litigation, XTend seeks to compel the defendants to perform their obligations under an Asset Purchase Agreement that the parties signed last December, including assigning all of the intellectual property associated with the BioHarp technology to XTend. The mediation proceeding is scheduled for September 30, 2010 at 9:30 am ET before the Honorable Sam Glasscock, III, Master in Chancery.

Mr. Paul D. Lisenby, the CEO of XTend, stated, “XTend Medical has secured a date from the Delaware Chancery Court for mediation between XTend and Sam Lee and the other defendants. It is our intention to present the facts of this case to Master Glasscock and to rely on his wisdom and expertise in complex business matters to assist the parties in resolving the case. The delays and disruption that the defendants have imposed on the company and its shareholders will hopefully finally come to an end through the mediation process. XTend feels very confident in the merits of its case against the defendants. Nevertheless, we look forward to putting this dispute behind us and moving forward with the development of the BioHarp.”

About XTend Medical

XTend Medical Corporation is a company that specializes in the sale, manufacturing, and distribution of the latest in medical devices and telemedicine solutions for the healthcare industry. The company is dedicated to insuring that the products and services that it offers to healthcare organizations, third-world countries, and physician groups are at the forefront of medical technology. For further information, please contact the company at [email protected] or visit its website at www.bioharpunius.com.

Forward-Looking Statements

This press release may contain forward-looking statements covered within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions, and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words “plan,” “expect,” “believe,” and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets.

CHICAGO, IL–(Marketwire – August 19, 2010) –  The National Council of State Boards of Nursing (NCSBN^®)(www.ncsbn.org) recognized its dedicated and exceptional membership and guests at its annual awards ceremony on Thursday, Aug. 12, 2010. This ceremony was part of the NCSBN Annual Meeting and Delegate Assembly held in Portland, Ore., Aug. 11 -13, 2010.

Specific award recipients include:
Ann L. O’Sullivan, PhD, MSN, CRNP, CPNP, FAAN, board president, Pennsylvania State Board of Nursing, received the Meritorious Service Award, which is presented to a board or staff member of a member board for positive impact and significant contributions to the purposes of NCSBN.

Cathy Giessel, MS, RN, ANP, FAANP, recent past board chair, Alaska Board of Nursing, received the Exceptional Leadership Award, which is bestowed to an individual who has served as president of a member board and has made significant contributions to NCSBN in that role.

Sue Tedford, MNSc, RN, CNS, APN, board staff, Arkansas State Board of Nursing, and Valerie Smith, MS, RN, FRE, board staff, Arizona State Board of Nursing, each received the Exceptional Contribution Award, which is given for significant contribution by a board of nursing staff member who does not serve as an executive officer or a board member who is not the current board president.

The Texas Board of Nursing was awarded the Regulatory Achievement Award that recognizes the member board that has made an identifiable, significant contribution to the purpose of NCSBN in promoting public policy related to the safe and effective practice of nursing in the interest of public welfare.

In addition, service awards were given to the following executive officers of boards of nursing:

Five Years
Toaga Seumalo, MS, RN, executive secretary, American Samoa Health Services
Charlotte Beason, EdD, RN, NEA, executive director, Kentucky Board of Nursing
Rula Harb, MS, RN, executive director, Massachusetts Board of Registration in Nursing
Betsy Houchen, JD, MS, RN, executive director, Ohio Board of Nursing

10 Years
Barbara Zittel, PhD, RN, executive secretary, New York State Board of Nursing
Claire Doody Glaviano, MN, RN, executive director, Louisiana State Board of Practical Nurse Examiners

15 Years
Joey Ridenour, MN, RN, FAAN, executive director, Arizona State Board of Nursing
Laura Skidmore Rhodes, MSN, RN, executive director, West Virginia Board of Examiners for Registered Professional Nurses
Kathy Thomas, MN, RN, executive director, Texas Board of Nursing

25 Years
Libby Lund, MSN, RN, executive director, Tennessee State Board of Nursing

The following boards of nursing are celebrating 100 years of nursing regulation in 2010:
South Carolina State Board of Nursing
Massachusetts Board of Registration in Nursing

The National Council of State Boards of Nursing (NCSBN) is a not-for-profit organization whose members include the boards of nursing in the 50 states, the District of Columbia and four U.S. territories — American Samoa, Guam, Northern Mariana Islands and the Virgin Islands. There are also seven associate members.

The statements and opinions expressed are those of NCSBN and not the individual member state or territorial boards of nursing.

Mission: NCSBN provides education, service and research through collaborative leadership to promote regulatory excellence for patient safety and public protection.

National Council of State Boards of Nursing, Inc.
111 E. Wacker Drive, Suite 2900
Chicago, IL 60601-4277

CHICAGO, IL–(Marketwire – August 19, 2010) –  The National Council of State Boards of Nursing (NCSBN^®)(www.ncsbn.org) elected new members to its Board of Directors during its 2010 Delegate Assembly. Those elected include:

President
Myra A. Broadway, JD, MS, RN, executive director, Maine State Board of Nursing, was previously vice president from 2008-2010 and Area IV director from 2003-2007. During her tenure, Broadway was the board liaison to the Disciplinary Resources, Finance, Examination and Commitment to Ongoing Regulatory Excellence Committees and the Member Board Leadership Development Task Force. She also served as a director-at-large from 2000-2002 when she was board liaison to Commitment to Excellence and Model Rules Subcommittee. Broadway holds a J.D. from Franklin Pierce Law Center, an M.S.B.A. from Boston University, Metropolitan College, an M.S. from the University of Colorado and a B.S. from Hunter College in New York. Broadway served in the United States Air Force Nurse Corps on both active duty and in the Reserves, retiring as a colonel in 1998.

Vice President
Shirley Brekken, MS, RN, executive director, Minnesota Board of Nursing, previously served as Area II Director from 1990-1992. She has served on 12 NCSBN committees/task forces as either chair or committee member. Brekken is a partner in several Minnesota efforts related to patient safety and advancing a “Just Culture” (Minnesota Alliance for Patient Safety); nursing excellence (Stratis Health Institute); nursing workforce (Minnesota Center for Nursing BOD, Minnesota Colleagues in Caring and Minnesota Health Education and Industry Partnership Steering Committees); technology (Governor’s e-Licensing Steering Committee); and nursing leadership (Minnesota Organization of Leaders in Nursing).

Treasurer
Randall Hudspeth, MS, APRN-CNS/NP, FRE, FAANP, board member, Idaho Board of Nursing, was reelected treasurer. He previously served as a director-at-large. Hudspeth is an inducted Fellow of the NCSBN Institute of Regulatory Excellence, and has served two terms as board chairman and two terms as vice chairman of the Idaho Board of Nursing during his seven-year tenure as the advanced practice registered nurse representative.

Directors-at-Large
Julio Santiago, MSN, RN, CCRN, has served as director-at-large since 2009 and was the board liaison to the Nursys® Committee. He is the chairperson of the Illinois Board of Nursing and the member representing clinical practice since March 2005. Since 1990, Santiago has had extensive experience in nursing, including critical care, behavioral health and in administrative positions.

Katherine Thomas, MS, RN, executive director, Texas Board of Nursing, was reelected as director-at-large, having served her first term from 2008-2010. She previously served as the NCSBN representative to the APRN Joint Dialogue Group. She was also on several NCSBN Advanced Nursing Practice committees, chairing the APRN Advisory Committee from 1995-2007.

NCSBN delegates also elected members of the Leadership Succession Committee (LSC):

Area II Member
Lisa Emrich, MSN, RN, manager, Practice, Education and Administration, Ohio Board of Nursing

Area III Member
Brenda McDougal, associate executive director — Operations, North Carolina Board of Nursing

Area IV Member
Sue Petula, PhD, MSN, RN, NEA-BC, nursing education advisor, Pennsylvania State Board of Nursing

Additionally, the NCSBN Board of Directors appointed Louise Bailey, MEd, RN, interim executive director, California Board of Registered Nursing, to serve as the Area I Member on the LSC.

The National Council of State Boards of Nursing (NCSBN) is a not-for-profit organization whose members include the boards of nursing in the 50 states, the District of Columbia and four U.S. territories — American Samoa, Guam, Northern Mariana Islands and the Virgin Islands. There are also seven associate members.

The statements and opinions expressed are those of NCSBN and not the individual member state or territorial boards of nursing.

Mission: NCSBN provides education, service and research through collaborative leadership to promote regulatory excellence for patient safety and public protection.

National Council of State Boards of Nursing, Inc.
111 E. Wacker Drive, Suite 2900
Chicago, IL 60601-4277

CHICAGO, IL–(Marketwire – August 19, 2010) –  The National Council of State Boards of Nursing (NCSBN^®) (www.ncsbn.org) inducted its fourth group of Fellows of the NCSBN Regulatory Excellence Institute on Aug. 12, 2010, during the NCSBN Annual Meeting and Delegate Assembly held in Portland, Ore. The Institute of Regulatory Excellence (IRE) began in 2004 with the purpose of providing boards of nursing with high quality regulatory education, expanding the body of knowledge related to regulation through research and scholarly work, developing the capacity of regulators to become expert leaders, and developing a network of regulators who collaborate to improve regulatory practices and outcomes.

The 2010 class of Fellows includes:

Susan K. Odom, PhD, RN Chair, Idaho Board of Nursing

William E. Spooner, Regulatory Supervisor Consultant, Florida Board of Nursing

The IRE is a series of educational conferences held annually with the following topics rotated on a four-year cycle: Public Protection/Role Development of Nursing Regulators, Discipline, Competency and Evaluation/Remediation Strategies, and Organizational Structure/Behavior.

The IRE Fellowship Program is a four-year comprehensive educational and professional development program designed for current regulators who want to enhance their knowledge of and leadership in nursing regulation. The program includes experiences in analyzing issues involving public policy and regulation, strategic planning, patient safety and communication. It also requires the application of evidence-based concepts in decision making and leadership.

Individuals who complete the Fellowship Program requirements are called a Fellow of the NCSBN Regulatory Excellence Institute (FRE) and are entitled to use the initials FRE after their name in recognition of their accomplishment.

The National Council of State Boards of Nursing (NCSBN) is a not-for-profit organization whose members include the boards of nursing in the 50 states, the District of Columbia and four U.S. territories — American Samoa, Guam, Northern Mariana Islands and the Virgin Islands. There are also seven associate members.

Mission: NCSBN provides education, service and research through collaborative leadership to promote regulatory excellence for patient safety and public protection.

The statements and opinions expressed are those of NCSBN and not the individual member state or territorial boards of nursing.

National Council of State Boards of Nursing, Inc.
111 E. Wacker Drive, Suite 2900
Chicago, IL 60601-4277

IRVING, TX–(Marketwire – August 19, 2010) –  WaveTwo, LLC and its Health IT 2015 division have been chosen by the North Texas Regional Extension Center (NTREC) to be an official agent to all Physicians in North Texas. As an official agent, WaveTwo will assist North Texas physicians in implementing electronic health records (EHR) and qualifying for incentive payments from the Centers for Medicare and Medicaid Services (CMS).

NTREC was recently awarded an $8.5 million grant from the Office of the National Coordinator for Health Information Technology (ONC) to assist primary care providers, in a 41 county North Texas region, to adopt and achieve Meaningful Use of electronic health records (EHR). NTREC is the region’s designated federal expert in Meaningful Use standards as promulgated by the Office of National Coordinator for Health Information Technology (ONC). WaveTwo is now NTREC’s official agent to these physicians.

WaveTwo services to physicians will include education, technical EHR assistance, guidance in meeting Meaningful Use criteria and obtaining CMS incentive payments. WaveTwo’s goal is to assist 1,498 physicians in reaching Meaningful Use by April 2012. Physicians who do so will then qualify for incentive payments up to $44,000 per eligible professional.

“We are very proud to be chosen to perform this important work for Physicians and NTREC,” said John Arnott Sr., Managing Partner for WaveTwo. “Our entire Health IT 2015 division’s focus — for the next two years — will be to lead each of the applicants to ‘meaningful use’ and qualify for all of the incentive funds available to them.”

About WaveTwo. WaveTwo is a leading Texas provider of professional services focused on solving business problems through technology and processes, with a strong focus on healthcare clients. Founded in 2002 , WaveTwo provides Business Intelligence, Enterprise Systems, Managed IT Services, and CIO On-Demand Services. Its Health IT 2015 division provides vendor-agnostic healthcare technology planning and implementation services. For more information, contact WaveTwo at 214-271-0033 or visit www.wavetwo.com and www.healthIT2015.com.

About North Texas Regional Extension Center. The North Texas Regional Extension Center (NTREC) was established as a program by the Dallas Fort Worth Hospital Council Education and Research Foundation (DFWHC-ERF) in April 2010. Its primary purpose is to promote the adoption and meaningful use of Electronic Health Records (EHR) in the practices of priority primary care providers.

Click here to see all recent news from this company

CHICAGO, IL–(Marketwire – August 19, 2010) –  Sullivan, Cotter and Associates, Inc., a healthcare compensation and human resource management consulting firm, is in the process of publishing the 2010 Survey of Manager and Executive Compensation in Hospitals and Health Systems now in its eighteenth edition. This year, 288 health systems and 906 hospitals participated in the survey, a respected industry resource. Participants submitted data for nearly 22,000 executives and managers between February and June 2010. SullivanCotter’s national healthcare survey provides not only cash compensation data for executive and management jobs in hospitals and health systems, but also data on pay practices, annual incentive plans, supplemental benefits, perquisites, nonqualified retirement plans, and much more. Modern Healthcare, the nation’s leading healthcare weekly magazine, released portions of Sullivan, Cotter and Associates survey in its annual issue on healthcare executive compensation this week. 

When comparing the data from 211 health systems and 642 hospitals that participated in both 2009 and 2010, base salaries increased on average 2.9% and 2.6%, respectively. These increases are consistent with the projected 2010 salary increase budgets, which were 3.2% for health systems and 2.8% for hospitals. 

“Salary increases continue to be moderate,” noted SullivanCotter Managing Principal Tom Pavlik. “We continue to see this moderation in the reported executive and manager projected salary increase budgets for next year; the preliminary data indicate budgets of 3.0% for health systems and 2.7% for hospitals. However, we did see around a 5.5% increase in total cash compensation levels.”

The 2010 Survey of Manager and Executive Compensation in Hospitals and Health Systems will be available for purchase in September. The cost to healthcare organizations agreeing to participate in next year’s survey is $950; for those not wishing to participate, the cost is $1,950. The survey is also available to non-healthcare organizations. To order a copy, please visit the Sullivan, Cotter and Associates website at www.sullivancotter.com or contact Mary Kowalczyk, survey manager, at 312/739-2000, toll-free at 888/739-7039, or email [email protected].

Sullivan, Cotter and Associates, Inc. specializes in the development and implementation of strategic total compensation and reward programs for the healthcare industry. Since 1992, SullivanCotter has worked closely with healthcare organization executives, boards, and compensation committees to devise innovative compensation solutions that attract and retain leadership talent while satisfying not-for-profit missions and regulatory requirements. A leader in independent consulting, benchmarking, trends, and analyses, SullivanCotter has developed the most widely recognized physician and executive compensation surveys in the United States. SullivanCotter has offices in Atlanta, Boston, Chicago, Dallas, Detroit, Minneapolis, New York City, Parsippany, San Francisco, Washington DC, and Westport. For more information, visit www.sullivancotter.com or call 888-739-7039.

Click here to see all recent news from this company

HOUSTON, TX–(Marketwire – August 19, 2010) –  Nothing is worse than needing a good night’s sleep, but waking in the middle of the night with leg pain and movement. Houston Chiropractor Dr. Karen Thomason of 1960 West Chiropractic Center notes that many patients suffer from Restless leg syndrome (RLS), the irresistible urge of an individual to move their legs.

Restless leg syndrome can begin at any age, but it is more common in older patients and women, who are more likely to develop this condition than men. The symptoms include cramping, tingling, aching and a “crawling” sensation in the legs, thighs and calves. RLS affects most people at night, and lying down and trying to relax activates the symptoms. As a result, sleep is affected and exhaustion often ensues.

While many turn to prescription medications, Dr. Thomason notes that chiropractic treatment can alleviate many of the unpleasant symptoms of RLS and allow patients to have an uninterrupted night’s sleep, which is essential for good health.

“The symptoms of RLS are very uncomfortable and difficult to withstand,” said Dr. Thomason. “We have helped many patients with treatments to release the tension in the legs and calves. Chiropractic sessions have been effective in alleviating pain naturally, without the use of drugs.”

RLS affects as many as 12 million Americans and Houston chiropractic care is available through 1960 West Chiropractic to enable individuals suffering from RLS, or many other physical conditions such as back pain, neck pain, headaches, leg numbness and many more physical ailments, to heal naturally.

About 1960 West Chiropractic Center
1960 West Chiropractic Center was founded by native Houstonian, Dr. Karen S. Thomason. The practice, specializing in Chiropractic Care, has proven results in realigning or resetting the body to proper balance. Chiropractic treatment has been effective for patients in recovery from job injuries, accidents, sports injuries and chronic pain. Services include Chiropractic care, massage therapy, X-Ray Services and onsite active rehabilitation. 1960 West Chiropractic is a member of the Texas Chiropractic Association and the American Chiropractic Association.

Click here to see all recent news from this company

WASHINGTON, DC–(Marketwire – August 19, 2010) –  The National Risk Retention Association will open its 22^nd annual conference October 5 with an all day session devoted to issues affecting healthcare Risk Retention Groups, Sanford “Sandy” Elsass, Conference Chairman and President/CEO of Uni-Ter Underwriting Management Corporation, announced. Gloria Everett, President/CEO of MedAmerica Mutual Risk Retention Group, is Chair of the Healthcare Pre-Conference.

“Two thirds of the 247 RRGs in business today provide liability insurance to healthcare organizations so the pre-conference program will cover issues important to this sector of the industry,” Elsass said.

NRRA is the national trade association that represents the interests of Risk Retention Groups — insurance companies authorized by the federal Liability Risk Retention Act of 1986 to operate nationally without additional regulation when licensed in a single state. RRGs generated more than $2.5 billion of premiums in 2009.

“The pre-conference will provide healthcare RRG CEOs, captive managers, and related professional services firms information essential to successful operations in today’s rapidly changing healthcare environment,” Everett said. The program will feature topics ranging from State reporting requirements and tax issues to how to compete in a soft market.

Program topics, expert speakers, and panelists include:

Historical Perspectives on the Importance and Impact of Expert Witnesses: Dr. William Luria, President, Lancet Indemnity RRG; Kirsten Ullman, Managing Partner Southeast Region, Lewis Brisbois Bisgaard & Smith, LLP.

Gauging the Results of Proactive Claims Portfolio Management: John Spinella, Spinella & Associates, Inc.

Insurance Claims Coverage Issues: Moderator, Kimberley Wynkoop, Ophthalmic Mutual Insurance Co. RRG; Panelists: Jeffrey Johnson, attorney, Primmer Piper Eggleston & Cramer; Myra Barsoum Stockett, Reminger Attorneys at Law.

Reinsurance Placement: Moderator, Ken Barrett, Besso Re, Ltd.; Panelists: Jo McCann, Beazley Furlonge, Ltd.; Paul Western, Amlin Underwriting, Ltd.

Can RRGs Compete with Commercial Carriers in a Soft Market: Robert Bates, Continuing Care RRG;Gloria Everett, President, MedAmerica Mutual RRG; Sanford “Sandy” Elsass, President, The Uni-Ter Group.

Medical Professional Liability Claims Reporting: Michael Stinson, Physician Insurers Association of America and Kimberley Wynkoop, Ophthalmic Mutual Insurance Co. RRG

Trends in Losses and Reserves — Hard Markets Follow Drops in Surplus: Moderator, Joseph Petrelli, President/CEO, Demotech, Inc.; Panelists: Kevin Bingham, Deloitte Consulting, LLP; Richard Lord, Milliman.

Investment Strategies for Long-Tail Liability Reserves: Moderator, Patrick Tuohy, Senior Vice President, Prime Advisors, Inc.; Panelists: Steven Lee, Managing Director, Logan Capital Management; Christopher Mertes, CFO, MedAmerica Mutual RRG.

The conference will be held at The Ritz Carlton Pentagon City Hotel, Washington, DC. Attendees can register online and the full Conference schedule is available on the web site, www.riskretention.org.

Click here to see all recent news from this company

KANSAS CITY, MO–(Marketwire – August 18, 2010) –  Xact Data Discovery (XDD) is excited to announce the completion of HIPAA certification in its national offices. The Health Insurance Portability and Accountability Act (HIPAA) of 1996 was enacted to ensure that individuals would be able to maintain their health insurance between jobs as well as to ensure the security and confidentiality of patient information/data.

Xact Data Discovery’s HIPAA certification process included development of new policies surrounding the handling of client information. As a Business Associate, XDD is compliant with the regulations in all areas of HIPAA and will conduct annual risk assessments as well as associate training to ensure that all electronic personal health information (EPHI) and personal health information (PHI) is protected. XDD’s Director of Human Resources, Katie Ervin will administer the program. Ervin has nearly 13 years experience working with HIPAA achieving certification as a Certified HIPAA Professional (CHP).

“While we have always protected all information we process for clients, this certification just takes it to a higher level,” said Robert Polus, President and CEO of XDD. “We take the extra steps above and beyond to be sure we are compliant. This allows us to work with those covered entities that must follow HIPAA such as hospitals, insurance carriers, and pharmacies to name a few.”

Xact Data Discovery is a national Data Discovery and Management company that provides streamlined Forensic, Electronic Discovery, Data Hosting, Data Management, Imaging/Coding and Paper Discovery Services to law firms, corporations and government agencies. At Xact Data Discovery, communication is everything — because clients need to know where their data is throughout the entire process, as well as understand the valuable information and knowledge they can attain from it.

Via a personable “human-interface” approach, Xact Data Discovery streamlines the complex communication process between people, technology and data by orchestrating proactive, clear, consistent and relentless communication throughout all project phases. Xact Data Discovery helps clients and their customers find, produce, use and understand information crucial to their organizations.

IRVINE, CA–(Marketwire – August 18, 2010) –  Sun Healthcare Group, Inc. (NASDAQ: SUNH) today announced the closing of its previously announced underwritten public offering of 26,750,000 shares of its common stock, as well as the closing of the underwriters’ over-allotment option to purchase an additional 4,012,500 shares of common stock. The net proceeds of the offering, after giving effect to the issuance and sale of all 30,762,500 shares of common stock at a price to the public of $7.75 per share, were approximately $224.8 million after deducting the underwriting discount and estimated offering expenses. Sun intends to use the net proceeds from the offering to repay a portion of the outstanding term loans under its existing credit facility.

Richard K. Matros, Sun’s chairman and chief executive officer, commented, “We are pleased with the response to the equity offering, which provides us the ability to pay down a significant portion of our indebtedness. Following the success of this offering, we are looking forward to completion of the proposed separation of our operating businesses and our real estate assets.”

This press release does not constitute an offer to sell or a solicitation of any offer to buy the shares of Sun’s common stock described herein, nor shall there be any offer, solicitation or sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful.

The prospectus supplement and the related prospectus relating to the offering may be obtained by written request to Jefferies & Company, Inc., Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY 10022; by telephone at (877) 547-6340; or by e-mail at [email protected]; or Credit Suisse Securities (USA) LLC, Attention: Credit Suisse Prospectus Department, One Madison Avenue, New York, NY 10010 or by telephone at (800) 221-1037.

About Sun Healthcare Group, Inc.

Sun Healthcare Group, Inc.’s (NASDAQ: SUNH) subsidiaries provide nursing, rehabilitative and related specialty healthcare services principally to the senior population in the United States. Sun’s core business is providing, through its subsidiaries, inpatient services, primarily through 166 skilled nursing centers, 16 combined skilled nursing, assisted and independent living centers, 10 assisted living centers, two independent living centers and eight mental health centers. On a consolidated basis, Sun has annual revenues of $1.9 billion and approximately 30,000 employees in 46 states. At June 30, 2010, SunBridge centers had 23,209 licensed beds located in 25 states, of which 22,427 were available for occupancy. Sun also provides rehabilitation therapy services to affiliated and non-affiliated centers through its SunDance subsidiary, medical staffing services through its CareerStaff Unlimited subsidiary and hospice services through its SolAmor subsidiary. 

Forward-Looking Statements

Statements made in this release that are not historical facts are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995) that involve risks and uncertainties and are subject to change at any time. These forward-looking statements may include, but are not limited to, statements containing words such as “anticipate,” “believe,” “plan,” “estimate,” “expect,” “hope,” “intend,” “may” and similar expressions. Factors that could cause actual results to differ are identified in the public filings made by the Company with the Securities and Exchange Commission and include our ability to complete the separation of our operating businesses and our real estate assets. More information on factors that could affect our business and financial results are included in our public filings made with the Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, copies of which are available on Sun’s web site, www.sunh.com. The forward-looking statements involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond our control. We caution investors that any forward-looking statements made by Sun are not guarantees of future performance. We disclaim any obligation to update any such factors or to announce publicly the results of any revisions to any of the forward-looking statements to reflect future events or developments.

ALEXANDRIA, VA–(Marketwire – August 18, 2010) –  Alpha Kappa Alpha Sorority (AKA) is joining forces with the American Diabetes Association‘s African American Initiatives — known as Live EMPOWERED — to stop diabetes in the African American Community. The collaboration is driven by the reality that African Americans are greatly affected by diabetes; they are 1.8 times more likely to have type 2 diabetes than non-Latino whites. 

To combat this epidemic, beginning in the spring of 2011, the AKAs will designate 10 undergraduate chapters at Historically Black Colleges and Universities to lead diabetes workshops and activities. Through this initiative, the Sorority hopes to spread the message about how to prevent diabetes and provide tools to assist those with diabetes to live a productive life with this disease. In announcing the partnership, AKA’s newly installed international president Attorney Carolyn House Stewart stated, “Alpha Kappa Alpha Sorority’s goal is to help our community recognize the risks of this disease, its many complications and treatment options. We will host forums that will heighten awareness and offer prevention strategies to help eliminate this deadly disease that shortens lives and impacts the quality of life of many African Americans of all ages.” 

AKA and the American Diabetes Association share common priorities and interests in reaching African Americans, students and other key constituents with important awareness messaging relating to diabetes, including risk factors, prevention strategies, warning signs, and management of the disease.

Both organizations have unique competencies to address these issues and believe that there will be a greater opportunity to promote mutual goals through multiple communications channels. This collaboration is especially significant, because African-American women are at a greater risk for the number one complication of diabetes: heart disease.

“By getting this powerful group of women to join us in our movement to Stop Diabetes, we have the potential to change many lives and communities,” said Earnestine Walker, Director of Community Outreach at the American Diabetes Association.

About Alpha Kappa Alpha Sorority:
Founded in 1908, on the campus of Howard University in Washington, DC, Alpha Kappa Alpha (AKA) is the oldest Greek-lettered organization established by African-American college-educated women. AKA’s membership is comprised of 260,000 distinguished women in graduate and undergraduate chapters in the United States and abroad who boast excellent academic records, proven leadership skills, and who are involved in the global community through advocacy and service. Attorney Carolyn House Stewart is the 28th International President and will serve from 2010 – 2014. Her administration’s theme is “Global Leadership Through Timeless Service.”

About the American Diabetes Association:
The American Diabetes Association is leading the fight to stop diabetes and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, our mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit www.diabetes.org. Information from both these sources is available in English and Spanish.

Click here to see all recent news from this company

CHICAGO, IL–(Marketwire – August 18, 2010) –  The National Council of State Boards of Nursing (NCSBN^® )(www.ncsbn.org) sets an ambitious research agenda designed to advance the science of nursing regulation. NCSBN recently added to its body of research with the publication of four new briefs titled, Report of Findings from the 2009 TUNING Analysis: A Comparison of U.S. and International Nursing Educational Competencies; Report of Findings from the 2009 Job Analysis of Nurse Aides Employed in Nursing Homes/Long-term Care, Hospitals/Acute Care and Community/Home Health Care Settings; Report of Findings from the Comparison of Entry-level Registered Nurses in the U.S. and Ontario, Canada; and Report of Findings from the Comparison of Entry-level Registered Nurses in the U.S. and British Columbia, Canada.

Report of Findings from the 2009 TUNING Analysis: A Comparison of U.S. and International Nursing Educational Competencies is an account of a new initiative that seeks to understand the role of nurses and nursing education from an international perspective. The goal of this study was to evaluate the consistency of nursing educational competencies globally.

Report of Findings from the 2009 Job Analysis of Nurse Aides Employed in Nursing Homes/Long-term Care, Hospitals/Acute Care and Community/Home Health Care Settings reports the importance ratings for activities performed by certified entry-level nurse aides/nursing assistants (NAs) employed in various health care settings. The findings from this study are used to evaluate the validity of the test plan, content outline and examination questions for the nurse aide certification examination.

Report of Findings from the Comparison of Entry-level Registered Nurses in the U.S. and Ontario, Canada compares entry-level nursing activities of U.S. registered nurses with a cohort from Ontario, Canada. The College of Nurses of Ontario (CNO) collaborated with NCSBN on this initiative.

Report of Findings from the Comparison of Entry-level Registered Nurses in the U.S. and British Columbia, Canada compares entry-level nursing activities of U.S. registered nurses with a cohort from British Columbia, Canada. The College of Registered Nurses of British Columbia (CRNBC) collaborated with NCSBN on this initiative.

NCSBN offers 48 volumes of research that include practice analyses and national surveys of the profession, covering topics such as nursing education and professional issues. Previously only available for purchase through NCSBN, these research briefs are now downloadable free of charge by visiting www.ncsbn.org.

The National Council of State Boards of Nursing (NCSBN^®) is a not-for-profit organization whose members include the boards of nursing in the 50 states, the District of Columbia and four U.S. territories — American Samoa, Guam, Northern Mariana Islands and the Virgin Islands. There are also seven associate members.

Mission: NCSBN provides education, service and research through collaborative leadership to promote regulatory excellence for patient safety and public protection.

The statements and opinions expressed are those of NCSBN and not the individual member state or territorial boards of nursing.

National Council of State Boards of Nursing, Inc.
111 E. Wacker Drive, Suite 2900
Chicago, IL 60601-4277

CHICAGO, IL–(Marketwire – August 18, 2010) –  The National Council of State Boards of Nursing (NCSBN^® )(www.ncsbn.org) is raising the passing standard for the National Nurse Aide Assessment Program (NNAAP^®) Written and Oral Examination. The new passing standard is 1.57 logits, 0.24 logits higher than the current standard of 1.33 logits. The new passing standard will take effect on Jan. 1, 2011.

The updated passing standard was set during a standard-setting workshop, held April 21-22, 2010. A panel of 10 registered nurses (RNs) representing a variety of practice settings across the country volunteered as subject matter experts (SMEs) for the workshop. After consideration of all available information, the SMEs determined that safe and effective certified entry-level nurse aide/nursing assistant (NA) work requires a greater level of knowledge, skills and abilities than was required in 2006, when the current standard was implemented. The passing standard was increased in response to changes in U.S. health care delivery that have resulted in a wider range of knowledge required by certified entry-level NAs to perform their authorized duties. The SMEs used multiple sources of information, including the results of a criterion-reference standard-setting workshop, to guide their evaluation and discussion regarding the change in passing standard.

In accordance with contractual agreements with client jurisdictions, NCSBN is responsible for evaluating the passing standard of NNAAP every five years to protect the public by assuring minimal competence for entry-level certified NAs. NCSBN coordinates the passing standard analysis with the five-year cycle of test plan evaluation. This five-year cycle was developed to keep the test plan and passing standard current and reflective of entry-level work expectations for certified NAs. The 2011 NNAAP^® Examination Test Plan/Test Specifications Report is available to download free of charge at www.ncsbn.org/2011_NNAAP_Test_Plan-Test_Specifications_Report_links.pdf.

The National Council of State Boards of Nursing (NCSBN^®) is a not-for-profit organization whose members include the boards of nursing in the 50 states, the District of Columbia and four U.S. territories — American Samoa, Guam, Northern Mariana Islands and the Virgin Islands. There are also seven associate members.

Mission: NCSBN provides education, service and research through collaborative leadership to promote regulatory excellence for patient safety and public protection.

The statements and opinions expressed are those of NCSBN and not the individual member state or territorial boards of nursing.

National Council of State Boards of Nursing, Inc.
111 E. Wacker Drive, Suite 2900
Chicago, IL 60601-4277

CHICAGO, IL–(Marketwire – August 18, 2010) – With health insurance all over the news and a main topic in politics, it’s more important than ever to get the right coverage for the future. Health insurance can be a complicated service for those that are not well versed in the industry. It can be difficult for individuals and businesses to find the right plan. In many cases consumers and companies either have a plan that does not fit their needs or may be paying too much. It is always a good idea to research and talk with professionals about their health insurance coverage in order to make sure they are getting the coverage they need.

ChicagoGroupHealthInsurance.net connects individuals and consumers with a group health insurance agent, where they can speak with an insurance agent about their prospective plan. This can open up new possibilities for Illinois residents seeking health insurance.

For small business owners group health insurance has various cost and tax incentives for both them and their employees. These benefits can vary depending on the individual and business owner’s situation. Connecting with a professional can help them assess their situation.

ChicagoGroupInsurance.net offers a free consultation with a group health insurance representative which can be taken advantage of at their company website www.ChicagoGroupInsurance.net/

Click here to see all recent news from this company

YPSILANTI, MI–(Marketwire – August 18, 2010) –  The Hemophilia Foundation of Michigan is pleased to announce: Walkin’ on the Wild Side for Hemophilia, its second annual fundraising walk at the Detroit Zoo. Walkin’ on the Wild Side for Hemophilia takes place on Sunday, August 29, 2010. Join hundreds of walkers to raise money to support the many programs of the HFM while taking in the beauty of the Detroit Zoo.

Form a team, walk by yourself, or be a virtual walker — support the cause without actually walking! Adults, children, families, co-workers, and friends; people of all ages are encouraged to join. Registration (with breakfast) begins at 7:45 am; the 2.1 mile Walk kicks off at 8:45 am. There will be entertainment, prizes, and fun for all ages. 93.9 The River will be there with music and giveaways. Everyone is invited to stay and enjoy a day at the zoo after the Walk.

In 2009, Walkin’ on the Wild Side for Hemophilia raised over $100,000 — just about the annual cost of treatment for a person with hemophilia; had 64 walk teams, 770 walkers and 50 volunteers. This year, HFM is aiming to increase the numbers in all those categories!

NEW for 2010: For every contribution of $100 made by Wednesday, August 25th, the individual donor’s name will be put in a drawing for three exciting prizes! These prizes include: A 50″ plasma TV, an Apple iPad, and an Amazon Kindle. Winners will be drawn immediately after the Walk ends at 10:30 am on the Grassy Knoll at the Detroit Zoo. Winners need NOT be present.

For a minimum donation of $15, an individual will receive admission to the event, refreshments, a Walk t-shirt, and the rest of the day at the zoo. There is no admission charge for children under 2 years of age. Please keep in mind this event is a FUNDRAISER — we need everyone’s help to exceed last year’s amount of $101,000 to support services for individuals with bleeding disorders and their families.

Will you be Walkin’ on the Wild Side for Hemophilia? To form a team online or donate to a team, go to www.hfmich.org or contact Dawn at 1-800-482-3041.

Click here to see all recent news from this company

NATICK, MA–(Marketwire – August 18, 2010) –  To provide healthcare IT professionals with continuing education, purchase planning assistance and peer networking around issues facing hospitals and healthcare systems, Interbit Data has partnered with Iatric Systems, Inc. and Array Software to form the Healthcare IT Solutions Exchange (HITSE). HITSE will host an ongoing series of healthcare IT conferences starting this fall with HITSE New England 2010, to be held October 26 and 27 at the Doubletree Hotel, Westborough, MA.

“The primary intention of HITSE is to fill a void left by other healthcare IT conferences and user associations,” states Arthur Young, president of Interbit Data. “Other conferences have missed opportunities to extend the educational process on certain topics and allow vendors to convey beneficial, user-valued product solutions information outside of the exhibit area, which is often disregarded by attendees. HITSE was designed to provide a setting in which users and vendors can communicate and collaborate in order to develop and implement solutions that improve healthcare.” 

HITSE’s initial healthcare IT conferences will include educational tracks on Computerized Physician Order Entry (CPOE), MEDITECH 6.0, Meaningful Use and Revenue Cycle Improvement, with sessions on industry updates, technology and compliance, and panel discussions featuring industry experts. Vendor sessions will offer case studies, product demonstrations and user group discussions. Each conference will include the Solutions Exchange, which will bring together hospital information systems users and vendors to discuss the selection, planning, implementation and support of healthcare IT solutions. The HITSE conference agenda will continuously evolve according to emerging trends and healthcare IT user needs.

All members of the healthcare IT community can participate and benefit from HITSE, including CIOs, IT managers, IT department managers, IT staff and consultants, as well as IT vendors. Vendors can participate in HITSE healthcare IT conferences by exhibiting, attending or serving as a sponsor, as well as conducting vendor sessions.

More information on HITSE and the October New England conference can be found at http://www.hitse.org.

About Interbit Data
Founded in 1997 and named to the 2009 Inc. 5000 list of America’s fastest growing companies, Interbit Data helps healthcare organizations deliver better, more consistent patient care with secure, reliable and cost-effective software solutions that improve operational efficiency. The company’s information distribution products deliver information securely over the Internet in multiple formats, such as fax, print, email, encrypted file or HL7 message format, and integrate it easily into physicians’ practice EMRs. Interbit Data’s business continuance products give healthcare providers continuous access to patient data in the event of a network or system outage. Interbit Data products are used by more than 650 MEDITECH^® customers worldwide. For more information about Interbit Data and its NetSolutions products, visit the company Website at www.interbitdata.com.

Click here to see all recent news from this company

TAMPA, FL–(Marketwire – August 18, 2010) –  Sage North America Healthcare Division, which provides practice management software and services to approximately 80,000 physicians in North America, today announced that Good Neighbor Community Health Center, based in Columbus, Neb., has selected Sage Intergy CHC as its electronic health records system. Sage products are used by approximately 25 percent of all Community Health Centers throughout the U.S. to manage their practices.

Sage Intergy CHC is an integrated, scalable practice management and electronic health records system, specifically designed for community health centers. Patient data can be shared or isolated across practices and locations, allowing access from anywhere for clinical, financial and administrative management.

Sage Intergy easily tracks the details of a patient’s clinical history, shares and manages clinical information and combines complex medical practice functions into easy-to-navigate menus and buttons, and fully integrates with EDI services to manage payments, Intergy Practice Portal to manage secure patient communications, Sage Intergy RIS to manage medical images and Sage Intergy Practice Analytics to report on practice efficiency and patient trends that can help to improve patient care.

“Good Neighbor Community Health Center is a data-driven clinic and we feel the analytic capabilities of the Sage Intergy system will allow us to best care for our patients while helping us track key health trends in the population we serve,” said Becky Rayman, Executive Director of Good Neighbor Community Health Center.

Additionally, Rayman’s experience with Sage’s customer support won her over. “Sage continues to provide us with great responses, and great customer service. We’re not a networked clinic, it’s us here alone, and if it were not for Sage and their support, we might not be able to implement the EHR,” Rayman added.

Good Neighbor Community Health Center is a multi-specialty clinic offering medical, pediatric, dental and mental health services, with seven physicians serving more than 8,000 patients annually. Sage Intergy CHC enables Good Neighbor Community Health Center to customize its system to adapt to existing workflows throughout the clinic and enables clinic staff to access the entire medical record online, in real time.

Currently, all patient records are paper based. Sage Intergy CHC will allow for a seamless transition to an electronic health record and propel the clinic closer to its goal of meeting the federally-backed meaningful use.

Sage has been providing ambulatory healthcare systems for almost 30 years, serving approximately 80,000 physicians in the United States with practice management, electronic health records, and other services to streamline patient care. 

View Sage Healthcare Division YouTube interviews.
View Sage Healthcare Division information.

About Good Neighbor Community Health Center
Good Neighbor Community Health Center works to increase access to primary preventive healthcare and to improve the health of the underserved and vulnerable populations. Since 1998, Good Neighbor Community Health Center has been providing primary care to anyone in the community who desires to visit our clinic.

About Sage North America
Sage North America is part of The Sage Group plc, a leading global supplier of business management software and services. Sage North America employs 4,000 people and supports 3.1 million small and midsized business customers including approximately 80,000 physicians. The Sage Group plc, formed in 1981, was floated on the London Stock Exchange in 1989 and now employs 13,100 people and supports 6.2 million customers worldwide. For more information, please visit the website at www.sagenorthamerica.com.

© 2010 Sage Software, Inc. All rights reserved. Sage, Sage Software, Sage logos and the Sage product and service names mentioned herein are registered trademarks or trademarks of Sage Software, Inc. or its affiliated entities. All other trademarks are the property of their respective owners.

VICTORIA, BRITISH COLUMBIA–(Marketwire – Aug. 18, 2010) – GrowthPoint Capital Corp. (“GrowthPoint”) is issuing this press release pursuant to the early warning requirements of applicable securities laws in Canada with respect to Vigil Health Solutions Inc. (“Vigil”).

Pursuant to a private agreement, on July 27, 2010, GrowthPoint acquired ownership of $100,000 in debt which is convertible into, subject to adjustment, 1,000,000 common shares of Vigil at a conversion price of $0.10 per common share, representing approximately 1.0% of Vigil’s outstanding common shares.

Following this transaction, in addition to the $100,000 in convertible debt which if converted would represent approximately 1.0% of Vigil’s outstanding common shares, GrowthPoint and its affiliates also hold 9,929,000 common shares representing approximately 9.9% of Vigil’s outstanding common shares; 650,000 Deferred Stock Units representing approximately 0.7% of Vigil’s outstanding common shares; and 744,000 Stock Options representing approximately 0.7% of Vigil’s outstanding common shares. In aggregate, assuming the full exercise and conversion of the aforementioned securities, GrowthPoint and its affiliates would hold approximately 12.3% of the issued and outstanding common shares of Vigil.

In addition to owning or exercising control over the Vigil securities through GrowthPoint Capital Corp., GrowthPoint acts jointly or in concert with Greg Peet and GrowthPoint Ventures (VCC) Corp.

GrowthPoint acquired these securities for investment purposes. GrowthPoint may, depending on market conditions and other factors as well as applicable securities laws, acquire additional securities of Vigil through the facilities of the TSX Venture Exchange, private agreements or otherwise. At the current time, however, GrowthPoint does not intend to acquire more than 19.99% of the outstanding common shares of Vigil (assuming full exercise or conversion of any securities of Vigil that GrowthPoint may acquire). GrowthPoint may, depending on market conditions, sell any or all of its common shares of Vigil.

For additional information, or for a copy of the early warning report filed in respect of the above transaction, please see contact information below.

BETHESDA, MD–(Marketwire – August 18, 2010) – GetWellNetwork, Inc., the leader in interactive patient care solutions, today announced a new solution — GetWellNetwork for Seniors — designed to improve senior patients’ hospital experience and outcomes. Based upon extensive patient and caregiver research, GetWellNetwork for Seniors addresses the impact of aging and the ability of the senior population to use technology in a hospital setting. Using the bedside TV, GetWellNetwork for Seniors enables elderly patients to easily take part in their care process and to affect their own health outcomes.

“Our hospital participated in the testing of the new GetWellNetwork for Seniors, and I was immediately impressed,” said Barb Ochsner, RN, clinical director, Medical Center of the Rockies, “Our patients really get it — they knew who their care team would be and appreciated having all the information available at their fingertips.”

Elderly patients often leave the hospital with incomplete knowledge of their medications, diagnosis, dietary regimens and safety information, all of which impact their overall health and recovery. The GetWellNetwork solution is a proven way to engage patients and to increase learning opportunities by giving patients the option to review medical information at their own pace and return to specific health information as many times as needed throughout their hospital stay. In addition, GetWellNetwork for Seniors supports important patient care priorities by providing easy and reliable access to information on medication, safety, health education, and services right from the patient’s bedside TV.

In addition to the vast array of care features, GetWellNetwork for Seniors accommodates the broad range of familiarity seniors have with consumer technology devices. It is specially designed so that little or no knowledge of computing is necessary to interact comfortably with the GetWellNetwork system. Design elements include large, high-contrast text and generous spacing between buttons so that it creates a friendly, comfortable experience for elderly patients. In addition, a subtle, audible tone notifies users when they have made a selection and on-screen messages alert patients when a task is complete.

“Coming off the R&D success of our GetWell Town for children, we took a similarly deep approach to understanding the senior population over the past two years to better meet their needs. We are proud to introduce GetWellNetwork for Seniors, which we believe will make a dramatic improvement in patient outcomes and quality of life for elderly patients,” said Michael O’Neil, CEO and founder, GetWellNetwork. “Effective patient education is the first step in ensuring a successful hospital stay and, more importantly, the critical link in promoting a full recovery and a healthy lifestyle when they return home.”

About GetWellNetwork, Inc.
GetWellNetwork, Inc. uses the bedside TV to entertain, educate and empower hospital patients and caregivers to be more actively engaged in their care. This patient-centered approach improves both satisfaction and outcomes for patients and hospitals. GetWellNetwork is the leader in interactive patient care solutions and exclusively endorsed by the American Hospital Association. More information about GetWellNetwork can be found at www.GetWellNetwork.com.

Click here to see all recent news from this company

BETHESDA, MD–(Marketwire – August 18, 2010) – GetWellNetwork, Inc., the leading provider of interactive patient care solution, today announced the availability of QuickCare, a new feature that provides clinicians and staff with the ability to order patient education and execute service requests at the point of care using the patient’s bedside TV. QuickCare assists clinicians and staff by enabling them to log-in to a secure GetWellNetwork system menu to perform six frequent care tasks for patients. Ultimately, this will help clinicians and staff to deliver better, more efficient care and to improve patient satisfaction.

By executing key nursing tasks directly from the patient’s room, clinicians optimize their time with patients and can take advantage of valuable teachable moments to initiate patient education without waiting to get back to the nurse’s station or computer terminal. Patients also feel confident that their service requests are quickly handled because clinicians and staff are initiating the orders right from their bedside. These service requests are then directed to the appropriate department, thereby off-loading non-clinical tasks from the clinician’s busy schedule.

“Using QuickCare, our nurses are able to easily complete important medication teaching without ever leaving the patient’s room. This helps expedite care and our patients feel more involved and personally cared for; ultimately, making a positive impact on patient satisfaction,” said Katherine E. Pereira-Ogan, RN, BSN, BC, MSSL, director of service excellence at Christiana Care Health System.

The bedside tools available in QuickCare assist clinicians in delivering timely, consistent education that yields better patient comprehension and provides better patient care through more efficiently managed service requests. 

QuickCare provides fast, one-click access in six key care areas:

• Patient Safety: Clinicians can prescribe safety education for their patients at the point of care, such as falls prevention information or hand hygiene, which also helps meet The Joint Commission requirements for patient safety.
• Patient Education: QuickCare enables clinicians to consistently and effectively engage patients in learning about their condition by initiating patient-specific education sessions at optimal teachable moments from the point of care. Improving patient education leads to improved patient outcomes.
• Medication Teaching: Clinicians can improve patient satisfaction by helping to engage patients in learning more about the importance of their medication regimen. QuickCare lets clinicians access the full medication database and retrieve real-time list of their patients’ prescribed medications.
• Patient Care Plan: Clinicians can reduce the number of readmission by guiding their patients through a comprehensive multi-phase care plan such as heart failure or asthma on the GetWellNetwork system. 
• Admissions and Discharge: Helping patients complete the steps for discharge ensures that patients can go home on time and reduce the length of stay. It also gives clinicians the ability to keep patients well informed about any aftercare instructions to ensure better patient outcomes. 
• Service Requests: Makes it easy for clinicians to contact the right department for non-clinical service requests such as notifying environmental services for room cleaning or sending a message to dietary services for their patients.

“We have put more control in the hands of caregivers at the point of care — QuickCare gives clinicians and staff the ability to assess patients’ needs and act on them immediately,” said Carrie Hallock, RN, BSN, product line director, nursing practice at GetWellNetwork. “The more we can do to optimize nursing workflows, the more time clinicians have for delivering the kind of patient care that inspired them into the nursing profession.” 

About GetWellNetwork
GetWellNetwork, Inc. uses the bedside TV to entertain, educate and empower hospital patients and caregivers to be more actively engaged in their care. This patient-centered approach improves both satisfaction and outcomes for patients and hospitals. GetWellNetwork is the leader in interactive patient care solutions and exclusively endorsed by the American Hospital Association. More information about GetWellNetwork can be found at www.GetWellNetwork.com.

Click here to see all recent news from this company

CENTERVILLE, MA–(Marketwire – August 18, 2010) –  UV Flu Technologies, Inc. (OTCBB: UVFT) (the “Company”) is pleased to announce that it has signed an agreement with Trade Network, Inc., dba Creative Media and Buying Services, to produce a series of television advertisements in order to publicize a national awareness campaign featuring the ViraTech UV-400 product line, and its proven health benefits in relationship to the ongoing and growing dangers presented by poor indoor air quality in homes, and workplaces across the nation.

The commercials are slated to air beginning in October, just prior to the onset of the traditional flu season, and will be broadcast on a variety of national television networks at various airtimes. They will be broadcast throughout this heightened period of awareness and, as such, are designed to offer an informative and educational outlook demonstrating the design and proven effectiveness of the UV-400 bacteria killing air purifier in action.

The indoor air quality (“IAQ”) sector is a vast market that grows in significance every time an airborne illness penetrates public mainstream awareness. This generally occurs in the fall and spring seasons and is usually in the forefront of public awareness during the fall season when the Company’s advertisements are scheduled for broadcast.

“This campaign is expected to not only to raise national awareness of the ViraTech UV-400 and its ability to kill bacteria and other contaminants, but to also spotlight the epidemic increase in respiratory problems due to poor indoor air quality generally,” stated Jack Lennon, President of UV Flu Technologies. “These television spots are an integral part of our overall marketing plan intended to capture a significant percentage of the worldwide multibillion dollar air-purification and filtration product marketplace, by demonstrating a product that actually works, and which has been cleared by the FDA as a medical device specifically for killing bacteria. The UV-400 product, along with several other products currently under development is directly aimed at reducing the extraordinary number of deaths attributed to poor indoor air quality that occur around the world every year.”

The UV-400 is uniquely positioned to attract serious attention by consumers due to its listing as a Medical Device with the FDA which resulted after a battery of rigorous laboratory tests proved the UV-400 kills 99% of airborne bacteria in its patented UV chamber. The device is designed to easily circulate the air within the average home or work environment multiple times per hour, and will be demonstrated within a number of real life situations and applications throughout the television presentations.

Further details regarding the Company’s business, financial reports and agreements are filed as part of the Company’s continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission’s (“SEC”) EDGAR database.

About UV Flu Technologies, Inc. (OTCBB: UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality (“IAQ”) industry sector. The Company manufactures the VIRATECH UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device.

Notice Regarding Forward-Looking Statements
This news release contains “forward-looking statements” as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

ON BEHALF OF THE BOARD

UV Flu Technologies, Inc.
—————————–
John J. Lennon, President & CEO

Click here to see all recent news from this company

LAKE FOREST, IL–(Marketwire – August 18, 2010) –  Hospitals and health systems can double revenue from their own employee health plans by implementing the right benefit strategies, according to research released today by CoreSource, one of the nation’s leading administrators of employee benefit plans for self-funded hospitals, health systems and other employers.

“When deciding how to offer medical benefits to their employees, hospitals and health systems embark on a complex process because they serve as both a health plan sponsor and a provider of healthcare services. For a hospital, offering an employee health plan and managing its costs require the institution to balance the need to grow patient volume and revenue with the need to control labor costs,” said Rob Corrigan, Vice President of Product Management and Planning, CoreSource.

A comprehensive analysis of the employee benefit strategies of nearly 70 CoreSource hospital and health system clients from across the country shows that a hospital using its domestic network of healthcare providers can increase its revenue, on average, by more than $1,200 per employee per year compared to a hospital that outsources its network to a commercial PPO contracting with all health system providers.

The study finds that hospitals employing this “direct contracting” model for their own employee health plans average about $2,500 in revenue per employee per year, compared to about $1,250 for those who employ the “outsourced PPO” model. The findings are contained in the CoreSource white paper, “Hospitals and Healthcare Systems: An Inside Look at Group Health Plan Strategies To Control Costs and Provide Access to Healthcare.”

According to the CoreSource study, hospitals generally use one of five benefit strategies when offering a self-funded PPO to their employees. The study also found that self-funded hospitals and health systems have, on average, six percent higher health benefit costs per employee than other CoreSource clients.

“The primary driver of the higher benefit costs for hospitals and health systems is their demographics,” Corrigan said. “Our analysis shows that hospitals and health systems typically employ more women, employees older than 40 and individuals with chronic conditions than other self-funded groups. These sectors of the population use healthcare services more often than other groups of individuals.”

The analysis also demonstrates how important employee compliance is for cost control. Compliance with preventive testing and disease management for employees of hospitals is better than for other self-funded employers, according to the research, while the average length of stay is 28 percent lower than other groups. “Without this level of compliance, it is fair to reason that hospital and health systems benefit plan costs would be even higher,” he said.

Understanding how different benefit strategies work is important for any hospital or healthcare system seeking to control costs and boost revenue, but it is critical for a hospital that wishes to become designated an Accountable Care Organization (ACO), a new payment and healthcare delivery system created by healthcare reform legislation.

“An ACO is designed to drive healthcare quality while stepping away from the traditional fee-for-service payment approach. A hospital using a domestic network or contracting directly with providers will have operational mechanisms in place that will help the institution make the transition. A hospital that outsources its network may not have the mechanisms readily available to make the shift easily,” Corrigan said.

Hospitals must look at their employee population, market conditions, reimbursement levels and relationships with physicians, and weigh many other factors before determining how to proceed with their benefit strategy. “Information gleaned from the analysis can help guide them in determining the right plan design for their institution,” Corrigan said. “Regardless of the strategy selected, a hospital must monitor cost and utilization trends so that it maintains the desired balance between competing financial objectives and positive relationships with employees, doctors and other stakeholders.” 

For more information on CoreSource and hospital and health system benefit administration, visit this website.

About CoreSource
 CoreSource is one of the nation’s leading TPAs, delivering integrated, customized employee benefit solutions to self-funded employers. CoreSource utilizes cutting-edge products and services designed to facilitate effective cost-containment strategies. CoreSource is a subsidiary of Trustmark Mutual Holding Company and has nine sales and customer service offices across the country. Trustmark has assets of more than $1.7 billion and, through CoreSource and other subsidiaries, administers more than $2.5 billion in health and life benefits annually. For more information, visit www.coresource.com.

ALISO VIEJO, CA–(Marketwire – August 17, 2010) –  CNS Response (OTCBB: CNSO) submitted an application to FDA for obtaining 510k clearance for its Referenced-EEG (rEEG®) service as a Class II device in April 2010. CNS Response CEO George Carpenter commented, “Based on our latest discussions with the FDA, it’s clear that 510k clearance will not occur in September, as we had originally hoped. We also thought shareholders should know that our business continues to move forward, with greater focus on pharma bioinformatics and clinical services.”

The Company has always considered rEEG to be a reference data service, not a traditional medical device under FDA regulation, since rEEG is a reference database accessed by qualified medical professionals over the web. However, in December 2009, Jeffrey Shuren, MD — now director of the Center for Devices and Radiological Health — presented a clear and reasonable route to 510k clearance, citing several packaged software products currently regulated as Class II devices, and which the FDA believed to be similar to rEEG. Based on this clear pathway and the commercial advantages of such approval, the Company filed for 510k clearance in April. In late July, however, reviewers indicated that they now believe rEEG is not substantially equivalent to those software products, but is in fact a new device with a new indication for use requiring a 510k filing with different predicate devices or application for Premarket Approval (PMA). 

Carpenter continued, “This brings us back to our original position, which was never waived. The growth of the internet and medical informatics have led to an explosion of similar services which offer physicians objective information about patient treatment options. rEEG was developed by physicians to solve a critical information gap in medicine, and it is now the largest reference database correlating electrophysiology (EEG) with standard pharmacotherapy. We will continue to grow our non-device business, and we will also continue our dialog with the FDA toward a mutual understanding of its regulatory relationship to rEEG services.”

About CNS Response
Today, most physicians are able to base treatment on objective test data, such as EKGs, MRIs, blood tests, etc. Broadly speaking, such advances have not yet come to those physicians practicing psychiatry.

Referenced-EEG was developed by physicians to provide objective, personalized, statistical data on patient neurophysiology. In clinical trials, physicians using rEEG data have consistently achieved superior clinical results compared to physicians using trial and error pharmacotherapy.

The Company announced publication last week of results from its most recent clinical trial in The Journal of Psychiatric Research, in which physicians using Referenced-EEG (rEEG^®) had success rates reaching 65 percent for patients with treatment-resistant depression.

To read more about the benefits this patented technology provides physicians, patients and insurers, please visit the CNS Response website, www.cnsresponse.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements involve risks and uncertainties as set forth in the Company’s filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.

MONTVALE, NJ–(Marketwire – August 17, 2010) – SRS, the leader in hybrid EMRs, today announced that Sacramento Maternal-Fetal Medicine (Sac MFM) has selected the productivity-enhancing SRS hybrid EMR for its high-risk pregnancy practice. With offices located in Sacramento and Chico, Sac MFM provides exceptional care to expectant women in Northern California.

“Our high-risk OB/GYN patients require complex care from our physicians and staff throughout their pregnancies,” says Lynn K. McLean, M.D., Sac MFM. “The SRS hybrid EMR allows us to deliver more complete care by freeing us to focus our time and energy on our patients. The advantages of SRS also extend beyond the walls of our practice. Having meticulously organized clinical information helps me to more quickly and more completely communicate with referring physicians, which in turn enables them to provide better care to our mutual patients.”

“We explored a wide spectrum of EMR solutions and it was clear that the SRS hybrid EMR would add the most value,” says Deborah Sennett, Administrator of Sac MFM. “One of the important benefits is malpractice risk management — we feel more confident in the protection that digitized, organized, and complete records will deliver in this regard.”

SRS was designed with direct input by its high-performance physicians to provide them with a system that fits their needs, helps them to work more efficiently, and enables them to achieve a rapid return on their investment. SRS, which has built the largest national network of high-performance practices that successfully use an EMR, attributes its unmatched adoption rate to ease of use, fast implementation, and an accelerated timeframe for training physicians and office staff.

“The SRS hybrid EMR provides an efficiency-enhancing solution to practices that do not want to be slowed down by unnecessarily complex point-and-click systems,” says Evan Steele, CEO of SRSsoft. “Sacramento Maternal-Fetal Medicine prides itself on delivering exceptional care to their high-risk patients. We are confident that our solution will enhance their ability to do so, and we are happy that they are part of the growing family of over 5,000 SRS users.”

About Sacramento Maternal-Fetal Medicine
Sacramento Maternal-Fetal Medicine Medical Group is the only comprehensive high-risk pregnancy medical group in the Sacramento region. For over 20 years, their physicians have provided care for women in Northern California, specializing in ultrasound, prenatal diagnosis, genetics, medical and surgical complications of pregnancy, as well as the management of multiple gestations (e.g. triplets, quadruplets). Visit them at: http://sacmfm.com.

About SRSsoft
SRS is the recognized leader in providing healthcare IT solutions to OB/GYN practices nationwide. The award-winning SRS hybrid EMR offers powerful and flexible solutions to the complex requirements of clinical workflows, patient care, and OB/GYN practice operations. Prominent OB/GYN groups overwhelmingly choose SRS because of its unique fit with the demands of their specialty. For more information on SRS, visit www.srssoft.com, e-mail [email protected], fax 201.802.1301, or call 800.288.8369.

CHARLOTTE, NC–(Marketwire – August 16, 2010) – Healthcare payers will now be able to reduce expenses and time spent on meeting the IRS requirements for 1099 filing and subsequent W9 requests with W9 Corrections, Inc.‘s “1099 Solution.” Gerard Szatkowski, President of W9 Corrections, Inc., a subsidiary of Bases Loaded, Inc., announced this new offering that promises to alleviate one of the more troublesome problems for Healthcare Payers.

“All Payers realize the need for the IRS to receive accurate information on the payments they make,” said Szatkowski. “The real issue is the amount of time and effort required to meet the IRS requirements and avoid large penalties. With new regulations that add more requirements to Payers in meeting their 1099 filing obligations, payers are even more anxious. After listening to our clients’ pleas we are excited to release our proactive 1099 Solution.”

Through its work with Provider records, W9 Corrections developed a proactive product that will eliminate errors in required 1099 filings. W9 Corrections spent 10 years in research and development on the 1099 Solution product that takes the entire 1099 workload away from the Healthcare Payer and allows them to focus on the business of Healthcare.

About W9 Corrections

W9 Corrections is a subsidiary of Bases Loaded, Inc. Founded in 1999 and headquartered in Charlotte, NC, Bases Loaded is a database management company solely focused on healthcare provider information. BLI has focused on the health and dental insurance markets since their inception. BLI specializes in helping Healthcare payers manage Provider data in the claims process. W9 Corrections can be reached at (704) 424-9889, www.w9corrections.com.

NORMAN, OK–(Marketwire – August 16, 2010) – Access Plans, Inc. (OTCBB: APNC), a leading membership benefits marketing company, today announced its operating results for the third quarter and first nine months of FY2010. An investor conference call is scheduled for 11:30 a.m. EDT today, August 16, 2010 (see details below).

Third Quarter Results

Revenues for the three months ended June 30, 2010 increased 3% to approximately $14.4 million, compared with approximately $14.0 million in the third quarter of FY2009. Operating income increased 7% to $1.34 million, versus $1.26 million in the prior-year period.

Net income for the third quarter of FY2010 improved to $0.95 million, which represented an increase of 10% when compared with net income of $0.86 million in the year-earlier quarter. Earnings per share, fully diluted, increased 25% to $0.05, versus $0.04 in last year’s third quarter. The number of weighted average diluted shares outstanding approximated 19.8 million during the most recent quarter, compared with 21.6 million shares in the third quarter of FY2009. The decrease in the weighted average number of diluted shares outstanding resulted from the Company’s repurchase in the first quarter of FY2010.

“I am confident that we are taking the steps necessary to grow our revenues and earnings on a long-term basis,” commented Danny Wright, Chief Executive Officer of Access Plans, Inc. “The Wholesale Plans division generated a 15% increase in revenues during the most recent quarter, reflecting increased customer participation at existing locations, along with an increase in the number of locations offering our plans. The Retail Plans division’s growth continues to more than offset the revenue losses from the run-off of legacy programs that we inherited following the acquisition of Access Plans USA in April 2009. We are also investing in new product offerings and marketing strategies in the Retail Plans division. Meanwhile, we continue to work on transitioning the Insurance Marketing division’s sales mix from its previous emphasis on major medical policies towards innovative solutions that combine supplemental and life products with major medical sales. We believe this new approach, which was prompted by certain aspects of the Healthcare Reform Act, should maintain commission income for agents, while improving the division’s operating margins. We are in the final stages of designing this new supplemental offering, and rollout is scheduled for the first quarter of Fiscal 2011.”

Wholesale Plans

Revenues at the Wholesale Plans division increased 15% to $5.8 million in the most recent quarter, versus $5.0 million in the prior-year period. The increase was attributable to improved sell-through at existing locations, as well as the addition of new accounts. Gross margin doubled to $1.8 million, compared with $0.9 million a year earlier, due to the revenue increase and a reduction in involuntary unemployment waiver expenses resulting from lower levels of national unemployment. Operating income at the division increased 169% to $1.4 million, versus $0.5 million in the prior-year period. 

Retail Plans

Revenues at the Retail Plans division in the third quarter of FY2010 increased 9% to $4.9 million, prior to inter-company eliminations, versus $4.5 million in the prior-year period. The increase was attributable primarily to investments in new programs that offset revenue declines in the legacy business. Gross margins decreased $0.6 million due to upfront sales and marketing costs associated with a new product rollout. The division’s operating income declined to $0.4 million in the third quarter of FY2010, versus $0.9 million in the third quarter of FY2009, as a result of expenses related to a new product rollout, as discussed above.

Insurance Marketing

Insurance Marketing division revenues decreased to $5.0 million, versus $5.7 million in the third quarter of FY2009. The decline was due in large part to the exit of two major medical carriers from the market. Operating income (loss) decreased to ($0.05 million), versus $0.1 million in last year’s third quarter. As discussed above, due to the recent passage of the Health Care Reform Act, our Insurance Marketing division, AHCP, will shift its product mix over the next several quarters to emphasize association-based supplemental insurance products and membership plans offered in conjunction with individual health insurance policies.

Nine-Month Results

Revenues for the nine months ended June 30, 2010 increased 61% to approximately $41.1 million, compared with approximately $25.5 million in the first nine months of FY2009. Operating income increased 35% to $4.2 million, versus $3.1 million in the prior-year period.

Net income for the first nine months of FY2010 increased to $2.6 million, which represented an improvement of 20% when compared with net income of $2.1 million in the corresponding period of the previous fiscal year. On a diluted per-share basis, earnings remained at $0.13 for the nine months ended June 30, 2010 and 2009. The number of weighted average diluted shares outstanding increased to 20.1 million during the first nine months of FY2010, versus 16.5 million in the year-earlier period. 

Other Matters

Cash, cash equivalents and restricted cash totaled $5.1 million at June 30, 2010, versus $4.6 million at September 30, 2009. The modest increase resulted from a $1.0 million note payoff in the second fiscal quarter and higher upfront sales commissions on a new product in the Retail Plans division. The Company has no long-term debt outstanding. Meanwhile, stockholders’ equity has increased 33% from $10.2 million on June 30, 2009 to $13.6 million on June 30, 2010.

Conference Call and Webcast Information

Access Plans will host a conference August 16, 2010 at 11:30 a.m. EDT. To access the conference call, please dial 877-317-6789 (U.S.) or 412-317-6789 (international) and ask to be placed into the “Access Plans” conference call. The conference call will also be available via “live” webcast under the Investor Relations section of the Company’s website at www.accessplans.com, or by visiting http://www.videonewswire.com/event.asp?id=71766 to access the webcast directly.

A replay of the conference call will be available through August 24, 2010 and can be accessed by dialing 877-344-7529 (U.S.) or 412-317-0088 (international) and entering the conference ID number 443633. An archived version of the webcast will also be available under the Investor Relations section of the Company’s website at www.accessplans.com.

About Access Plans, Inc.

Access Plans, Inc. (OTCBB: APNC) is a leading membership benefits marketing company with two distribution channels. The Wholesale/Retail Plans distribution channel specializes in turnkey, private-label membership benefit plans that provide discount products and services, protection benefits and retail services to more than one million customers in the United States and Canada. America’s Health Care Plans (AHCP), the Company’s Insurance Marketing distribution channel, is one of the nation’s largest independent agent networks and provides major medical, life and supplemental insurance products to individuals. For more information, please visit: www.accessplans.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, Section 27A of the Securities Act of 1933, as amended and pursuant to the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may relate to financial results and plans for future business activities, and are thus prospective. Such forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from future results expressed or implied by such forward-looking statements. Among the important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are competitive pressures, loss of significant customers, the mix of revenue, changes in pricing policies, delays in revenue recognition, lower-than-expected demand for the Company’s products and services, general economic conditions, and the risk factors detailed from time to time in the Company’s periodic reports and registration statements filed with the Securities and Exchange Commission. Any forward-looking statements are made pursuant to the Private Securities Litigation Reform Act of 1995 and the Company assumes no responsibility for updating such forward-looking statements after the date of this release.

 

TAMPA, FL–(Marketwire – August 16, 2010) –  Zimek Technologies (www.zimek.com) is pleased to announce today the addition of James Lee Witt, Chief Executive Officer of Witt Associates, as Senior Advisor at Zimek, the industry leader in infection control and biohazard remediation systems. Witt was Cabinet-level Director of FEMA (Federal Emergency Management Agency) during the Clinton Administration.

As a Senior Advisor to Zimek Technologies, Witt will work closely with Advisory Board members including former Illinois State Senate President Emil Jones Jr.; Dr. Brad Spellberg, infectious disease specialist at the David Geffen School of Medicine at UCLA and Harbor-UCLA Medical Center; Dr. Peder Bo Nielsen, consultant in Microbiology with the United Kingdom’s North West London NHS Trust; and Dr. Lindsey Shaw, Assistant Professor of Molecular Microbiology at the University of South Florida.

“Zimek Technologies is thrilled to have James Lee Witt join our team,” stated Kurt Grosman, CEO of Zimek. “Having Mr. Witt onboard is a testament to the effectiveness of our products and the need for stronger decontamination protocols. He will provide unprecedented leadership in the growth of our company.” Zimek’s sophisticated three-dimensional touch-less decontamination technology is being implemented in many facilities nationwide to effectively prevent the spread of deadly viruses and bacteria.

Witt’s firm recently joined the support and recovery operations of Gulf Coast communities in the wake of the oil and gas spill in the Gulf of Mexico. Witt currently serves as a Special Advisor to the State of Louisiana, assisting with the nation’s largest long-term recovery effort in the aftermath of Hurricanes Katrina and Rita.Witt Associates, a public safety and crisis management consulting firm based in Washington D.C., focuses on disaster recovery and mitigation management services to state and local governments, educational institutions, the international community and corporations.

“There must be a stronger focus on prevention of infection, not just remediation after the infection occurs,” Witt added. “Decontamination can play a larger role in our efforts to combat deadly viral and bacterial infections, and is giving us a powerful new tool in the arsenal to fight biohazard attacks.”

Zimek Technologies, based in Tampa, Florida, has been developing and marketing its patented automatic Micro-Mist^® decontamination technologies for more than five years. Zimek’s industry-leading technologies are used by the U.S. Department of Homeland Security, fire and EMS departments, healthcare facilities, public health agencies, transit systems, correctional facilities, and local law enforcement agencies across America.

NEW YORK, NY–(Marketwire – August 12, 2010) –  Final meaningful use rules that relax criteria slightly for electronic medical records (EMR) reflect a more “realistic approach” given the slow adoption rates of EMR among physicians over the past few years, according to Kalorama Information. The healthcare market research publisher had predicted that the market would grow to $25 billion by 2014, and believes that achievable but progressively challenging criteria for incentives are optimal. 

The proposed rule would have required doctors to e-prescribe 75 percent of their drug orders to meet incentive requirements. The final rule lowers that threshold to 40 percent. Also, CMS’s proposed rule would have required physicians to meet 25 “meaningful use” objectives, with hospitals asked to meet 23 markers. The final rule splits those objectives into a group of core measures — 15 for doctors and 14 for hospitals — and offers a menu of 10 additional measures, from which providers can choose five to report. HHS has also indicated that the rules would be tightened the following year. 

“I think most people watching how healthcare IT has worked in the past would say the final rules are realistic,” said Bruce Carlson, publisher of Kalorama Information. “The goals are reachable, but at the same time, HHS is taking care not to issue credits merely for buying software. And the better the incentives work, the better the impact on the market and for the companies competing in EMR systems.”

According to Kalorama’s review of several physician EMR surveys for the past three years, prior to the incentives only about a third of physicians used EMR and perhaps a tenth used it exclusively, though incentives are expected to change that. Physicians who meet the criteria will be able to collect incentives as high as $44,000 starting in 2011. Those who do not use EMR systems according to the criteria will face a 3% reduction in payments in 2015.

“The HITECH Act incentives are a carrot and a stick system,” said Carlson. “With any such system it is greatly preferable to get maximum use of the carrot and reserve the stick for what are hopefully just a few holdouts who do not comply after being given multiple chances to do so. Otherwise, what was a well-thought out policy would become just a mandate.”

Kalorama Information’s report, “EMR 2010 (Market Analysis, ARRA Incentives, Key Players, and Important Trends),” contains more information on market forecasts, company profiles, and trends in the EMR market. The report is available at: http://www.kaloramainformation.com/redirect.asp?progid=79444&productid=2503320.

About Kalorama Information
Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter (http://www.twitter.com/KaloramaInfo) and LinkedIn (http://www.linkedin.com/groups?gid=2177845&trk=hb_side_g).

TAMPA, FL–(Marketwire – August 11, 2010) – MedCo Data, a leading provider of technology and informatics expertise for physician practices, unveiled the Dermesse™ Online Shopping Cart at the American Academy of Dermatology Summer Academy Meeting. The Online Shopping Cart is an innovative shopping service designed to enable dermatology practices, as well as medical professionals specializing in aesthetic and cosmetic procedures, to enhance revenues through secure online sales of the Dermesse line of quality skin care products.

The Online Shopping Cart package consists of a customized “portal,” built and maintained by MedCo Data, where authorized patients of the practice can securely shop and order Dermesse products, access exclusive promotions and purchase gift cards for procedures and other practice services. The shopping portal integrates into the practice’s existing website, creating an online information destination that brings value to both the patient and provider.

“The Dermesse Online Shopping Cart is a unique way for us to extend the patient relationship by providing easy and convenient access to high quality skin care products,” said Dr. Robert D. Rehnke, M.D., FACS, The Center for Surgical Excellence, a state-of-the-art, fully accredited cosmetic and reconstructive plastic surgery center in St. Petersburg, Fla. “At the same time, it creates a viable revenue stream for our practice without disrupting workflows or diverting resources from other areas.”

Inventory and order fulfillment is managed entirely by Axia Medical Solutions, which manufactures and sells the Dermesse line exclusively through medical professionals. “The Online Shopping Cart provides our physicians with the power and convenience of the Internet while maintaining the exclusive distribution channel upon which our success is based,” said Jim Krulisky, CEO, Axia Medical Solutions. “Most importantly, they are able to leverage our lean inventory management processes without making a sizable upfront investment, thereby creating a win-win for Dermesse and the practice.”

Promotional support is provided by MedCo Data in the form of a high-quality integrated online and in-practice marketing campaign. This includes professionally designed and produced banner ads on the practice’s existing website, lobby signage, displays at the check in/out desk and appointment reminder cards. 

“What is most appealing about the Dermesse Online Shopping Cart is the marketing support, providing our clients with access to Dermesse products without adding to our staff’s workload to manage marketing or fulfillment,” said Marissa Hervey, Licensed Paramedical Aesthetician and Principal, DayGlo Med-Spa. 

Adds Rob Cash, COO, MedCo Data: “By aligning the Dermesse product with a targeted marketing campaign that utilizes the online technology portfolio of MedCo Data, as well as inventory management and order fulfillment, we have aligned the primary stakeholders and established a foundation of success for any practice that wants to add new profit centers and enhance patient communications.”

About MedCo Data, LLC
MedCo Data (www.medcodata.com) provides the technology and informatics expertise that enables physician practices and other ambulatory care organizations to leverage EMR/EHR systems and other software to improve, expand and evolve their services. The firm offers managed technology services centered on its Proactive Care Help Desk, which serves as a one-stop support service for all office technology. On the consulting side, MedCo Data’s patent-pending Workflow Centric® offering guides practices through the EMR/EHR selection, implementation and decision-making process, with the goal of matching the client organization with the CCHIT-certified software vendor that best meets its unique needs.

About Axia Medical, LLC
Axia Medical Solutions is a privately held global specialty pharmaceutical company that develops, manufactures, and commercializes skin care products to medical professionals specializing in dermatologic, aesthetic, and cosmetic procedures. Products include prescription drugs, OTC and cosmeceutical products. The main brand, Dermesse, was introduced in 2003 to address the signs of aging. The Dermesse skin care products effectively penetrate the skin barrier and are indicated for the treatment of melasma, chloasma, lentigines, and hyperpigmentation, and are effective against sun and environmental damage. Private label programs are available for all products. Axia Medical Solutions corporate offices are in Carlsbad, California. For more information, visit www.axiamedical.com.

HOLLYWOOD, MD–(Marketwire – August 11, 2010) –  Smartronix, Inc., a global information technology and engineering solutions provider, announced today that it has acquired Cogon Systems, Inc., to expand its growing health information technology portfolio. The new company operating as Cogon Systems, LLC is a wholly owned subsidiary of Smartronix led by Cogon’s current CEO, Dr. Huy Nguyen.

Founded by Dr. Huy Nguyen, M.D., Cogon facilitates healthcare connectedness by way of its value-driven innovations and comprehensive thought leadership. Through its Virtual Health Network (VHN) platform, a SOA-based architecture using an enterprise service bus that provides business logic flexibility, network scalability, data interoperability, and application extensibility, Cogon is committed to facilitating value based healthcare. The VHN is implemented with basic services that enhance the exchange of health information supporting referral management of patients who receive care from multiple providers. These basic services include continuity of care information, patient demographic and administrative information, diagnoses/problem lists, providers, allergies, medications, laboratory results, radiology results, previous procedures, and clinical notes. Currently, Cogon’s VHN allows for the first time sharing of tens of thousands of health records between the Department of Defense and commercial hospitals. Leveraging Smartronix’ business maturation, growth in the federal healthcare, and its expertise in network operations and cyber-security, Cogon is well positioned to provide premium services in the federal health sector.

Smartronix CEO, John Parris, said, “The addition of Cogon, its visionary leadership, and its intellectual property are a great complement to Smartronix’ growing health information technology business. We are confident that our network operations, enterprise software solutions, and cyber security core competencies will assist in leveraging and augmenting Cogon Systems’ Virtual Health Network platform.”

About Smartronix

Smartronix is a global professional solutions provider specializing in NetOps, Cyber Security, Enterprise Software Solutions, Mission-Focused Engineering, and Health IT. Smartronix is headquartered in Hollywood, Maryland, with operating offices in Virginia (3), North Carolina, Florida (2), Alabama, Georgia, Ohio, Texas, and Arizona; and 600 employees throughout the United States and at strategic locations in Germany, Korea, Japan, and the Philippines. The company has been recognized as an Employer of Choice by Northern Virginia Family Service and as one of the 50 fastest-growing companies in the Greater Washington D.C. area and one of the top 500 and top 5,000 nationally as ranked by Washington Post and Inc 500 media, respectively. 

JOHANNESBURG, SOUTH AFRICA–(Marketwire – August 11, 2010) – Virtual Pharma Rep™ (VPR), an e-marketing firm with a patent pending, e-detailing marketing platform, today announced that it will be launching South Africa’s first e-detailing campaign, in partnership with a major South African pharmaceutical company. This is the first ever marketing project of its kind in the South African pharmaceutical industry.

Virtual Pharma Rep™ recently opened operations in South Africa, and is a pioneer in bringing a new virtual sales approach to the market that revolutionizes expensive pharmaceutical sales models, supplements existing sales forces and reduces marketing and promotional budgets significantly. Virtual Pharma Rep™ leverages technology to deliver powerful multimedia messages to doctors that educate and provide important product and service information directly from the pharmaceutical company, much like a field sales rep. This new sales approach is designed to provide consistent, controlled and fully customized messages to multiple doctors simultaneously through an online communication channel, along with various ways for doctors to communicate with companies in return. Messages can be accessed by doctors at their convenience, when their schedule allows, thereby saving precious time in their schedules.

“New marketing strategies are necessary to stay competitive in any industry, and this is especially true now within South Africa as marketing trends shift due to new technological advances,” said Jim Rediehs, CEO of Virtual Pharma Rep. “We are most excited to be launching our revolutionary marketing concept in the South African pharmaceutical market. We will demonstrate that e-detailing, in conjunction with current marketing and sales strategies, is an effective way to penetrate target audiences, even those in hard to reach white spaces. E-detailing fills in communication gaps, and therefore reaches more doctors, which ultimately provides patients with better access to the pharmaceutical products they require for a healthy life.”

For more information, visit www.virtualpharmarep.com

About Virtual Pharma Rep™

Virtual Pharma Rep is revolutionizing the pharmaceutical industry by leading the paradigm shift to virtual sales support and service models that enhance or replace existing and expensive pharmaceutical marketing strategies. Virtual Pharma Rep is led by a highly experienced team of pharmaceutical industry veterans and growth strategists. For more information visit www.virtualpharmarep.com

NUEVA YORK, NY–(Marketwire – August 9, 2010) – El verano es tiempo para practicar deportes
al aire libre, disfrutar de un asado con familiares y amigos, salir al
campo, ir la playa y mucho más. Sin embargo, algunas creencias comunes
entre la comunidad Hispana podrían estar impidiendo a esta comunidad
disfrutar de su salud. Por eso, un equipo de médicos del Hospital Mount
Sinai aclara cuatro de los mitos más comunes sobre el verano entre los
latinos.

1. Piel morena no necesita protección solar

“Es un error común entre los latinos creer que si el tono de piel es
oscuro, no es necesario protector solar. Para evitar el cáncer en la piel,
todos los latinos, sin importar su color de piel, deben aplicar protector
solar cada 30 minutos, la primera aplicación 30 minutos antes de exponerse
al sol y cubriendo todas las áreas que se expondrán al sol, con mínimo dos
onzas de bloqueador cada vez”, dice el Doctor y Cardiologo Samer Kottiech,
añadiendo, “no importa donde esté; asegúrese de usar protector solar. Si se
encuentra al aire libre necesita protector solar”.

2. Tomando café, gaseosas y cervezas, no necesito agua

Con temperaturas de más de 90 grados, el cuerpo debe estar hidratado y
pocas bebidas, hidratan su cuerpo como el agua. “El agua no es la opción
más popular entre los latinos”, dice el Doctor Carlos Driggs, especialista
en medicina interna, y agrega, “para evitar deshidratación, lo mejor es
tomar entre 1 y 2 vasos de agua por hora cuando se está al aire libre, si
se consume alcohol o hace ejercicio, se recomiendan 2-3 vasos por hora,
especialmente con temperaturas cada vez más altas. Asegúrese de llevar su
botella durante los días calurosos”.

3. Si la comida está cocinada, no se daña

Las clínicas reciben cada verano pacientes intoxicados por alimentos no
refrigerados adecuadamente. Las actividades al aire libre son muy populares
entre los latinos, lo cual aumenta los riesgos para esta población durante
le verano. El doctor Rajeev Sindhwani, especialista en cuidado
cardiovascular, recomienda, “se puede evitar intoxicación siguiendo 5
reglas: 1. tener manos limpias para manejar alimentos; 2. usar una tabla
para picar carne y otra para vegetales; 3. no dejar los alimentos al aire
libre por tiempo prolongado; 4. asegurarse que las carnes estén bien
cocidas; y 5. limpiar la parrilla antes de cocinar alimentos frescos, para
evitar la contaminación de residuos de otros alimentos cocidos”.

4. Si usted elimina la grasa, se pierde el sabor

“Existe la idea de que quitar la piel del pollo o reducir la grasa de la
carne, hará que la comida pierda sabor. Todos los alimentos, pueden tener
un sabor exquisito incorporando especias, frutas y verduras”, dice el Dr.
Eliscer Guzman, MD FACC, y agrega, “eso ayudará a que los latinos disfruten
una vida libre de dos de las enfermedades que más afectan a esta comunidad,
la diabetes y las enfermedades cardiovasculares”.

Guzmán también recomienda aprovechar las frutas frescas que son abundantes
durante el verano y están disponibles a buen precio. “Su barbacoa debe
tener tantos colores como alimentos saludables existen, verdes, amarillos,
rojos. También hay que cuidar los tamaños de las porciones, para medir el
tamaño de la carne, por ejemplo, asegúrese que esta sea del tamaño de la
palma de su mano”, agrego el Dr. Guzmán.

“Recuerde mantener su parrilla limpia, si quiere darle sabor de asado a sus
platos, puede usar un poco de carbón con sus condimentos predilectos, para
darle el toque de asado y el sabor a su carne”, recomendó El Dr. Guzmán.

Acerca del Centro Médico Mount Sinai

El Centro Médico Mount Sinai incluye el Hospital Mount Sinai y el Colegio
de Medicina. Desde 1968, es uno de los pocos colegios médicos en EEUU parte
de un hospital, con más de 3,400 profesores, 32 departamentos y 15
instituciones, es uno de los 20 colegios médicos según el Instituto
Nacional de Salud y U.S. News & World Report. El Hospital Mount Sinai, se
fundó en 1852, cuenta con 1,171 camas. Es uno de los más antiguos, grandes
y respetados hospitales del país. En el 2009, fue clasificado dentro de los
20 hospitales principales de la nación. Más de 60,000 personas fueron
atendidas en el Mount Sinai en 2009 y recibió aproximadamente 530,000
visitas de pacientes.

Más información visite www.mountsinai.org o síganos en Twitter
@mountsinainyc.

NEW YORK, NY–(Marketwire – August 9, 2010) –  Summer is the time for playing outdoor sports, eating at picnics and BBQs with family and friends. However, some commonly made mistakes keep Latinos for being healthy. That is why a team of physicians at Mount Sinai Hospital took it upon themselves to debunk four of the most common summertime myths among Latinos.  

1. Since some Latinos have dark skin, they believe that they don’t need sunscreen
“A misunderstanding among Latinos is that, because many have dark skin tones, sunscreen is not necessary,” says Dr. Samer Kottiech, M.D. and Cardiologist. “However, to avoid skin cancer, everyone needs to frequently apply sunscreen regardless of their skin tone,” he adds. Dr. Kottiech recommends reapplying the sunscreen every 30 minutes after the first application. Also, be sure to cover your entire body and use at least one shot glass of sunscreen with each application.

2. If I drink beverages like coffee, soda and beer, I do not need water
With temperatures rising, it’s critical that your body is well hydrated. “Water is not the popular drink among most Latinos,” says Dr. Carlos Driggs, MD and specialist in Internal Medicine. “However, in order to avoid heat stroke, it is best to drink between 1-2 glasses of water before going outdoors, especially during summer.” Also, Dr. Driggs suggests to increase the consumption of water by 2 glasses an hour, if you are drinking alcohol or exercising, making sure you carry a bottle of water with you at all times to keep hydrated.

3. If food is cooked, it can’t spoil
During summer, emergency rooms see a lot of patients who contracted food poisoning due to food that was not properly refrigerated. Since outdoor eating functions are so popular among Latinos, they are often impacted. “One commonly made mistake is to leave food outside after a picnic or BBQ,” adds Dr. Rajeev Sindhwani, MD, Cardiovascular Disease Physician. “You can avoid food poisoning by following a few simple rules: 1. Handle food with clean hands; 2. Use separate cutting boards for meats and vegetables; 3. Don’t leave food outdoors; 4. Use a meat thermometer to ensure meat is cooked thoroughly,” and 5. Make sure to clean the grill or cover it with aluminum foil before cooking any fresh meat or vegetables to avoid contamination from previously cooked food residue.

4. If you trim the fat, you lose the flavor
Another misconception among Latinos, is if they remove the skin from their chicken or trim the fat from their beef, their food will be tasteless. “Meats will taste just as flavorful by incorporating a variety of spices, fruits and vegetables,” says Dr. Eliscer Guzmán, M.D. F.A.C.C. “By taking this approach, Latinos will live a healthier life and avoid cardiovascular diseases and diabetes, two diseases currently plaguing the Latino community.” Dr. Guzman recommends taking advantage of the abundant fresh fruits during the summer that are available at a reasonable price.

Dr. Guzmán adds, “Portions sizes can make a tremendous difference to your overall health also. A common rule of thumb for portions is to make sure the size of meat is roughly the size of the palm of your hand.”

About The Mount Sinai Medical Center
The Mount Sinai Medical Center encompasses both The Mount Sinai Hospital and Mount Sinai School of Medicine. Established in 1968, Mount Sinai School of Medicine is one of few medical schools embedded in a hospital in the United States. It has more than 3,400 faculty in 32 departments and 15 institutes. The school received the 2009 Spencer Foreman Award for Outstanding Community Service from the Association of American Medical Colleges.

The Mount Sinai Hospital, founded in 1852 is one of the nation’s oldest, largest and most-respected voluntary hospitals. In 2009,The Mount Sinai was ranked among the nation’s top 20 hospitals Nearly 60,000 people were treated at Mount Sinai as inpatients last year, and approximately 530,000 outpatient visits took place.

For more information, visit www.mountsinai.org. Follow us on Twitter @mountsinainyc.

MENOMONEE FALLS, WI–(Marketwire – August 9, 2010) – Assisted Living Concepts, Inc. (NYSE: ALC)

Highlights:

--  Increased average private pay occupancy by 122 and 8 units over the
    second quarter of 2009 and the first quarter of 2010, respectively
--  Increased overall and private pay rates by 5.8% and 3.8%, respectively
    over the second quarter of 2009
--  Increased Adjusted EBITDAR as a percent of revenues to 33.6%, up from
    32.3% in both the second quarter of 2009 and the first quarter of 2010
--  Adjusted EBITDAR as a percent of revenues would have been a record
    34.4% (excluding One-Time Charges)
--  Extended and expanded share repurchase program authorizing up to
    $15 million through August 9, 2011

Assisted Living Concepts, Inc. (“ALC”) (NYSE: ALC) reported net income of
$2.9 million in the second quarter of 2010. During the second quarter of
2010, ALC recorded the following “One-Time Charges”: an impairment charge
relating to a non-cash write-down of certain equity investments ($1.3
million net of income tax benefits); expenses associated with the
realignment of our divisions ($0.3 million net of income tax benefits);
and write-off of expenses incurred with an expansion project that the
company decided not to complete ($0.1 million net of income tax benefits).
Excluding the One-Time Charges, net income in the second quarter of 2010
would have been $4.6 million as compared to net income of $3.9 million in
the second quarter of 2009.

“Second quarter operating results were solid. For the fourth quarter in a
row we achieved positive private pay occupancy and revenue growth,”
commented Laurie Bebo, President and Chief Executive Officer. “Despite
continuing challenges in the economy and in particular with high
unemployment rates, we continue to be confident in our ability to increase
private pay occupancy and Adjusted EBITDAR margins throughout 2010.”

For the first six months of 2010, ALC reported net income of $6.5 million.
Excluding the One-Time Charges, net income for the first six months of 2010
would have been $8.2 million compared to a net loss from continuing
operations and a net loss of $7.7 million and $7.9 million in the first
six months of 2009, respectively. Excluding an impairment charge related
to the non-cash, non-recurring write-off of all goodwill ($14.7 million net
of income tax benefits) recorded in the first quarter of 2009, net income
from continuing operations and net income for the first six months of 2009
would have been $7.0 million and $6.8 million, respectively.

Diluted earnings per common share for the second quarter and the first six
months ended June 30, 2010 and 2009 were:

                                        Quarter ended    Six months ended
                                           June 30,          June 30,
                                        2010     2009     2010     2009
                                       ------   ------   ------   ------
Diluted earnings (loss) per common
 share from continuing operations      $ 0.25   $ 0.33   $ 0.55   $(0.65)
Diluted earnings (loss) per common
 share                                 $ 0.25   $ 0.33   $ 0.55   $(0.66)
Pro forma diluted earnings per common
 share from continuing operations
 excluding One-Time Charges            $ 0.39   $ 0.33   $ 0.70   $ 0.59(1)

(1) Excludes the goodwill write-off, net of income tax benefits.

One-Time Charges in the quarter ended June 30, 2010 resulted from:

1.  The reclassification of a decline in the fair market value of equity
    securities from a component of the Company's stockholders' equity to
    the Company's income statement. These equity securities represent
    legacy investments transferred from Extendicare Inc. in connection with
    the capitalization of ALC in November 2006.
2.  The realignment of ALC's divisional level management structure. In
    connection with this realignment, ALC incurred certain expenses
    primarily related to personnel.
3.  The decision not to complete an expansion project due to higher than
    anticipated site costs. We continue to evaluate existing owned
    properties for expansion growth.

Certain non-GAAP financial measures are used in the discussions in this
release in assessing the performance of the business. See attached tables
for definitions of Adjusted EBITDA and Adjusted EBITDAR, reconciliations of
net income (loss) to Adjusted EBITDA and Adjusted EBITDAR, calculations of
Adjusted EBITDA and Adjusted EBITDAR as a percentage of total revenues, and
non-GAAP financial measure reconciliation information.

As of June 30, 2010, ALC operated 211 senior living residences comprising
9,280 units.

The following discussions include the impact of the One-Time Charges and
exclude the impact of discontinued operations unless otherwise specified.

Quarters ended June 30, 2010, June 30, 2009, March 31, 2010

Revenues of $58.3 million in the second quarter ended June 30, 2010
increased $1.6 million or 2.9% from $56.7 million in the second quarter of
2009 and increased $0.4 million or 0.8% from the first quarter of 2010.

Adjusted EBITDA for the second quarter of 2010 was $14.5 million or 24.9%
of revenues and

--  increased $1.2 million or 9.1% from $13.3 million and 23.4% of revenues
    in the second quarter of 2009; and
--  increased $0.9 million or 6.7% from $13.6 million and 23.5% of revenues
    in the first quarter of 2010.

Adjusted EBITDAR for the second quarter of 2010 was $19.6 million or 33.6%
of revenues and

--  increased $1.3 million or 7.3% from $18.3 million and 32.3% of revenues
    in the second quarter of 2009; and
--  increased $0.9 million or 5.0% from $18.7 million and 32.3% of revenues
    in the first quarter of 2010.

Second quarter 2010 compared to second quarter 2009

Revenues in the second quarter of 2010 increased from the second quarter of
2009 primarily due to higher average daily revenue as a result of rate
increases ($2.2 million) and an increase in private pay occupancy ($1.2
million), partially offset by the planned reduction in the number of units
occupied by Medicaid residents ($1.8 million). Average private pay rates
increased in the second quarter of 2010 by 3.8% over average private pay
rates for the second quarter of 2009. Average overall rates, including the
impact of improved payer mix, increased in the second quarter of 2010 by
5.8% over comparable rates for the second quarter of 2009.

Both Adjusted EBITDA and Adjusted EBITDAR increased in the second quarter
of 2010 primarily due to an increase in revenues discussed above ($1.6
million) and a decrease in residence operations expenses ($0.5 million)
(this excludes the loss on disposal of fixed assets), partially offset by
an increase in general and administrative expenses ($0.8 million) (this
excludes non-cash equity based compensation) and, for Adjusted EBITDA only,
an increase in residence lease expense ($0.1 million). Residence
operations expenses decreased primarily from lower labor expenses.
Staffing needs in the second quarter of 2010 as compared to the second
quarter of 2009 decreased primarily because of a decline in the number of
units occupied by Medicaid residents who tend to have higher care needs
than private pay residents. In addition, general economic conditions
enabled us to hire new employees at lower wage rates. General and
administrative expenses increased as a result of expenses associated with
an all-company conference held in the second quarter of 2010 and expenses
associated with the realignment of our divisions.

Second quarter 2010 compared to the first quarter 2010

Revenues in the second quarter of 2010 increased from the first quarter of
2010 primarily due to one additional day in the second quarter ($0.6
million), an increase in the number of units occupied by private pay
residents ($0.1 million), and higher average daily revenue as a result of
rate increases ($0.1 million), partially offset by the planned reduction in
the number of units occupied by Medicaid residents ($0.4 million).

Increased Adjusted EBITDA and Adjusted EBITDAR in the second quarter of
2010 as compared to the first quarter of 2010 resulted primarily from a
decrease in residence operations expenses ($0.9 million) (this excludes the
loss on disposal of fixed assets) and an increase in revenues discussed
above ($0.4 million), partially offset by an increase in general and
administrative expenses ($0.4 million) (this excludes non-cash equity-based
compensation). Residence operations expenses decreased primarily from
decreases in utility expenses resulting from normal seasonal fluctuations.
General and administrative expenses increased as a result of expenses
associated with an all-company conference held in the second quarter of
2010 and expenses associated with the realignment of our divisions.

Six months ended June 30, 2010 and June 30, 2009

Revenues of $116.2 million in the six months ended June 30, 2010 increased
$2.4 million or 2.1% from $113.8 million in the six months ended June 30,
2009.

Adjusted EBITDA for the six months ended June 30, 2010 was $28.1 million,
or 24.2% of revenues and

--  increased $3.3 million or 13.1% from $24.8 million and 21.8% of
    revenues in the six months ended June 30, 2009.

Adjusted EBITDAR for the six months ended June 30, 2010 was $38.3 million,
or 33.0% of revenues and

--  increased $3.5 million or 10.2% from $34.7 million and 30.6% of
    revenues in the six months ended June 30, 2009.

Six months ended June 30, 2010 compared to six months ended June 30, 2009

Revenues in the six months ended June 30, 2010 increased from the six
months ended June 30, 2009 primarily due to higher average daily revenue
from rate increases ($4.2 million) and an increase in private pay occupancy
($2.1 million), partially offset by the planned reduction in the number of
units occupied by Medicaid residents ($3.9 million). Average private pay
rates increased in the six months ended June 30, 2010 by 3.8% over average
private pay rates for the six months ended June 30, 2009. Average overall
rates, including the impact of improved payer mix, increased in the six
months ended June 30, 2010 by 5.6% over the comparable rates for the six
months ended June 30, 2009.

Both Adjusted EBITDA and Adjusted EBITDAR increased in the six months ended
June 30, 2010 primarily from a decrease in residence operations expenses
($2.2 million) (this excludes the loss on disposal of fixed assets), and
the increase in revenues discussed above ($2.4 million), partially offset
by an increase in general and administrative expenses ($1.1 million) (this
excludes non-cash equity based compensation) and, for Adjusted EBITDA only,
an increase in residence lease expense ($0.3 million). Residence
operations expenses decreased primarily from lower labor and kitchen
expenses. Staffing needs in the six months ended June 30, 2010 as compared
to the six months ended June 30, 2009 decreased primarily because of a
decline in the number of units occupied by Medicaid residents who tend to
have higher care needs than private pay residents. In addition, general
economic conditions enabled us to hire new employees at lower wage rates.
Kitchen expenses were lower due to new group purchasing plans and lower
overall occupancy. General and administrative expenses increased primarily
from upfront costs associated with transitioning payroll and benefits from
a third party vendor to in-house, expenses associated with an all-company
conference held in the second quarter of 2010, and expenses associated with
the realignment of our divisions.

Liquidity

At June 30, 2010 ALC maintained a strong liquidity position with cash of
approximately $12.2 million and undrawn lines of $70 million.

Share Repurchase Program

On August 9, 2010, ALC’s Board of Directors extended and expanded its share
repurchase program by authorizing the purchase of up to $15 million in
Class A common stock through August 9, 2011. In 2010, through August 9,
2010, ALC repurchased 61,461 shares of Class A Common Stock at a cost of
$1.9 million and an average price of $30.45 per share (excluding fees).

Investor Call

ALC has scheduled a conference call for tomorrow, August 10, 2010 at 10:00
a.m. (ET) to discuss its financial results for the second quarter. This
earnings release will be posted on ALC’s website at www.alcco.com. The
toll-free number for the live call is (800) 230-1096 or international (612)
332-0107; the conference name is “ALC Second Quarter Results.” A taped
rebroadcast of the conference call will be available approximately three
hours following the live call until midnight on September 10, 2010, by
dialing toll free (800) 475-6701, or international (320) 365-3844; the
access code is 165684.

About Us

Assisted Living Concepts, Inc. and its subsidiaries operate 211 senior
living residences comprising 9,280 residents in 20 states. ALC’s senior
living facilities typically consist of 40 to 60 units and offer residents a
supportive, home-like setting and assistance with the activities of daily
living. ALC employs approximately 4,100 people.

Forward-looking Statements

Statements contained in this release other than statements of historical
fact, including statements regarding anticipated financial performance,
business strategy and management’s plans and objectives for future
operations, including management’s expectations about improving occupancy
and private pay mix, are forward-looking statements. Forward-looking
statements generally include words such as “expect,” “point toward,”
“intend,” “will,” “indicate,” “anticipate,” “believe,” “estimate,” “plan,”
“strategy” or “objective.” Forward-looking statements are subject to risks
and uncertainties that could cause actual results to differ materially from
those expressed or implied. In addition to the risks and uncertainties
referred to in the release, other risks and uncertainties are contained in
ALC’s filings with United States Securities and Exchange Commission and
include, but are not limited to, the following: changes in the health care
industry in general and the senior housing industry in particular because
of governmental and economic influences; changes in general economic
conditions, including changes in housing markets, unemployment rates and
the availability of credit at reasonable rates; changes in regulations
governing the industry and ALC’s compliance with such regulations; changes
in government funding levels for health care services; resident care
litigation, including exposure for punitive damage claims and increased
insurance costs, and other claims asserted against ALC; ALC’s ability to
maintain and increase census levels; ALC’s ability to attract and retain
qualified personnel; the availability and terms of capital to fund
acquisitions and ALC’s capital expenditures; changes in competition; and
demographic changes. Given these risks and uncertainties, readers are
cautioned not to place undue reliance on ALC’s forward-looking statements.
All forward-looking statements contained in this report are necessarily
estimates reflecting the best judgment of the party making such statements
based upon current information. ALC assumes no obligation to update any
forward-looking statement.

                   ASSISTED LIVING CONCEPTS, INC.
              Consolidated Statements of Operations
             (In thousands, except earnings per share)

                                Three Months Ended    Six Months Ended
                                     June 30,             June 30,
                               --------------------- ---------------------
                                 2010      2009(1)     2010      2009(1)
                               ---------- ---------- ---------- ----------
Revenues                       $   58,305 $   56,683 $  116,164 $  113,750
Expenses:
  Residence operations
   (exclusive of depreciation
   and amortization and
   residence lease expense
   shown below)                    34,805     35,181     70,517     72,434
  General and administrative        4,256      3,341      8,030      6,775
  Residence lease expense           5,111      4,993     10,194      9,923
  Depreciation and amortization     5,698      5,218     11,368     10,149
    Goodwill impairment                --         --         --     16,315
                               ---------- ---------- ---------- ----------
  Total operating expenses         49,870     48,733    100,109    115,596
                               ---------- ---------- ---------- ----------
Income (loss) from operations       8,435      7,950     16,055     (1,846)
Other expense:
    Other-than-temporary
     investments impairment        (2,026)        --     (2,026)        --
    Interest income                     4          7          8         19
  Interest expense                 (1,899)    (1,834)    (3,787)    (3,537)
                               ---------- ---------- ---------- ----------
Income (loss) from continuing
 operations before income
 taxes                              4,514      6,123     10,250     (5,364)
Income tax expense                 (1,618)    (2,182)    (3,741)    (2,326)
                               ---------- ---------- ---------- ----------
Net income (loss) from
 continuing operations              2,896      3,941      6,509     (7,690)
Loss from discontinued
 operations, net of tax                --        (34)        --       (178)
                               ---------- ---------- ---------- ----------
Net income (loss)              $    2,896 $    3,907 $    6,509 $   (7,868)
                               ========== ========== ========== ==========
Weighted average common shares:
  Basic                            11,567     11,808     11,572     11,882
  Diluted                          11,738     11,927     11,741     11,882
Per share data:
  Basic earnings per common
   share
  Earnings (loss) from
   continuing operations       $     0.25 $     0.33 $     0.56 $    (0.65)
  Loss from discontinued
   operations                          --         --         --      (0.01)
                               ---------- ---------- ---------- ----------
  Net income (loss)            $     0.25 $     0.33 $     0.56 $    (0.66)
                               ========== ========== ========== ==========

    Diluted earnings per
     common share
  Earnings (loss) from
   continuing operations       $     0.25 $     0.33 $     0.55 $    (0.65)
  Loss from discontinued
   operations                          --         --         --      (0.01)
                               ---------- ---------- ---------- ----------
  Net income (loss)            $     0.25 $     0.33 $     0.55 $    (0.66)

Adjusted EBITDA (2)            $   14,503 $   13,291 $   28,100 $   24,840
                               ========== ========== ========== ==========
Adjusted EBITDAR (2)           $   19,614 $   18,284 $   38,294 $   34,763
                               ========== ========== ========== ==========

(1) Reflects the reclassification of the operations of 118 units previously
reported as continuing operations to discontinued operations.
(2) See attached tables for definitions of Adjusted EBITDA and Adjusted
EBITDAR and reconciliations of net income to Adjusted EBITDA and Adjusted
EBITDAR.




                   ASSISTED LIVING CONCEPTS, INC.
                    Consolidated Balance Sheets
           (In thousands, except share and per share data)

                                                  June 30,    December 31,
                                                    2010          2009
                                                ------------  ------------
                 ASSETS                          (unaudited)
Current Assets:
  Cash and cash equivalents                     $     12,239  $      4,360
  Investments                                          3,568         3,427
  Accounts receivable, less allowances of
   $1,096 and $738, respectively                       3,627         2,668
  Prepaid expenses, supplies and other
   receivables                                         4,095         3,537
  Deposits in escrow                                   1,763         1,993
  Income taxes receivable                                 --           723
  Deferred income taxes                                4,590         4,636
  Current assets of discontinued operations              168            36
                                                ------------  ------------
     Total current assets                             30,050        21,380
Property and equipment, net                          411,894       415,454
Intangible assets, net                                11,003        11,812
Restricted cash                                        3,017         4,389
Other assets                                           1,977         1,935
Non-current assets of discontinued operations             --           399
                                                ------------  ------------
    Total Assets                                $    457,941  $    455,369
                                                ============  ============

    LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
  Accounts payable                              $      5,749  $      8,005
  Accrued liabilities                                 16,177        19,228
  Deferred revenue                                     6,008         6,368
  Current maturities of long-term debt                 1,884         1,823
  Income tax payable                                   1,212            --
  Current portion of self-insured liabilities            500           500
  Current liabilities of discontinued
   operations                                             --            34
                                                ------------  ------------
     Total current liabilities                        31,530        35,958
Accrual for self-insured liabilities                   1,416         1,416
Long-term debt                                       118,954       119,914
Deferred income taxes                                 14,281        13,257
Other long-term liabilities                           11,801        11,853
Commitments and contingencies
                                                ------------  ------------
     Total Liabilities                               177,982       182,398
                                                ------------  ------------
Preferred Stock, par value $0.01 per share,
 25,000,000 shares authorized; no shares issued
 and outstanding                                          --            --
Class A Common Stock, $0.01 par value,
 80,000,000 shares authorized at June 30, 2010
 and December 31, 2009; 12,403,499 and
 12,397,525 shares issued and 10,108,938 and
 10,048,674 shares outstanding, respectively             124           124
Class B Common Stock, $0.01 par value,
 15,000,000 shares authorized at June 30, 2010
 and December 31, 2009; 1,523,085 and 1,528,650
 shares issued and outstanding, respectively              15            15
Additional paid-in capital                           314,964       314,602
Accumulated other comprehensive loss                    (775)       (2,012)
Retained earnings                                     39,995        33,486
Treasury stock at cost, 2,384,561 and 2,348,851
 shares, respectively                                (74,364)      (73,244)
                                                ------------  ------------
 Total Stockholders' Equity                          279,959       272,971
                                                ------------  ------------
Total Liabilities and Stockholders' Equity      $    457,941  $    455,369
                                                ============  ============



                  ASSISTED LIVING CONCEPTS, INC.
              Consolidated Statements of Cash Flows
                         (In thousands)
                          (unaudited)

                                                       Six Months Ended
                                                           June 30,
                                                     ---------------------
                                                        2010       2009
                                                     ---------- ----------
OPERATING ACTIVITIES:
Net income (loss)                                    $    6,509 $   (7,868)
Adjustments to reconcile net income (loss) to net
 cash provided by operating activities:
    Depreciation and amortization                        11,368     10,344
    Other-than-temporary investments impairment           2,026         --
    Goodwill impairment                                      --     16,315
    Amortization of purchase accounting adjustments
     for leases                                            (197)      (198)
    Provision for bad debts                                 358        (27)
    Provision for self-insured liabilities                  262        392
    Loss on disposal of fixed assets                        315         34
    Unrealized gain on investments                          (17)        --
    Equity-based compensation expense                       362        188
    Change in fair value of derivatives                      23         --
    Deferred income taxes                                   306       (154)
Changes in assets and liabilities:
    Accounts receivable                                  (1,317)       360
    Supplies, prepaid expenses and other receivables       (558)    (1,027)
    Deposits in escrow                                      230        388
    Current assets - discontinued operations               (132)        --
    Accounts payable                                     (1,432)    (1,735)
    Accrued liabilities                                  (3,051)      (231)
    Deferred revenue                                       (360)       424
    Current liabilities - discontinued operations           (34)        --
    Payments of self-insured liabilities                   (261)      (320)
    Income taxes payable / receivable                     1,935      4,296
    Changes in other non-current assets                   1,330        809
    Other non-current assets - discontinued
     operations                                             399         --
    Other long-term liabilities                             100        553
                                                     ---------- ----------
      Cash provided by operating activities              18,164     22,543
INVESTING ACTIVITIES:
    Payment for executive retirement plan securities       (110)       (95)
    Payments for new construction projects               (3,208)   (11,768)
    Payments for purchases of property and equipment     (4,930)    (6,930)
                                                     ---------- ----------
      Cash used in investing activities                  (8,248)   (18,793)
FINANCING ACTIVITIES:
    Purchase of treasury stock                           (1,120)    (4,860)
    Repayment of revolving credit facility                   --    (19,000)
  Proceeds from issuance of new mortgage debt                --     14,000
  Repayment of mortgage debt                               (917)    (8,114)
                                                     ---------- ----------
      Cash used by financing activities                  (2,037)   (17,974)
                                                     ---------- ----------
Increase (decrease) in cash and cash equivalents          7,879    (14,224)
Cash and cash equivalents, beginning of year              4,360     19,905
                                                     ---------- ----------
Cash and cash equivalents, end of period             $   12,239 $    5,681
                                                     ========== ==========
Supplemental schedule of cash flow information:
Cash paid during the period for:
  Interest                                           $    3,575 $    3,663
  Income tax payments, net of refunds                     1,494     (1,892)



                ASSISTED LIVING CONCEPTS, INC.
              Financial and Operating Statistics

Continuing residences*                           Three months ended
                                           -------------------------------
                                           June 30,   March 31,   June 30,
                                             2010       2010        2009
                                           ---------  ---------  ---------
Average Occupied Units by Payer Source
Private                                        5,476      5,468      5,354
Medicaid                                         162        214        445
                                           ---------  ---------  ---------
Total                                          5,638      5,682      5,799
                                           =========  =========  =========

Occupancy Mix by Payer Source
Private                                         97.1%      96.2%      92.3%
Medicaid                                         2.9%       3.8%       7.7%

Percent of Revenue by Payer Source
Private                                         98.1%      97.5%      95.0%
Medicaid                                         1.9%       2.5%       5.0%

Average Revenue per Occupied Unit Day      $  113.64  $  113.13  $  107.42

Occupancy Percentage*                           62.7%      63.0%      64.2%

* Depending on the timing of new additions and temporary closures of our
residences, we may increase or reduce the number of units we actively
operate. For the three months ended June 30, 2010, March 31, 2010 and June
30, 2009 we actively operated 8,991, 9,025 and 9,154 units, respectively.



Same residence basis**                           Three months ended
                                           -------------------------------
                                           June 30,   March 31,   June 30,
                                             2010       2010        2009
                                           ---------  ---------  ---------
Average Occupied Units by Payer Source
Private                                        5,417      5,423      5,304
Medicaid                                         162        210        387
                                           ---------  ---------  ---------
Total                                          5,579      5,633      5,691
                                           =========  =========  =========

Occupancy Mix by Payer Source
Private                                         97.1%      96.3%      93.2%
Medicaid                                         2.9%       3.7%       6.8%

Percent of Revenue by Payer Source
Private                                         98.1%      97.5%      95.6%
Medicaid                                         1.9%       2.5%       4.4%

Average Revenue per Occupied Unit Day      $  113.49  $  112.92  $  107.28

Occupancy Percentage                            63.4%      64.0%      64.6%

** Excludes quarterly impact of 111 completed expansion units and 76
re-opened renovated units.



                   ASSISTED LIVING CONCEPTS, INC.
                 Financial and Operating Statistics

Continuing residences*                                  Six months ended
                                                      --------------------
                                                       June 30,   June 30,
                                                        2010        2009

Average Occupied Units by Payer Source
Private                                                   5,472      5,369
Medicaid                                                    188        483
                                                      ---------  ---------
Total                                                     5,660      5,852
                                                      =========  =========

Occupancy Mix by Payer Source
Private                                                    96.7%      91.7%
Medicaid                                                    3.3%       8.3%

Percent of Revenue by Payer Source
Private                                                    97.8%      94.4%
Medicaid                                                    2.2%       5.6%

Average Revenue per Occupied Unit Day                 $  113.39  $  107.38

Occupancy Percentage*                                      62.9%      64.9%

* Depending on the timing of new additions and temporary closures of our
residences, we may increase or reduce the number of units we actively
operate. For the six months ended June 30, 2010 and June 30, 2009 we
actively operated 9,004 and 9,014 units, respectively.



Same residence basis**                                  Six months ended
                                                      -------------------
                                                       June 30,   June 30,
                                                        2010        2009

Average Occupied Units by Payer Source
Private                                                   5,392      5,327
Medicaid                                                    186        419
                                                      ---------  ---------
Total                                                     5,578      5,746
                                                      =========  =========

Occupancy Mix by Payer Source
Private                                                    96.7%      92.7%
Medicaid                                                    3.3%       7.3%

Percent of Revenue by Payer Source
Private                                                    97.8%      95.0%
Medicaid                                                    2.2%       5.0%

Average Revenue per Occupied Unit Day                 $  113.08  $  107.73

Occupancy Percentage                                       64.3%      66.3%

** Excludes quarterly impact of 245 completed expansion units, 39 units
temporarily closed for renovation and 76 re-opened renovated units.

Non-GAAP Financial Measures

Adjusted EBITDA and Adjusted EBITDAR

Adjusted EBITDA is defined as net income from continuing operations before
income taxes, interest expense net of interest income, depreciation and
amortization, equity based compensation expense, transaction costs and
non-cash, non-recurring gains and losses, including disposal of assets and
impairment of long-lived assets (including goodwill) and loss on
refinancing and retirement of debt. Adjusted EBITDAR is defined as
Adjusted EBITDA before rent expenses incurred for leased assisted living
properties. Adjusted EBITDA and Adjusted EBITDAR are not measures of
performance under accounting principles generally accepted in the United
States of America, or GAAP. We use Adjusted EBITDA and Adjusted EBITDAR as
key performance indicators and Adjusted EBITDA and Adjusted EBITDAR
expressed as a percentage of total revenues as a measurement of margin.

We understand that EBITDA and EBITDAR, or derivatives thereof, are
customarily used by lenders, financial and credit analysts, and many
investors as a performance measure in evaluating a company’s ability to
service debt and meet other payment obligations or as a common valuation
measurement in the long-term care industry. Moreover, ALC’s revolving
credit facility contains covenants in which a form of EBITDA is used as a
measure of compliance, and we anticipate EBITDA will be used in covenants
in any new financing arrangements that we may establish. We believe
Adjusted EBITDA and Adjusted EBITDAR provide meaningful supplemental
information regarding our core results because these measures exclude the
effects of non-operating factors related to our capital assets, such as the
historical cost of the assets.

We report specific line items separately, and exclude them from Adjusted
EBITDA and Adjusted EBITDAR because such items are transitional in nature
and would otherwise distort historical trends. In addition, we use
Adjusted EBITDA and Adjusted EBITDAR to assess our operating performance
and in making financing decisions. In particular, we use Adjusted EBITDA
and Adjusted EBITDAR in analyzing potential acquisitions and internal
expansion possibilities. Adjusted EBITDAR performance is also used in
determining compensation levels for our senior executives. Adjusted EBITDA
and Adjusted EBITDAR should not be considered in isolation or as a
substitute for net income, cash flows from operating activities, and other
income or cash flow statement data prepared in accordance with GAAP, or as
a measure of profitability or liquidity. We present Adjusted EBITDA and
Adjusted EBITDAR on a consistent basis from period to period, thereby,
allowing for comparability of operating performance.

Adjusted EBITDA and Adjusted EBITDAR Reconciliation Information

The following table sets forth a reconciliation of net income (loss) to
Adjusted EBITDA and Adjusted EBITDAR:

                              Three months ended         Six months ended
                          ----------------------------  ------------------
                          June 30,  June 30,  March 31, June 30,  June 30,
                            2010      2009      2010      2010      2009
                          --------  --------  --------  --------  --------
                                           (in thousands)
Net income (loss)         $  2,896  $  3,907  $  3,613  $  6,509    (7,868)
Less: Income (loss) from
 discontinued operations,
 net of tax                      -       (34)        -         -      (178)
Add: provision for income
 taxes                       1,618     2,182     2,123     3,741     2,326
                          --------  --------  --------  --------  --------

Income (loss) from
 continuing operations
 before income taxes      $  4,514  $  6,123  $  5,736    10,250    (5,364)
Add:
  Depreciation and
   amortization              5,698     5,218     5,670    11,368    10,149
  Interest expense, net      1,895     1,827     1,884     3,779     3,518
  Non-cash equity based
   compensation                225       123       137       362       188
  Loss on disposal of
   fixed assets                145         -       170       315        34
  Write-down of equity
   investments               2,026         -         -     2,026
  Goodwill impairment            -         -         -         -    16,315
                          --------  --------  --------  --------  --------

Adjusted EBITDA             14,503    13,291    13,597    28,100    24,840
Add: Lease expense           5,111     4,993     5,083    10,194     9,923
                          --------  --------  --------  --------  --------
Adjusted EBITDAR          $ 19,614  $ 18,284  $ 18,680  $ 38,294  $ 34,763
                          ========  ========  ========  ========  ========

Adjusted EBITDA             14,503    13,291    13,597    28,100    24,840
Add: Division realignment
 expense                       453         -         -       453         -
                          --------  --------  --------  --------  --------
Adjusted EBITDA before
 division realignment
 expense                    14,956    13,291    13,597    28,553    24,840
Add: Lease expense           5,111     4,993     5,083    10,194     9,923
                          --------  --------  --------  --------  --------
Adjusted EBITDAR before
 division realignment
 expense                  $ 20,067  $ 18,284  $ 18,680  $ 38,747  $ 34,763
                          ========  ========  ========  ========  ========

The following table sets forth the calculations of Adjusted EBITDA,
Adjusted EBITDAR, Adjusted EBITDA before division realignment and Adjusted
EBITDAR before division realignment as percentages of total revenue:

                           Three months ended           Six months ended
                     -------------------------------  --------------------
                     June 30,   June 30,   March 31,  June 30,   June 30,
                      2010(1)     2009       2010      2010(1)     2009
                     ---------  ---------  ---------  ---------  ---------
                                         (in thousands)
Revenues             $  58,305  $  56,683  $  57,859  $ 116,164  $ 113,750
                     =========  =========  =========  =========  =========

Adjusted EBITDA      $  14,503  $  13,291  $  13,597  $  28,100  $  24,840
                     =========  =========  =========  =========  =========

Adjusted EBITDAR     $  19,614  $  18,284  $  18,680  $  38,294  $  34,763
                     =========  =========  =========  =========  =========

Adjusted EBITDA as
 percent of total
 revenues                 24.9%      23.4%      23.5%      24.2%      21.8%
                     =========  =========  =========  =========  =========

Adjusted EBITDAR as
 percent of total
 revenues                 33.6%      32.3%      32.3%      33.0%      30.6%
                     =========  =========  =========  =========  =========


     (1) Includes division realignment expenses of $453 in both the
     quarter and six months ended June 30, 2010. Excluding division
     realignment expenses,  Adjusted EBITDA, Adjusted EBITDAR, Adjusted
     EBITDA as a percent of sales and Adjusted EBITDAR as a percent of
     sales for the quarter ended June 30, 2010 would have been $14,956,
     $20,067, 25.7% and 34.4%, respectively.   Adjusted EBITDA, Adjusted
     EBITDAR, Adjusted EBITDA as a percent of sales and Adjusted EBITDAR as
     a percent of sales for the six months ended June 30, 2010 would have
     been $28,553, $38,747, 24.6% and 33.4%, respectively.




                     ASSISTED LIVING CONCEPTS, INC.
                  Reconciliation of Non-GAAP Measures
                              (unaudited)


                                             Three       Six        Six
                                             Months     Months     Months
                                             Ended      Ended      Ended
                                            June 30,   June 30,   June 30,
                                             2010       2010       2009
                                             (dollars in thousands except
                                                   per share data)
Net income (loss)                          $   2,896  $   6,509  $  (7,868)
Add: Loss from discontinued operations,
 net of tax                                        -          -        178
                                           ---------  ---------  ---------
Income (loss) from continuing operations       2,896      6,509     (7,690)
                                           ---------  ---------  ---------
Add one time charge:
  Write down of equity investments             2,026      2,026          -
  Goodwill impairment                              -          -     16,315
  Loss on disposal of fixed assets related
   to expansion project                          125        125          -
Division realignment expense                     453        453          -
Less: Income tax benefits from one-time
 charges                                         933        933      1,622
                                           ---------  ---------  ---------
  Pro forma net income from continuing
   operations excluding one-time charges   $   4,567  $   8,180  $   7,003
                                           =========  =========  =========

Weighted average common shares:
Basic                                         11,567     11,572     11,882
Diluted                                       11,738     11,741     11,882

Per share data:
  Basic earnings per common share
  Income (loss) from continuing operations $    0.25  $    0.56  $   (0.65)
  Less: loss from discontinued operations          -          -      (0.01)
  Less: loss from one-time charges             (0.14)     (0.14)     (1.24)
                                           ---------  ---------  ---------
  Pro forma net income from continuing
   operations excluding one-time charges   $    0.39  $    0.70  $    0.60
                                           =========  =========  =========

  Diluted earnings per common share*
  Income (loss) from continuing operations $    0.25  $    0.55  $   (0.65)
  Less: loss from discontinued operations          -          -      (0.01)
  Less: loss from one-time charges             (0.14)     (0.14)     (1.24)
                                           ---------  ---------  ---------
  Pro forma net income from continuing
   operations excluding one-time charges   $    0.39  $    0.70  $    0.60
                                           =========  =========  =========

* Per share numbers may not add due to rounding

CAMBRIDGE, MA–(Marketwire – August 9, 2010) –  Myomo, Inc., the developer of neuro-robotic stroke rehabilitation technology, has launched myomo@home, a program that enables stroke survivors to purchase the Myomo System directly for use at home. The system is a neuro-robotic rehabilitation device that helps impaired stroke survivors increase movement in their arms, and has been clinically proven effective from two days to 21 years post stroke. Used in the clinical setting since 2008, the Myomo System is now available directly to consumers with a physician’s prescription. Myomo has successfully completed FDA requirements to demonstrate that the device is safe for use in the home.

“Our goal is to make the Myomo System available to as many people as can benefit from it,” explains Steve Kelly, Myomo’s CEO. “Stroke is the leading cause of disability in the US. There is a great need to restore independence to those who have suffered a stroke. Our new program expands access to world-class rehabilitation therapy and technology to any individual at home regardless of geography.”

“We were able to get therapy with the Myomo System, but the nearest clinic was a four hour round trip drive,” said Dean Kenefick, who suffered a stroke in 2004. “When Myomo started a pilot program for home use, we purchased one. I use the Myomo device three times a week and consistently get more return of muscle and movement.”

A Model for Delivering High-Frequency Stroke Rehabilitation

myomo@home is a comprehensive program that leverages evidence-based techniques to restore arm movement. It combines the Myomo System with therapy from a trained and certified Myomo physical or occupational therapist. Direction from a therapist and adherence to a prescribed protocol is critical to the success of stroke patients using the Myomo System at home. 

“Myomo was developed based on a well-known principle that if you work at it, you will get better at it,” said Steve Williams, MD, Chief, Chairman, Department of Rehabilitation Medicine at Boston Medical Center. “Just like learning and getting better at a sport or a craft, re-learning to move your arm requires repetitive practice to keep getting better at it.”

To acquire the product, Myomo has a defined process that includes an in-person or a Web-based video screening and the participation of a clinical partner or a local therapist. If the patient doesn’t have access to a local therapy resource, Myomo works with them to connect with a local therapist through its independent therapist network. 

Myomo provides therapist training and certification through a multi-level certification program that is completed either in-person or live via the Web. Each therapy protocol is customized for the individual patient and follow-up is conducted to adjust treatment for the most potential improvement. Unlimited phone customer service is included with the program.

About Myomo

Myomo develops neuro-robotic technology that helps impaired stroke survivors regain movement in their arms. The company combines technology developed at Massachusetts Institute of Technology (MIT), with rehabilitation professionals trained at the best hospitals in the country, to help stroke patients regain independence. For more information, visit www.myomo.com. Join us on Facebook at http://www.facebook.com/pages/Cambridge-MA/Myomo/196353791770.

VICTORIA, BRITISH COLUMBIA–(Marketwire – Aug. 9, 2010) –Marketwire would like to issue a correction for the press release issued at 12:30 PM ET. The URL for Vigil’s Financial Statements contained incorrect HTML coding. The proper link is http://www.vigil.com/?Investors:Financial_Statements. The corrected release follows:

 Vigil Health Solutions Inc. (TSX VENTURE:VGL) (“Vigil”) announces the results of operations for the quarter ending June 30, 2010.

Business highlights

• Grew bookings 26% for the quarter to $955 thousand compared to $755 thousand for the three-month period ended June 30, 2009.
• Increased backlog 14% to approximately $3.1 million compared to approximately $2.72 million at June 30, 2009.
• Revenue was $641 thousand for the three-months ended June 30, 2010 compared to $1.37 million in the three-month period ended June 30, 2009, a decrease of 53%. The decrease reflects lower bookings in FYE2010 and the timing in projects commissioned.
• Expanded revenue from service and maintenance agreements and one-off sales by 72% during the quarter ended June 30, 2010 to $298 thousand.

“I am encouraged with our increased sales bookings which I believe is a positive indication of both the improvement in the economy, as well as our continued investment in sales and marketing,” stated Troy Griffiths, President and CEO of Vigil Health Solutions Inc.

Financial Results

Revenue for the three-months ended June 30, 2010 was $641 thousand compared to $1.37 million in the three-month period ended June 30, 2009, a decrease of 53%. The decrease in revenue reflects both the reduced number and size of the projects completed during the quarter. Because Vigil records revenue using the completed contract method the number of projects completed this quarter directly reflects a lag related to the timing of the US economic downturn.

Bookings for the quarter were $955 thousand up 26% compared to $755 thousand in the three-month period ended June 30, 2009. The increase in bookings relates to an improvement in the United States economy, specifically, in funding availability for new construction in the seniors living industry as well as the Company’s investment in it sales program.

At June 30, 2010, Vigil had a backlog of approximately $3.1 million (including $1.64 million in deposits and progress billings, recorded as deferred revenue on the balance sheet) a 14% increase compared to approximately $2.72 million (including $1.34 million in deposits and progress billings, recorded as deferred revenue on the balance sheet) at June 30, 2009. This increase is the result of booking more new projects than recorded as revenue during the quarter.

The gross margin percentage for the three months ended June 30, 2010 was 45% compared to 48% for the three months ended June 30, 2009. The gross margin during the period was with in management’s expectations of margins of between 42% and 47%.

Expenditures for the three months ended June 30, 2010 were $465 thousand down 22% from operating expenditures of $599 thousand for the same period ended June 30, 2009. The Company decreased expenditures in all areas. These decreases were the result of a combined strategic effort to focus resources where they would be best utilized.

Net loss for the three month period ended June 30, 2010 was $180 thousand, or $0.002 per share compared to a gain of $66 thousand, or $0.001 per share for the previous year. The increase in losses is primarily attributable to the lower in revenue in the period.

Detailed financial statements along with Management Discussion and Analysis have been filed with SEDAR and may be viewed on the Company web site (http://www.vigil.com/?Investors:Financial_Statements) or at (www.sedar.com).

Financial information will be mailed to entitled security holders on August 16, 2010. Or, upon notice to the Company, entitled security holders may request a copy of financials in advance.

Summary Financial Information

Non-GAAP Measure

For the three months ended June 30, 2010, we are disclosing Adjusted EBITDA, a non-GAAP financial measure, as a supplementary indicator of operating performance. We define Adjusted EBITDA as net income before, interest, income taxes, amortization, stock based compensation and currency gains or losses including derivative foreign exchange differences. We are presenting the non-GAAP financial measure in our filings because we use it internally to make strategic decisions, forecast future results and to evaluate our performance and because we believe that our current and potential investors and analysts use the measure to assess current and future operating results and to make investment decisions. It is a non-GAAP measure, may not be comparable to other companies and it is not intended as a substitute for GAAP measures.

Adjusted EBITDA reconciliation

About Vigil Health Solutions Inc.

Vigil offers a proprietary technology platform combining software and hardware to provide comprehensive solutions to the expanding seniors’ housing market. Vigil has established a growing presence in North America and an international reputation for being on the leading edge of systems design and integration. The Vigil Integrated Care Management System™ (Vigil® System) includes the award-winning Vigil Dementia System, a nurse call system, bed monitoring, resident check in, and the latest development the Vigil Wireless call system. The first to supply dementia specific care technology, Vigil facilitates the highest standard of care for cognitive residents while helping dementia residents enjoy a higher quality of life and greater dignity.

Certain statements contained in this news release that are not based on historical facts may constitute forward-looking statements or forward-looking information within the meaning of applicable securities laws (“forward-looking statements”). These forward-looking statements are not promises or guarantees of future performance but are only predictions that relate to future events, conditions or circumstances or our future results, performance, achievements or developments and are subject to substantial known and unknown risks, assumptions, uncertainties and other factors that could cause our actual results, performance, achievements or developments in our business or in our industry to differ materially from those expressed, anticipated or implied by such forward-looking statements.

Forward-looking statements include all financial guidance, disclosure regarding possible events, conditions, circumstances or results of operations that are based on assumptions about future economic conditions, courses of action and other future events. We caution you not to place undue reliance upon any such forward-looking statements, which speak only as of the date they are made. These forward-looking statements appear in a number of different places in this presentation and can be identified by words such as “may”, “estimates”, “projects”, “expects”, “intends”, “believes”, “plans”, “anticipates”, or their negatives or other comparable words. Forward-looking statements include statements regarding the outlook for our future operations, plans and timing for the introduction or enhancement of our services and products, statements concerning strategies or developments, statements about future market conditions, supply conditions, end customer demand conditions, channel inventory and sell through, revenue, gross margin, operating expenses, profits, forecasts of future costs and expenditures, the outcome of legal proceedings, and other expectations, intentions and plans that are not historical fact.

The risk factors and uncertainties that may affect our actual results, performance, achievements or developments are many and include, amongst others, our ability to develop our sales force and generate revenue, the length of the sales cycle, management of the Company’s growth, ability to recruit and retain staff, fluctuations in demand for current and future products, our ability to develop, manufacture, supply and market existing and new products that meet the needs of customers, volatility in the exchange rate, ability to secure financing, ability to secure product liability insurance, the continuous commitment of our customers, increased competition, changes in regulation and reliance on third party suppliers. These risk factors and others are discussed in the Risks and Uncertainties section of our “Management Discussion and Analysis” segment of our fiscal 2009 Annual Report. Many of these factors and uncertainties are beyond the control of the Company. Consequently, all forward-looking statements in this news release are qualified by this cautionary statement and there can be no assurance that actual results, performance, achievements or developments anticipated by the Company will be realized.

Forward-looking statements are based on management’s current plans, estimates, projections, beliefs and opinions and, except as required by law, the Company does not undertake any obligation to update forward-looking statements should the assumptions related to these plans, estimates, projections, beliefs and opinions change.

VICTORIA, BRITISH COLUMBIA–(Marketwire – Aug. 9, 2010) – Vigil Health Solutions Inc. (TSX VENTURE:VGL) (“Vigil”) announces the results of operations for the quarter ending June 30, 2010.

Business highlights

• Grew bookings 26% for the quarter to $955 thousand compared to $755 thousand for the three-month period ended June 30, 2009.
• Increased backlog 14% to approximately $3.1 million compared to approximately $2.72 million at June 30, 2009.
• Revenue was $641 thousand for the three-months ended June 30, 2010 compared to $1.37 million in the three-month period ended June 30, 2009, a decrease of 53%. The decrease reflects lower bookings in FYE2010 and the timing in projects commissioned.
• Expanded revenue from service and maintenance agreements and one-off sales by 72% during the quarter ended June 30, 2010 to $298 thousand.

“I am encouraged with our increased sales bookings which I believe is a positive indication of both the improvement in the economy, as well as our continued investment in sales and marketing,” stated Troy Griffiths, President and CEO of Vigil Health Solutions Inc.

Financial Results

Revenue for the three-months ended June 30, 2010 was $641 thousand compared to $1.37 million in the three-month period ended June 30, 2009, a decrease of 53%. The decrease in revenue reflects both the reduced number and size of the projects completed during the quarter. Because Vigil records revenue using the completed contract method the number of projects completed this quarter directly reflects a lag related to the timing of the US economic downturn.

Bookings for the quarter were $955 thousand up 26% compared to $755 thousand in the three-month period ended June 30, 2009. The increase in bookings relates to an improvement in the United States economy, specifically, in funding availability for new construction in the seniors living industry as well as the Company’s investment in it sales program.

At June 30, 2010, Vigil had a backlog of approximately $3.1 million (including $1.64 million in deposits and progress billings, recorded as deferred revenue on the balance sheet) a 14% increase compared to approximately $2.72 million (including $1.34 million in deposits and progress billings, recorded as deferred revenue on the balance sheet) at June 30, 2009. This increase is the result of booking more new projects than recorded as revenue during the quarter.

The gross margin percentage for the three months ended June 30, 2010 was 45% compared to 48% for the three months ended June 30, 2009. The gross margin during the period was with in management’s expectations of margins of between 42% and 47%.

Expenditures for the three months ended June 30, 2010 were $465 thousand down 22% from operating expenditures of $599 thousand for the same period ended June 30, 2009. The Company decreased expenditures in all areas. These decreases were the result of a combined strategic effort to focus resources where they would be best utilized.

Net loss for the three month period ended June 30, 2010 was $180 thousand, or $0.002 per share compared to a gain of $66 thousand, or $0.001 per share for the previous year. The increase in losses is primarily attributable to the lower in revenue in the period.

Detailed financial statements along with Management Discussion and Analysis have been filed with SEDAR and may be viewed on the Company web site (http://www.vigil.com/?Investors:Financial_Statements) or at (www.sedar.com).

Financial information will be mailed to entitled security holders on August 16, 2010. Or, upon notice to the Company, entitled security holders may request a copy of financials in advance.

Summary Financial Information

Non-GAAP Measure

For the three months ended June 30, 2010, we are disclosing Adjusted EBITDA, a non-GAAP financial measure, as a supplementary indicator of operating performance. We define Adjusted EBITDA as net income before, interest, income taxes, amortization, stock based compensation and currency gains or losses including derivative foreign exchange differences. We are presenting the non-GAAP financial measure in our filings because we use it internally to make strategic decisions, forecast future results and to evaluate our performance and because we believe that our current and potential investors and analysts use the measure to assess current and future operating results and to make investment decisions. It is a non-GAAP measure, may not be comparable to other companies and it is not intended as a substitute for GAAP measures.

Adjusted EBITDA reconciliation

About Vigil Health Solutions Inc.

Vigil offers a proprietary technology platform combining software and hardware to provide comprehensive solutions to the expanding seniors’ housing market. Vigil has established a growing presence in North America and an international reputation for being on the leading edge of systems design and integration. The Vigil Integrated Care Management System™ (Vigil® System) includes the award-winning Vigil Dementia System, a nurse call system, bed monitoring, resident check in, and the latest development the Vigil Wireless call system. The first to supply dementia specific care technology, Vigil facilitates the highest standard of care for cognitive residents while helping dementia residents enjoy a higher quality of life and greater dignity.

Certain statements contained in this news release that are not based on historical facts may constitute forward-looking statements or forward-looking information within the meaning of applicable securities laws (“forward-looking statements”). These forward-looking statements are not promises or guarantees of future performance but are only predictions that relate to future events, conditions or circumstances or our future results, performance, achievements or developments and are subject to substantial known and unknown risks, assumptions, uncertainties and other factors that could cause our actual results, performance, achievements or developments in our business or in our industry to differ materially from those expressed, anticipated or implied by such forward-looking statements.

Forward-looking statements include all financial guidance, disclosure regarding possible events, conditions, circumstances or results of operations that are based on assumptions about future economic conditions, courses of action and other future events. We caution you not to place undue reliance upon any such forward-looking statements, which speak only as of the date they are made. These forward-looking statements appear in a number of different places in this presentation and can be identified by words such as “may”, “estimates”, “projects”, “expects”, “intends”, “believes”, “plans”, “anticipates”, or their negatives or other comparable words. Forward-looking statements include statements regarding the outlook for our future operations, plans and timing for the introduction or enhancement of our services and products, statements concerning strategies or developments, statements about future market conditions, supply conditions, end customer demand conditions, channel inventory and sell through, revenue, gross margin, operating expenses, profits, forecasts of future costs and expenditures, the outcome of legal proceedings, and other expectations, intentions and plans that are not historical fact.

The risk factors and uncertainties that may affect our actual results, performance, achievements or developments are many and include, amongst others, our ability to develop our sales force and generate revenue, the length of the sales cycle, management of the Company’s growth, ability to recruit and retain staff, fluctuations in demand for current and future products, our ability to develop, manufacture, supply and market existing and new products that meet the needs of customers, volatility in the exchange rate, ability to secure financing, ability to secure product liability insurance, the continuous commitment of our customers, increased competition, changes in regulation and reliance on third party suppliers. These risk factors and others are discussed in the Risks and Uncertainties section of our “Management Discussion and Analysis” segment of our fiscal 2009 Annual Report. Many of these factors and uncertainties are beyond the control of the Company. Consequently, all forward-looking statements in this news release are qualified by this cautionary statement and there can be no assurance that actual results, performance, achievements or developments anticipated by the Company will be realized.

Forward-looking statements are based on management’s current plans, estimates, projections, beliefs and opinions and, except as required by law, the Company does not undertake any obligation to update forward-looking statements should the assumptions related to these plans, estimates, projections, beliefs and opinions change.

MONTVALE, NJ–(Marketwire – August 9, 2010) –  SRS, the leader in high-performance hybrid EMRs, today announced that Sandhills Pediatrics has selected the SRS hybrid EMR for its 14 providers. Sandhills Pediatrics has four offices in the greater Columbia, South Carolina, area and has served the community’s families since 1975.

“I see 38-45 patients a day, so I wanted an EMR that would easily adapt to my workflow and not hinder the pace of my schedule,” says Kevin O. Wessinger, M.D., Sandhills Pediatrics. “The SRS hybrid EMR allows me to practice the way I like, while eliminating the gross inefficiencies of a paper-centric office. Implementation was smooth — we didn’t have to compromise our productivity at all, even during the first few days!”

“The stopwatch doesn’t lie. During our EMR selection process, we looked at several traditional, point-and-click systems and a free online EMR,” says Ken Fenchel, Practice Administrator, Sandhills Pediatrics. “We timed how long it takes to perform common workflow tasks with each EMR and realized that SRS is the easiest and fastest by far. The higher level of productivity is critical to our physicians’ ability to provide quality care to our high volume of patients.”

SRS was designed with direct input by its high-performance physicians to provide them with a system that fits their needs, helps them to work more efficiently, and enables them to achieve a rapid return on their investment. SRS, which has built the largest national network of high-performance practices that successfully use an EMR, attributes its unmatched adoption rate to ease of use, fast implementation, and an accelerated timeframe for training physicians and office staff.

“If more practices took the time to do comparative benchmarking, the rate of successful EMR adoptions would increase,” says Evan Steele, CEO of SRSsoft. “We are confident that Sandhills — like our other pediatric practice clients — will see immediate and ongoing benefits with SRS throughout their offices, and we are very happy to have them join our growing national network of 5,000 providers.”

About Sandhills Pediatrics
Sandhills Pediatrics has a long and distinguished history of caring for children. Established in 1975 by Dr. S. Nelson Weston and Dr. Charles A. James, Sandhills offers comprehensive and well-rounded medical services to children from birth through college age. Visit www.sandhillsped.com for more information.

About SRS
For over a decade, SRS has been the leading provider of productivity-enhancing EMR technology — with a successful adoption rate unparalleled in the industry. The robust SRS hybrid EMR increases physicians’ speed and practice revenue by offering powerful and flexible solutions that streamline clinical workflows and enhance patient care. Prominent pediatric groups choose SRS because of its fit with the demands of their specialty. For more information on SRS, visit www.srssoft.com, e-mail [email protected], fax 201.802.1301, or call 800.288.8369.

TAMPA, FL–(Marketwire – August 9, 2010) –  Sage North America today announced that Sage Healthcare Division, a leading provider of electronic health record (EHR) and practice management software, is showing its support for National Health Center Week (August 8 – 14, 2010) by offering volunteer assistance at community health centers across the country during the week through its ProjectSERVS (Sage Employees Reaching out with Volunteer Service).

National Health Center Week is an annual celebration designed to raise awareness about the valuable work that community health centers do. During this week, health centers across the country host events to educate people on healthcare and the types of services provided by the centers. Many events feature free health screenings, food and refreshments, prominent speakers, and more.

“National Health Center Week is a tremendous opportunity to highlight the vital role health centers play in their community. We are appreciative of Sage’s support to make the week even more successful for health centers across the country,” said Dan Hawkins, Senior Vice-President of Policy and Research at the National Association of Community Health Centers. “Sage’s efforts are helping to strengthen health centers in numerous communities, and we stand ready to work with everyone in the years ahead to make sure all people have a healthcare home at a community health center.”

Sage Healthcare Division has supported the event for four consecutive years. This year, Sage employees are volunteering their time at several health centers across the U.S., including:

• Health Linc in Michigan City, Indiana; Knox, Indiana; and Valparaiso, Indiana – Sage employees will host a back-to-school fair and carnival in which each clinic will provide free sports physicals, immunizations, school backpacks stuffed with supplies and lunch will be served at each site; and
• New Hanover Health Center in Wilmington, North Carolina – Sage employees will be scanning paper medical records into the clinic’s electronic system.

“Sage continues to dedicate itself to furthering the mission of improving patient outcomes and quality of care in the United States. Our involvement with National Association of Community Health Centers’ National Health Center Week proves our commitment to this goal,” said Lee Horner, Senior Vice President of Sales for Sage Healthcare Division. “Sage strives to continuously serve communities through programs where Sage employees volunteer countless hours and thousands of dollars to support worthy causes every year, including community health centers, which we salute for the important role they play in our healthcare system.”

Sage has been a longstanding provider of information technology solutions to the CHC and Federally Qualified Health Center (FQHC) market, said Tony Ryzinski, Senior Vice President of Marketing for Sage Healthcare Division, and maintains a strong commitment to this segment by developing products that address its unique needs. 

“We maintain a close relationship with our CHC partners and continually solicit their input and recommendations,” Ryzinski said. “Many of our CHC partners provide critical insight into the needs of their clinics, providers and patients, and Sage recognizes the increasingly important role of the CHC and FQHC in today’s evolving healthcare economy, as their mission broadens in providing access to care to broader segments of the population.”

View Sage Healthcare Division YouTube interviews.
View Sage Healthcare Division information.

About Sage Healthcare Division
Sage Healthcare Division provides integrated electronic health records, EDI applications and practice management systems to more than 80,000 physicians and thousands of ambulatory care practices throughout North America. These systems enable physicians and practice managers to better manage their practices and improve profitability. Sage Healthcare Division is based in Tampa, Fla., and is a division of Sage North America. For more information, please visit www.sagehealth.com or call (877) 932-6301.

About Sage North America
Sage North America is part of The Sage Group plc, a leading global supplier of business management software and services. Sage North America employs 4,000 people and supports 3.1 million small and midsized business customers including more than 80,000 physicians. The Sage Group plc, formed in 1981, was floated on the London Stock Exchange in 1989 and now employs 13,100 people and supports 6.2 million customers worldwide. For more information, please visit the website at www.sagenorthamerica.com.

© 2010 Sage Software, Inc. All rights reserved. Sage, the Sage logos, and the Sage product and service names mentioned herein are registered trademarks or trademarks of Sage Software, Inc. or its affiliated entities. All other trademarks are the property of their respective owners.

LEXINGTON, MA–(Marketwire – August 9, 2010) –  Imprivata®, Inc., the company that simplifies and secures user access, today announced that St Andrew’s Healthcare, the UK’s largest not-for-profit mental health charity, has selected Imprivata OneSign to provide 3,500 employees with faster and more efficient access to a range of applications via single sign-on (SSO) and strong authentication with smart cards. The rollout, completed in June 2010 across the organisation’s four sites in Basildon, Birmingham, Mansfield and Northampton will allow clinical and support staff to increase the speed at which they can securely access patient information and raise the levels of patient care.

The implementation of OneSign will improve clinical productivity by providing users with a single point of secure access though which they can connect to multiple applications, including electronic patient records, HR, Finance, a range of intranet-based applications and its in-house knowledge system.

With OneSign St Andrew’s will bolster the levels of security around user access management without compromising productivity or patient care. OneSign will also ensure IT staff can quickly and efficiently audit access to patient information, helping to avoid malpractice by uncovering instances of shared passwords. This is especially valuable with increasingly strict compliance regulations around the issue of psychiatric medicines and drugs.

St Andrew’s is regularly audited by the Care Quality Commission and the Department of Health, who assess the standards of care being provided at healthcare organisations across the UK. As part of the process, auditors request access to random patient records and other data to ensure these are being managed securely. Previously, auditing employee access to patient data would involve manual printing of SQL tables, however with OneSign IT staff can access records at the click of a switch, simplifying compliance reporting.

“The nature of our work within mental health organisations involves both sensitive patient data and the prescription of psychiatric drugs — which underscores the importance of having complete control of who accesses our IT systems without jeopardising the productivity of our staff,” said Paul Kirkpatrick, Director of IT. “Working with Imprivata to implement single sign-on and strong authentication has enabled us to ensure that only authorised employees can access patient information and applications whilst also making sure we can improve the efficiency of our auditing for regulatory bodies.” 

Additionally, as a 24-hour psychiatric hospital, St Andrew’s has to ensure that medical staff can access data and applications round-the-clock and the self-service password reset module within OneSign will help reduce some of the 400 password reset calls to the IT helpdesk per month, freeing up one full-time employee for other activities.

“Patient data security is one of the primary IT concerns within the healthcare sector today, but not at the expense of employee productivity or patient safety,” said Omar Hussain, CEO and President, Imprivata. “Imprivata OneSign has long been a trusted name for both the NHS and private healthcare institutions across the globe, and we look forward to helping St Andrew’s simplify and secure access to patient data, improve workflow and ultimately the level of care delivered by its staff.”

About Imprivata
Imprivata is the leading independent vendor focused on simplifying and securing user access. By strengthening user authentication, streamlining application access and simplifying compliance reporting across multiple computing environments, customers can align security with user workflows and realize substantial productivity gains while lowering IT costs.

Imprivata has received numerous product awards and top review ratings from leading industry publications and analysts. Headquartered in Lexington, Mass., Imprivata partners with over 200 resellers, and serves the access security needs of more than 1,000 customers around the world. For more information, please visit www.imprivata.com.

Imprivata is a registered trademark of Imprivata, Inc. in the USA and other countries. All other product or company names mentioned are the property of their respective owners.

RSS Feed to Imprivata News: http://feeds.feedburner.com/ImprivataNews

Follow Imprivata on Twitter: https://twitter.com/Imprivata

id=”nav_links”>

INDIANAPOLIS, IN–(Marketwire – August 9, 2010) – Indianapolis-headquartered iSALUS Healthcare was recently selected by Indiana Health Information Technology Extension Center (I-HITEC), as a collaborative statewide initiative led by Purdue University, as an electronic medical records (EMR) preferred software partner. This partnership and endorsement allows iSALUS to serve Indiana’s healthcare community as part of a federal stimulus program to implement EMR software systems.

“The entire team at iSALUS has a vested and personal interest in being chosen as a preferred software provider,” said Michael Hall, president and founder of iSALUS Healthcare. “These are the doctors we trust to take care of our families, and we are honored to be chosen to help them provide the very best care to all of their patients.”

iSALUS was selected by I-HITEC from among hundreds of EMR software firms. The company was chosen based on its ability to assist healthcare providers in implementing electronic medical records, allowing them to qualify for federal stimulus money, a proven technology platform, previous experience with small to medium size healthcare practices, ability to quickly and efficiently implement a large number of new providers, and affordable pricing. Through this partnership, iSALUS and I-HITEC will provide Indiana healthcare providers with a full electronic medical records solution, education, training, implementation, technical and customer support.

“The Indiana Health Information Technology Extension Center is tasked with helping 2,200 Indiana primary care providers (PCPs) achieve Meaningful Use of electronic health record technology by 2012,” said Monica Arrowsmith, I-HITEC’s director. “We are confident we can reach this ambitious goal in partnership with iSALUS Healthcare as one of our certified EMR software partners. Together we will bring understandable, implementable and affordable EMR solutions to Indiana’s healthcare community.”

About iSALUS Healthcare
Founded in 2000 and headquartered in Indianapolis, iSALUS Healthcare offers web-based, mobile-optimized EMR and practice management software solutions for small to medium sized physician practices, healthcare offices and medical clinics. Its proven suite of easy-to-learn and easy-to-use applications is accessible from any Internet connection and provided at an affordable monthly fee. iSALUS includes unlimited technical support and customer service with all of its software subscriptions. Throughout its history, the company has served thousands of doctors and practice managers across the country. For more information, visit www.isalushealthcare.com or call 888.280.6678.

About Indiana Health Information Technology Extension Center (I-HITEC)
Indiana Health Information Technology Extension Center (I-HITEC) is a federally-designated state-chartered non-profit led by Purdue University. The organization was formed as a result of the 2009 federal Health Information Technology for Economic and Clinical Health Act and is funded through a four-year, $12 million grant. I-HITEC provides subsidized EHR adoption assistance, Meaningful Use coaching and discounted EHR products and services to Indiana’s small physician practices, public or critical access hospitals, community health centers or rural health clinics as well as other medical settings that serve the uninsured, underinsured, underserved or other at-risk populations. I-HITEC is tasked with educating and helping these entities transition from traditional, paper-based electronic health record management systems to federally-mandated electronic health record (EHR) technology. This initiative benefits Indiana through improvements to the state’s existing health information technology delivery system which will ultimately improve patient outcomes and reduce healthcare costs. To receive reimbursement from the federal stimulus program, Indiana’s healthcare providers must achieve and prove Meaningful Use of EHR software. I-HITEC plays a critical role in this process. For more information about I-HITEC, please visit www.switch.purdue.edu or call (765) 496-1911.

SPRINGFIELD, OH–(Marketwire – August 4, 2010) –  AdCare Health Systems, Inc. (NYSE Amex: ADK), an Ohio-based long-term care, home care and management company, has closed the sale of an additional 225,400 shares of common stock at the offering price of $3.50 per share for gross proceeds of $788,900, pursuant to the over-allotment option exercised by the underwriter in connection with AdCare’s offering that closed on June 30, 2010.

The full exercise of the over-allotment option brings the total number of common shares sold by AdCare in the offering to 1,939,686 and gross proceeds to approximately $6.8 million. The aggregate net proceeds to the company from the offering totaled approximately $6.1 million, after deducting underwriting discounts, commissions, legal fees and other offering-related expenses payable by the Company. AdCare plans to use the net proceeds of the offering for acquisition purposes, working capital and general corporate purposes. As of the close of the exercise of the over-allotment, the Company has approximately 7.5 million common shares outstanding.

C. K. Cooper & Company was the sole manager for the public offering.

This press release does not constitute an offer to sell or solicitation of an offer to buy any securities. Any such offer may be made only pursuant to the company’s prospectus supplement and accompanying base prospectus for the offering and only in states in which the offering is registered or exempt from registration and by broker-dealers authorized to do so. The securities offered by the prospectus involve a high degree of risk. Copies of the prospectus supplement and accompanying base prospectus may be obtained from the SEC’s website at www.sec.gov or from C. K. Cooper & Company, 18300 Von Karman Avenue, Suite 700, Irvine, California 92612, Attention: Hue Lapham/Syndicate Department, or [email protected], or via fax +1-949-477-9211.

About AdCare Health Systems
AdCare Health Systems, Inc. (NYSE Amex: ADK) develops, owns and manages assisted living facilities, nursing homes and retirement communities and provides home healthcare services. Prior to becoming a publicly traded company in November of 2006, AdCare operated as a private company for 18 years. AdCare’s 900 employees provide high-quality care, management services and other services for patients and residents residing in 19 facilities, seven of which are assisted living facilities, 11 skilled nursing centers and one independent senior living community. The company owns eight of those facilities. In the ever-expanding marketplace of long-term care, AdCare’s mission is to provide quality healthcare services to the elderly. For more information about AdCare, visit www.adcarehealth.com.

Click here to see all recent news from this company

ROCHESTER, NY–(Marketwire – July 27, 2010) –  ImageXpres Corporation (PINKSHEETS: IMJX) today announced that its Surg-i-Scan™ “digital” Surgical Safety Checklist system has been approved by Apple Corporation and is now available as an Apple software “app” via the Apple iTunes Online Store. The Surg-i-Scan™ “digital” surgical safety checklist software has been designed to reinforce and document improved surgical safety protocols in hospitals and outpatient clinics using or considering use of surgical safety checklists during surgical procedures.

John Zankowski, ImageXpres President and CEO, states, “We are extremely pleased that the ImageXpres Surg-i-Scan™ ‘Digital’ Surgical Safety Checklist Software App has been fully tested and approved by the Apple software development team, and is now ready for large-scale utilization by hospitals, clinics and physicians’ offices. As previously announced, the downloadable software is available as a free, evaluation application by the hospital surgical staff to determine its effectiveness and performance in their own operating rooms.

“We are most confident that doctors and nurses will find the Surg-i-Scan™ Safety Checklist software extremely useful in its present form, and we are confident that use of the software app by surgeons and nurses will result in major sales of standalone Surg-i-Scan™ software sales. In addition, we are anticipating sales of hospital-wide client server extensions of the Surg-i-Scan™ safety checklist software, with certain HIPAA privacy and security features incorporated. Also, a very important result is the expected exponential increase in sales and utilization of physical, analog Surg-i-Scan™ Safety Checklist boards by hospitals just now considering adoption of a surgical safety checklist protocol.”

Mr. Zankowski adds, “Once the hospital surgical team has downloaded and used the free software app, customized Surg-i-Scan™ software, with requisite enhancements and design fields specific to that institution’s approved protocol, it will be licensed to the hospital for a fee, on a one-time, per user basis. ImageXpres will provide all upgrades and support for the software, as well as back-up storage for hospital provider personnel, at a yearly or monthly rate. In the custom Surg-i-Scan™ software versions, several unique productivity, storage and communication features will be available for hospitals and clinics seeking to incorporate surgical safety checklist protocols into their Electronic Health Record (EHR).

“ImageXpres is working closely with ITX Corporation, a key Apple software development partner, also located in Rochester, NY, along with a number of medical surgical supply organizations, in order to reach thousands of hospitals and deliver custom software, in a timely manner. ImageXpres and ITX have identified major software, hardware systems, and services offerings for the growing healthcare market, beginning with the Surg-i-Scan™ Safety Checklist System, and both companies expect to capitalize on the competitive product advantages of their strategic business relationship. ImageXpres recently announced the hiring of a lead apple software developer, and the company is in the process of becoming a certified Apple software developer.

“The U.S. market is estimated at over $25 million annually, based upon the number of surgical operating suites, and could reach over $100 million annually by 2012. The market for other invasive procedures where safety checklists are used, such as IV / Transfusions, emergency room, diagnostic procedures, labor/delivery, is ten times as large.

“ImageXpres currently manufactures and markets analog, custom-designed Surg-i-Scan™ Safety Checklist boards for operating rooms, and the new digital software product will augment the effectiveness of the analog Surg-i-Scan™ Safety Checklist boards, providing valuable documentation of all surgical procedures on an ongoing, daily basis. As an example of the synergy between digital and analog surgical safety checklist products, ImageXpres has been working with a Texas hospital consortium, designing and manufacturing custom analog surgical safety checklist boards, and the digital software version can provide effective, timely documentation of the improvements generated by use of surgical safety checklists within the group.”

Mr. Zankowski, concludes, “We are very excited about the availability of our Surg-i-Scan™ ‘digital’ Safety Checklist product, as it is one is one that truly can benefit every hospital and surgical suite no matter where they are located. The WHO study has documented the benefits of surgical safety checklists for hospitals and patients, in terms of lowered deaths and lowered surgical procedural errors, thus saving lives and improving healthcare delivery. Our Surg-i-Scan™ ‘digital’ Surgical Safety Checklist product is unique in the industry, and now makes it affordable and easy for any hospital, in any country, to test out the usefulness of a surgical safety checklist process, and make immediate improvements in patient safety. Our goal is to make the digital checklist very affordable for millions of hospital providers, thus generating strong market pull for this unique, patient safety product.”

About ImageXpres Corporation

ImageXpres is a digital imaging and printing company, headquartered in Rochester, NY. ImageXpres develops imaging systems solutions for commercial printing, consumer photo, health and business communications market segments. ImageXpres is currently manufacturing and marketing a family of self-service interactive digital kiosks, and LitePix Digital Displays, digital signs that provide unique advertising benefits for business owners. The Company’s website is www.imagexpres.com.

Statements in this press release about the company’s future expectations, including the rate of growth of the Company’s revenues derived from sales of its safety and security products, and all other statements in this release other than historical facts, are “forward-looking statements” within the meaning of Section 27 A of the Securities Act of 1933, Section 21 E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as changes in consumer demand, satisfaction or desire for our products for a variety of reasons. Such “forward-looking statements” are subject to risks and uncertainties set forth from time to time in the company’s reports and financial statements.

ENGLEWOOD, NJ–(Marketwire – July 22, 2010) –  Medical Nutrition USA, Inc. (NASDAQ: MDNU) (and referred to herein as “MNI”), a developer and distributor of nutrition-medicine products, today announced the completion of its previously announced merger with a subsidiary of Danone North America, Inc. (“Danone”). The closing of the merger occurred on Thursday, July 22, 2010. As a result of the merger, all of the outstanding common stock of MNI has been converted into the right to receive $4.00 per share in cash as set forth in the Agreement and Plan of Merger, dated as of June 10, 2010, which was attached as Exhibit 2.1 to MNI’s Current Report on Form 8-K filed on June 14, 2010 with the Securities and Exchange Commission. MNI is now a wholly owned subsidiary of Danone and public trading of MNI’s common stock on the NASDAQ Capital Market will cease prior to the commencement of trading on July 23, 2010.

About Medical Nutrition USA, Inc.
Medical Nutrition USA develops and distributes products for the nutritionally at risk who are under medical supervision. Its products are used primarily in long-term care facilities, hospitals, dialysis clinics and bariatric clinics. The Company’s product lines include Pro-Stat^®, Fiber-Stat^®, UTI-Stat^® and Diff-Stat^® as well as private label products. Additional information is available at www.mdnu.com.

About Danone
Danone is a Fortune 500 company and one of the most successful healthy food companies in the world. Its mission is to bring health through food to as many people as possible. Fulfilling this mission is a major contributor to Danone’s continuous rapid growth. Danone, with 160 plants and around 80,000 employees, has a presence in all five continents and over 120 countries. In 2009, Danone recorded EUR 15 billion in sales. Danone enjoys leading positions on healthy food in four businesses: fresh dairy products (#1 worldwide), water (#2 on the packaged water market), baby nutrition (#2 worldwide) and medical nutrition. Listed on Euronext Paris, Danone is also ranked among the main indexes of social responsibility: Dow Jones Sustainability Index Stoxx and World, ASPI Eurozone and Ethibel Sustainability index.

MCHENRY, IL–(Marketwire – July 21, 2010) –  Medcor, Inc. announced its receipt of Staples’ Supplier of the Year award for Loss Prevention, recognizing Medcor’s contribution to improving health outcomes and controlling health costs. Medcor provides a 24/7 telephonic injury triage service for all Staples retail stores in North America. The service gives Staples employees immediate access to a registered nurse via a toll-free line to help determine the best course of action in the event of injury or illness at work. The service directs employees in first aid and self care, and makes referrals to appropriate off-site care for further treatment and diagnosis when necessary. More than 100 other vendors were considered in the selection process for this award. The award was presented to Medcor by Staples executives Wayne Jacobson and Dan Provost. Staples is the world’s largest office products company. 

“This is an important honor from an important client,” said Medcor President and CEO Philip Seeger, as he shared the award with nurses in Medcor’s call center in McHenry, Illinois. “Our nurses combine their experience and training with our software and clinical algorithms to deliver a very effective clinical intervention. The whole system is designed to work seamlessly within our client’s safety and risk management program.”

Medcor’s triage process is covered by three US patents, with additional patents pending. Medcor’s triage service is currently used by over 70,000 work locations from a variety of industries, including many national retailers. 

About Medcor

Medcor helps employers reduce costs of workers’ compensation and general health care. Medcor services include telephonic injury triage, on-site health and wellness clinics, outsourced safety staff, and employee screening. Medcor’s services are available 24/7 nationwide for worksites of any size in many industries. Headquartered in McHenry, IL, the company provides triage services to nearly 70,000 worksites in all 50 states and operates 163 on-site workplace clinics. Medcor’s triage methods are covered by U.S. & foreign patents, including U.S. No. 7,668,733; 7,716,070; & 7,720,692; other patents pending.

For more information, please contact: Kate Woldhuis at [email protected]

CINCINNATI, OH–(Marketwire – July 21, 2010) –  The Vendor Managed Inventory (VMI) strategy being developed by Bracco Diagnostics, a leading provider of contrast media and related equipment to hospitals and imaging centers, was recently featured in a Gartner report on supply chain innovations in the healthcare industry titled “Case Study: Bracco Diagnostics Leverages Datalliance for Downstream Customer Alliances” published July 8, 2010. 

The case study discusses Bracco Diagnostics’ success with the first phase of their VMI program within its own distribution network, as well as the company’s strategy to offer VMI to key customers as a value-added service to manage inventory, prevent stock-outs, and optimize procure-to-pay processes. 

Addressing the challenges to collaborative supply chain processes such as VMI in the healthcare industry, the report lists the following as lessons learned:

• “Trading partners must be willing to collaborate on the development of improved business processes, increasing the level of trust by establishing bidirectional goals and measures.

• Both the hospital and upstream supplier must start by thinking from the patient back. They should then develop innovative solutions to age-old challenges, such as inefficient transactions, bloated network inventories and less-than-optimal customer satisfaction.

• There are a host of ancillary benefits to establishing robust VMI capabilities between trading partners. For example, the cycle time required to renegotiate supply contracts can be greatly reduced when both parties have a clear line of sight to expected volumes, supplier performance and customer satisfaction.”

The full report is available to Gartner clients at www.gartner.com/resId=1397037.

“VMI continues to expand in the healthcare industry and we’re proud to be working with forward-thinking suppliers like Bracco Diagnostics and others to leverage it as one means of bringing down the cost of patient care,” said Bob Jennings, Datalliance VP of Sales & Marketing. “This is another example of the many successful VMI programs within our customer community.” 

Earlier, Datalliance VMI was positively referenced in the AMR Research report titled “The Resurgence of Vendor Managed Inventory: A Landscape” published in October 2009. Visit www.datalliance.com/2009_dec_pr1.html for more information about that report, which is also available on the Gartner web site for companies with appropriate subscriptions. AMR Research is now part of Gartner.

About Datalliance
Datalliance is a leading provider of collaborative commerce services, and the world’s largest independent VMI service provider. Delivered via the Internet using the ‘Software as a Service’ (SaaS) model, Datalliance solutions make it easy for suppliers and their customers to establish sales and inventory management relationships that fully align business objectives, improve collaboration, and streamline supply chain operations. Datalliance manages billions of dollars in orders, millions of SKUs, and thousands of locations for leading Fortune 1000 companies in a number of industries. For more information about Datalliance, visit www.datalliance.com

TUSTIN, CA–(Marketwire – July 21, 2010) – Radient Pharmaceuticals Corporation (NYSE Amex: RPC), a US-based pharmaceutical company specializing in the research, development and sales of In Vitro Diagnostic (IVD) cancer tests, announced today it has entered into an exclusive distribution agreement with AMDL Australia Pty Ltd. to market and commercialize RPC’s Onko-Sure™ in vitro diagnostic (IVD) cancer test in Australia and New Zealand.

Led by a strong management team of well-respected physicians and diagnostics professionals, AMDL Australia Pty Ltd. is an established, privately?owned distributor of healthcare products to laboratories, clinics, hospitals and other health care providers and research organizations throughout Australia and New Zealand. The company is the newest addition to Radient Pharmaceuticals’ portfolio of international distributors and under the terms of the agreement, will market, sell and distribute at minimum 3700 Onko?Sure IVD cancer test kits for use as a monitoring test for colorectal cancer (CRC) in Australia and New Zealand. AMDL Australia also holds responsibility for developing and executing a full-scale marketing strategy to drive product awareness and engage healthcare decision makers, thought?leaders, lab directors, physicians, patients and healthcare consumers in product purchases. Targeted distribution channels will include medical centers, hospitals, clinical laboratories, university labs.

According to Douglas MacLellan, Chairman and CEO of RPC, “We are extremely pleased to further expand the commercial availability of Onko-Sure through this partnership with AMDL Australia, a leading distributor in Australia and New Zealand. AMDL Australia has a well-established and significant sales force with a successful track record in these markets where we have not yet established a full commercial sales presence for Onko-Sure. Through this partnership, Onko-Sure will be available sooner and to more patients than otherwise possible in these selected markets.”

AMDL Australia’s Dr Chris Dirks remarked, “Epidemiological evidence estimates there are more than 13,000 new cases of CRC in Australia annually. CRC is a leading cause of cancer death in this country and through national cancer screening programs with the use of Onko-Sure we can enable health care providers with the ability to provide early detection, treatment and more vigilant monitoring, which in turn can lead to decreased mortality rates. We are pleased to be the exclusive distributor of Onko-Sure in the Australian and New Zealand markets.”

Onko?Sure is a simple, non?invasive, patent?pending and regulatory?approved in vitro diagnostic test that enables physicians and their patients to effectively monitor and/or detect certain types of cancers by measuring the accumulation of specific breakdown products in the blood called Fibrin and Fibrinogen Degradation Products (FDP). FDP levels rise dramatically with the progression of cancer. The test is approved for laboratory use in Australia and follows FDA clearance for the post treatment phase monitoring of patients with CRC. The test is a standard ELISA test can be requested for patients with CRC on regular pathology request forms by their physicians.

RPC Contact Information:
For additional information on Radient Pharmaceuticals, ADI and its portfolio of products visit the Company’s corporate website at www.Radient-Pharma.com. For Investor Relations information contact Kristine Szarkowitz at [email protected] or 1.206.310.5323.

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is dedicated to saving lives and money for patients and global healthcare systems through the deployment of our Onko-Sure™ In Vitro Diagnostic cancer test. Our focus is on the discovery, development and commercialization of unique high-value diagnostic tests that help physicians answer important clinical questions related to early disease detection; treatment strategy; and the monitoring of disease progression, prognosis, and diagnosis to ultimately improve outcomes for patients. Radient Pharmaceutical’s current Onko-Sure™ cancer test is used to guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, perform additional testing, or assist in the selection of therapy. To learn more about our company, people and potentially life-saving cancer test, visit www.radient-pharma.com.

Forward Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company’s operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Click here to see all recent news from this company

EINDHOVEN, THE NETHERLANDS and GLOSTRUP, DENMARK–(Marketwire – July 21, 2010) – Royal Philips Electronics (NYSE: PHG)(AEX: PHI) and Dako, a Danish company specializing in tissue-based cancer diagnostics, today announced that they have signed an agreement to integrate a selection of Dako’s image analysis applications into Philips’ future digital pathology solutions.

“Anatomic pathology is an essential element of virtually every cancer diagnosis and the demand for it is ever-increasing. Our goal is to develop integrated digital solutions that enhance the operational efficiency and productivity of pathology departments, as well as increasing diagnostic confidence,” says Bob van Gemen, General Manager of Philips Digital Pathology. “I am convinced that our partnership with Dako, with its leading market position and expert knowledge in detecting and quantifying specific biomarkers in cancer tissue, will significantly accelerate our clinical applications development program.”

“We are very pleased to announce this collaboration with Philips, a leading company in the healthcare industry that is committed to entering the digital pathology market,” says Lars Holmkvist, CEO of Dako. “By joining forces with Philips, we will be able to deliver highly competitive diagnostic tools based on Philips’ extensive clinical expertise and technology know-how and Dako’s expertise in advanced staining and image analysis in order to benefit pathology laboratories, pathologists and ultimately patients.”

Currently, anatomic pathology workflows to examine tissue samples are based on the microscope, through which pathologists examine tissue sections mounted on glass slides and treated with different stains. The staining enhances the contrast between, or reveals the presence of, cellular and molecular components such as cell nuclei or specific proteins. Accurate interpretation of the results is critical to the diagnosis and staging of each individual patient’s disease and requires a great deal of skill and experience. Digitizing the images that pathologists normally view through a microscope may enable the introduction of objective and quantitative image analysis tools.

Dr. Clive Taylor, MD, PhD, Professor at University of Southern California, USA, and a renowned expert in pathology, expresses about the collaboration: “Digital pathology has been long in gestation, in comparison to radiology, where images also are the currency of practice, and where image acquisition, transfer, interpretation and storage is almost entirely digital. In part, this lag is because acquisition of histopathology images is dependent upon a 100 year old technique of ’tissue fixation’, sectioning and staining. In part, it is because, somewhat surprisingly, fully digitized histopathology images are much larger than CT files, and difficult to manage and analyze. Progress has been slow because there has been no single institution, or company, that embraces both of these areas. It is exciting that collaborations like that between Dako and Philips are now bringing diverse but appropriate expertise to bear on implementing a full digital pathology program.”

A fast pathology slide scanner and an associated image management system form the basis of Philips’ proposed integrated solutions for digitizing pathology workflows. The Philips-Dako collaboration will initially focus on leveraging Dako’s image analysis software for tissue-based breast cancer diagnosis using its reagents for staining HER2, Estrogen Receptor (ER), Progesterone Receptor (PR), p53 and Ki-67 proteins. The detection and quantification of these proteins in biopsy tissue are highly relevant for the classification of breast cancers and the selection of appropriate therapy. Philips and Dako will also explore the possibility of extending the collaboration to include image analysis software for immunohistology-based prostate and colon cancer diagnostics.

About Royal Philips Electronics
Royal Philips Electronics of the Netherlands (NYSE: PHG)(AEX: PHI) is a diversified health and well-being company, focused on improving people’s lives through timely innovations. As a world leader in healthcare, lifestyle and lighting, Philips integrates technologies and design into people-centric solutions, based on fundamental customer insights and the brand promise of “sense and simplicity”. Headquartered in the Netherlands, Philips employs more than 116,000 employees in more than 60 countries worldwide. With sales of EUR 23 billion in 2009, the company is a market leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as lifestyle products for personal well-being and pleasure with strong leadership positions in flat TV, male shaving and grooming, portable entertainment and oral healthcare. News from Philips is located at www.philips.com/newscenter.

About Dako
Dako, based in Denmark, is a global leader in tissue-based cancer diagnostics. Hospital and research laboratories worldwide use Dako’s know-how, reagents, instruments and software to make precise diagnoses and determine the most effective treatment for patients suffering from cancer. Employing more than 1000 people and being present in more than 80 countries, Dako covers essentially all of the anatomic pathology markets globally. Dako is owned by a private equity fund, EQT. www.dako.com

NEW YORK, NY–(Marketwire – July 21, 2010) –  Allied Healthcare International Inc. (NASDAQ: AHCI) (AIM: AHI) will host a conference call and webcast to discuss the financial and operating performance for its fiscal 2010 third quarter ended June 30, 2010 on Tuesday, August 3, 2010, at 10:00 AM Eastern Time / 3:00 PM UK Time. The call will be hosted by Sandy Young, Chief Executive Officer, and Paul Weston, Chief Financial Officer. The Company will issue its earnings press release prior to the call.

Dial-In Information
Allied invites all those interested in listening to management’s discussion of the results to join the call by dialing (877) 407-8031 for domestic participants and (201) 689-8031 for international participants. Participants may also access a live webcast of the conference call through the “Investors” section of Allied Healthcare’s Website: www.alliedhealthcare.com. 

A telephone replay will be available for one week following the call by dialing (877) 660-6853 for domestic participants and (201) 612-7415 for international participants. When prompted, please enter account number 286 and conference ID number 353906. A webcast replay will also be available and archived on the Company’s website for ninety days.

ABOUT ALLIED HEALTHCARE INTERNATIONAL INC.
Allied Healthcare International Inc. is a leading provider of flexible healthcare staffing services in the United Kingdom. Allied operates a community-based network of over 110 branches with the capacity to provide carers (known as home health aides in the U.S.), nurses, and specialized medical personnel to locations covering approximately 90% of the U.K. population. Allied meets the needs of private patients, community care, nursing and care homes, and hospitals. For more news and information please visit: www.alliedhealthcare.com.

MELVILLE, NY–(Marketwire – July 21, 2010) –  FONAR Corporation (NASDAQ: FONR), The Inventor of MR Scanning™ announces new breakthrough results for the FONAR UPRIGHT® Multi-Position™ MRI. The medical journal “Brain Injury” (July 2010:24(7-8):988-994) has just released the exciting results of a study of 1200 neck pain patients. The study was published by 10 authors from distinguished universities in the U.S. and around the world (University of Oregon, University of Aarhus, Denmark, University of Aberdeen, Scotland, Columbia University, Portland State University) of their results from the scans of 1200 patients. Their study reported that 150% more whiplash patients (Table II – % CTE Trauma Patients) had demonstrable radiographic pathology when scanned upright than when they were scanned lying down (recumbent). Their investigation also reported that “patients with a history of motor vehicle crash-associated neck pain have a substantially higher frequency of cerebellar tonsillar ectopia (CTE)* of 1mm or more than non-traumatic subjects” when examined by the FONAR UPRIGHT® MRI. The authors were Michael D. Freeman, Scott Rosa, David Harshfield, Francis Smith, Robert Bennett, Christopher J. Centeno, Ezriel Kornel, Ake Nystrom, Dan Heffez and Sean S. Kohles.

As the authors reported, the frequency of these fallen cerebellar tonsils (CTE)* was found “4 times more often” in neck pain patients who had experienced whiplash trauma versus neck pain patients that had not experienced recent trauma, when the FONAR UPRIGHT® MRI scanner was used.

The authors further reported, “CTE (tonsil ectopia) was found 2.5 times more often in the upright trauma vs. the recumbent group” if the patients were scanned in the FONAR UPRIGHT® Multi-Position™ MRI. In sum the anatomic origin of the patient’s whiplash symptoms was successfully visualized 2.5 times more frequently when the patient was scanned upright in the FONAR UPRIGHT® Multi-Position™ MRI than when he/she was scanned lying down in the conventional recumbent-only MRI.

The upright MRI examination, therefore, now makes it possible to provide definitive radiographic evidence and image characterization of the pathology giving rise to a patient’s whiplash symptoms so that it can be medically treated. For the first time, definitive anatomic evidence of the injuries sustained by whiplash victims in a motor vehicle accident can be provided. Currently, as the authors point out, some claim that patient whiplash pain is “non-pathologic chronic pain” engendered by “psychosocial factors such as litigation.” The newly published results from the FONAR UPRIGHT® Multi-Position™ MRI establish that this is not correct.

The July 2010 published report of 1200 neck pain patients that were examined in both the recumbent position in a conventional MRI and upright in the FONAR UPRIGHT® Multi-Position™ MRI establishes a “new standard of care” for victims of automotive whiplash injuries wherein the patients’ injuries can now be anatomically visualized and specifically defined so that the most expedient medical treatment can be provided.

Overall, the pathologic anatomy responsible for the patient’s whiplash symptoms was successfully identified in 23.3% of whiplash trauma patients (Table II, Brain Injury, July 2010: 24 (7-8):998) when the patient was scanned upright in the FONAR UPRIGHT® Multi-Position™ MRI. The cause of the patient’s symptoms was identified after a whiplash injury only 9.3% of the time (Table II) when the patient was lying down in a conventional recumbent-only MRI, a difference of 2 1/2 times or 150%.

Raymond V. Damadian, M.D., president and founder of FONAR said, “it has been published(1) that there are approximately 3,000,000 REAR IMPACT(2) crash related (or CAD(3)) INJURIES(2) in the U.S. annually. Accordingly, the publication by M.D. Freeman and co-authors in the July 2010 issue of “Brain Injury” has established that of the 3,000,000 motor vehicle CAD injuries occurring annually in the U.S. 700,000 (23.3%) would exhibit cranio-cervical anatomic changes associated with their symptoms when examined upright in the FONAR UPRIGHT® Multi-Position™ MRI, while only 279,000 would have their pathology detected by a conventional lie-down MRI. At the rate of 3,000,000 CAD whiplash injuries per year, 420,000 patients each year would have the pathology responsible for their symptoms go undetected if they were examined solely in a conventional recumbent-only MRI.”

Dr. Damadian further stressed, “the sudden rise in the incidence of patients suffering from the Chiari syndrome (cerebellar tonsil ectopia) is a fairly recent occurrence that needs to be addressed by both the medical and automotive professions. As Galasko et. al. from the University of Manchester, Salford, U.K., reported regarding the change in the incidence of whiplash disorders following the 1982 enactment of seat-belt legislation in the U.K. (J. Musculoskeletal Pain, Vol 8. (1/2) pgs 15-27), the incidence of whiplash associated disorders (WAD) rose “far in excess of general road traffic accident cases,” and as they also reported, “rose at an alarming rate”.

“Consequently,” Dr. Damadian stated, “it is very important that the approximately 3,000,000 people per year in the U.S. involved in the rear end auto collisions that give rise to whiplash injuries, receive an UPRIGHT® MRI examination soon after the accident. This will assure that a cerebellar tonsil ectopia has not resulted from the accident so that they can be protected going forward, and protected before they become symptomatic. If found to have CTE, they can then be warned by their physicians to exercise especial caution whenever driving and to have devices like the head restraint impact suppressor cushions installed (add On Head Rest, www.addonheadrest.com) to prevent the whiplash reaction from occurring again in the event of a collision. 

“A real concern,” added Dr. Damadian, ” is that a subsequent auto-accident for a patient who had developed tonsil ectopia from a prior auto accident, but did not develop symptoms from the ectopia, can subsequently develop symptoms from even a MINOR subsequent accident. Wan, et. al. (Wan, M. J., Nomura, H., Tator, C. H. Neurosurg. 2008; 63: 748-753.), described a symptomatic “conversion” of previously asymptomatic Chiari Type 1 following MINOR(2) head and neck trauma” (Freeman, M. D. et. al. Brain Injury, July 2010: 24 (7-8):989.

Considering that long term studies have shown that some patients suffered frequent residual symptoms 17 years after the accident, mostly comprising neck pain, radiating pain and headaches, (Eur. Spine J. 2002; 11:227-34), this publication in “Brain Injury” clearly demonstrates the need and the superiority of the FONAR UPRIGHT® Multi-Position™ MRI for imaging patients involved in motor vehicle crashes that sustain whiplash injuries.

* Cerebellar tonsillar ectopia (CTE) constitutes downward displacement of the cerebellum of the brain into the opening in the bottom of the skull, the foramen magnum, through which the spinal cord exits the skull. The downward displacement can result in compression of the medulla of the brain, fourth ventricle and cerebellar vermis, giving rise to neck pain, chronic recurrent occipital headaches, upper extremity weakness and “drop attacks”. While afflicting a low percentage of Chiari 1 patients, such patients can be subject to instantaneous unpredictable losses of consciousness known as “drop attacks” in which the standing patient, without warning, suddenly collapses to the floor.

(1) Foreman, S. M., Croft, A. C. (eds) third edition. Whiplash injuries: The cervical acceleration/deceleration syndrome. Baltimore: Lippincott, Williams & Wilkins, 2001, Pg. 359.

(2) Capitalization added.

(3) Cervical Acceleration/Deceleration syndrome aka “whiplash”.

To obtain a copy of the article published in the peer-reviewed journal, “Brain Injury,” please contact FONAR at 631-694-2929×451 or by email at [email protected]. You may also use a search engine such as Google and search for the journal article entitled “A case-control study of cerebellar tonsillar ectopia (Chiari) and head/neck trauma (whiplash).

For investor and other information visit: www.fonar.com.

UPRIGHT® and STAND-UP® are registered trademarks and The Inventor of MR Scanning™, Full Range of Motion™, pMRI™, Dynamic™, Multi-Position™, True Flow™, The Proof is in the Picture™, Spondylography™ Spondylometry™ and Upright Radiology™ are trademarks of FONAR Corporation.

This release may include forward-looking statements from the company that may or may not materialize. Additional information on factors that could potentially affect the company’s financial results may be found in the company’s filings with the Securities and Exchange Commission.

IRVINE, CA–(Marketwire – July 19, 2010) –  The Cystinosis Research Foundation has named three prominent researchers to its Scientific Review Board, which reviews and recommends applications for grants to study the rare and fatal metabolic disease and develop new treatments and a cure. Cystinosis afflicts about 2,000 persons, mostly children, worldwide.

Joining the CRF’s Scientific Review Board are: Drs. Stephanie Cherqui of The Scripps Research Institute, La Jolla, Calif.; Allison Eddy of the University of Washington, Seattle, Wash. and Francisco Emma of the Bambino Gesù Children’s Hospital in Rome.

Leaving the CRF’s Scientific Review Board and retiring from a historic career in metabolic disease research is Dr. Jerry Schneider, M.D., who was Professor of Pediatrics and Dean for Academic Affairs at the University of California, San Diego. He is a developer of the two breakthrough treatments for cystinosis, which he began studying in 1965.

“We are fortunate to have such pre-eminent scientists advising us on funding cystinosis research. Over the years, they have made valuable contributions to cystinosis research and are committed to finding improved treatments and a cure,” said Nancy Stack, President and co-founder of the CRF.

She added that the lifelong research on cystinosis by Dr. Schneider “has brought us to the threshold of a new treatment and a cure. He has encouraged and mentored new researchers who now, in turn, have dedicated their careers to cystinosis. Cystinosis patients and their families owe him eternal gratitude,” Stack said.

Dr. Cherqui, Ph. D., an assistant professor at The Scripps Research Institute, is credited with developing a breakthrough cell and gene therapy regimen that has improved cystinosis in mice. She is a member of the CRF Gene Therapy Consortium. Dr. Cherqui worked in Paris with a group led by Dr. Corinne Antignac that identified the cystinosis CTNS gene. Her 2002 doctoral thesis was on molecular studies of cystinosis and the generation of the mouse model for cystinosis. Dr. Cherqui is a member of the American Society of Gene and Cell Therapy. She has authored 12 publications on cystinosis, including a cover article in the October issue of the scientific journal “Blood.”

Dr. Eddy, M.D., professor of pediatrics at the University of Washington, is internationally recognized for her work on the cellular and molecular basis of kidney fibrosis and progressive kidney disease. She is the director of the Tissue and Cell Biology Research Center at Seattle Children’s Research Institute and in 2009 was elected to the Council of the International Society of Nephrology. Dr. Eddy holds the Robert O. Hickman Endowed Chair in Pediatric Nephrology at the University of Washington. She is a graduate of the McMaster University Medical School in Canada.

Dr. Emma, M.D., is head of Pediatric Nephrology at the Bambino Gesù Children’s Hospital in Rome, Italy, and president of the Italian Society of Pediatric Nephrology. Dr. Emma’s laboratory research on cystinosis has been focused on studying cell mechanisms that regulate the expression of the CTNS gene and different isoforms of the cystinosin protein. He recently began studying the therapeutic potentials of stem cells for treatment of cystinosis with the support of the CRF. Dr. Emma received his medical degree from the Catholic University of Louvain, Brussels, Belgium. He trained at Children’s Hospital, Harvard Medical School, Boston, Mass.

Cystinosis is a metabolic disease that slowly destroys every organ in the body, including the liver, kidneys, eyes, muscles, thyroid and brain. There is a medicine that prolongs the children’s lives, but there is no cure. Most cystinosis sufferers succumb to the disease or its complications by age 40.

In patients with cystinosis, the amino acid cystine accumulates in the tissue due to the inability of the body to transport cystine out of the cell. This causes development of crystals, resulting in early cell death. There is a medication but, as yet, no cure for the disease.

Twice a year the CRF announces worldwide calls to the scientific community for research proposals. Since 2003, the CRF’s Scientific Review Board has played a key advisory role for 78 research grants totaling $11.8 million to scientists studying cystinosis in North America and Europe. Currently, there are 48 CRF-funded studies underway along with 13 CRF research fellows in the United States, Canada, France, Italy, Belgium, Ireland, Germany and The Netherlands.

The CRF is the leading funding source for cystinosis research. The foundation recently approved requests totaling $988,759 for seven new grants. Every dollar raised by the CRF is committed for medical research. Administrative costs are privately underwritten.

Nancy Stack and her husband, Geoffrey, a managing director of the SARES REGIS Group, an Irvine real estate company, have a daughter, Natalie, 19, with cystinosis.

For more information about Cure Cystinosis International Registry and the Cystinosis Research Foundation of Irvine, Calif., call Zoe Solsby at (949) 223-7610 or visit www.cystinosisresearch.org.

HOUSTON, TX–(Marketwire – July 19, 2010) – Leading the charge in minimally invasive treatments for common hand and upper extremity conditions and injuries plaguing both men and women in society today, hand and upper extremity specialist, Dr. Evan Collins approves the use of new minimally invasive XIAFLEX® in the treatment of his patients suffering from Dupuytren’s Contracture.

The new injectable treatment first introduced in Europe recently received FDA approval for use in the United States and is now offered by a small group of specially trained orthopedic specialists. Dr. Collins, who was among the first to introduce the Percutaneous Needle Fasciotomy, also known as needle aponeurotomy (NA), in the treatment of Dupuytren’s Contracture nearly two years ago will offer the new XIAFLEX® treatment at The Methodist Hospital – Texas Medical Center.

XIAFLEX® is the first FDA-approved non surgical treatment for Dupuytren’s Contracture, enzymatically disrupting collagen when injected directly into a Dupuytren’s cord. Collagen disruption results in improved range of motion.

“There has been a great deal of work done in recent years to address the debilitating effects of Dupuytren’s Disease. This is among the first non surgical injection procedures approved by the FDA in the United States. We hope to restore range of motion to patients suffering from severe Dupuytren’s contractures, without the risks and recovery time of even the most advanced surgical procedures currently used to address them,” said Dr. Collins.

“Many people choose to live with the condition, which can dramatically affect even the most basic daily activities, because they are not comfortable with the treatments we have had to date. This non surgical approach may be a more appealing option for them,” Collins added.

Dupuytren’s disease is a progressive condition which causes the fibrous tissue of the palmar fascia (cords) to shorten and thicken. Eventually this will result in nodules causing fingers to contract, distorting the hand and reducing hand function. 

A Weill Cornell assistant professor and former Chief of Hand & Upper Extremity at Baylor College of Medicine, Dr. Evan Collins is awarded some of the highest nationally recorded patient satisfaction scores. He is featured among H Texas and Texas Monthly magazines’ recognized doctor’s listings and internationally renowned for his research in common hand and wrist conditions, tendinopathies, carpal tunnel syndrome, osteoarthritis and other debilitating joint conditions. 

Click here to see all recent news from this company

ORLANDO, FL–(Marketwire – July 19, 2010) –  WellCity, Inc. (http://www.WellCity.com), a wellness-related social network and subsidiary of WellTek, Inc. (OTCBB: WTKN), today announced it will host a national conference call on July 22, 2010 at 9:30 pm EDT to present an important message from David George, CEO of WellCity.

The Company is rallying all network marketers to listen in on why WellCity is the single most effective medium today for creating optimum health and long-term wealth.

Subject: Important Message from David George, CEO of WellCity
Date: Thursday, July 22, 2010
Time: 9:30 pm EDT
Telephone Dial In: 1-760-569-7676
Access Code: 239460#
Self Mute/Unmute: *6

Skype Dial In: Add freeconferencecallhd.7676 to your Skype contacts
Use the Skype Dial Pad to enter the Access Code: 239460# Self Mute/Unmute *6

Note: Using Skype for these calls has additional steps than a standard Skype call.
To locate the Skype keypad to enter your access code when calling the conference, select the contact first and then the green Dial button. In the same area as the Dial button, next to the volume to the right, you will see a round drop down icon. Click on the icon and select Display Keypad from the drop down menu. After the call is connected, wait for the prompt and enter your access code using the Skype keypad followed by the # key.

About WellCity Incorporated
WellCity is a social utility where health- and wellness-minded ‘residents’ can closely commune with one another; receive support, information and encouragement from their ‘neighbors’ and from a league of leading professional experts; shop for health and wellness-oriented product and services; compete in WellCity’s proprietary 90-Day Wellness Challenge; and even enjoy income opportunities by leveraging their personal network. For more information on the Company, please visit www.WellCity.com.

About WellTek Incorporated
WellTek is a global health, fitness and wellness company that provides proven solutions to help address some of the world’s most pressing and costly health and wellness challenges. The Company owns and operates WellCity, Inc., a premiere wellness-related social utility that helps ‘residents’ live longer, feel better, look younger and enjoy life more as they age. The Company’s subsidiary, MedX Limited, manufactures, markets and distributes the most advanced medical exercise equipment to the medical and fitness markets. Through its wholly owned subsidiary Pure HealthyBack, Inc., WellTek is redefining healthcare delivery by providing health plans, self-insured employer groups, and consumers with a viable non-surgical, lower cost treatment for patients who are seeking lasting relief from chronic neck and back pain. For more information on the Company, please visit www.WellTekinc.com. 

Certain statements contained in this press release, which are not based on historical facts, are forward-looking statements as the term is defined in the Private Securities Litigation Reform Act of 1995, and are subject to substantial uncertainties and risks in part detailed in the respective Company’s Securities and Exchange Commission filings, that may cause actual results to materially differ from projections. Although the Company believes that its expectations are reasonable assumptions within the bounds of its knowledge of its businesses, expectations, representations and operations, there can be no assurance that actual results will not differ materially from their expectations. Important factors currently known to management that could cause actual results to differ materially from those in forward-looking statements include the Company’s ability to execute properly its business model, to raise additional capital to implement its continuing business model, the ability to attract and retain personnel — including highly qualified executives, management and operational personnel, ability to negotiate favorable future debt facilities and capital raises, and the inherent risk associated with a diversified business to achieve and maintain positive cash flow and net profitability. In light of these risks and uncertainties, there can be no assurance that the forward-looking information contained in this press release will, in fact, occur. 

TAMPA, FL–(Marketwire – July 19, 2010) – Zimek Technologies (www.zimek.com) today announced the formation of the Zimek Global Health Foundation, a 501-C-3 non-profit organization, created to focus public awareness of increasing infection rates and bacteria becoming resistant to antibiotic drugs, according to Jen Grosman, President of the Board of Directors for the Foundation.

The Zimek Global Health Foundation will conduct infection control medical peer reviews on reducing infection rates utilizing Zimek’s automatic touchless decontamination systems, lab testing, pilot case studies, infection control technology research and development, as well as distribute Zimek decontamination systems to underprivileged population centers and disaster stricken areas across America and internationally. Zimek Global Health Foundation will seek out partnerships with key non-profit, emergency and charitable organizations to coordinate distribution of Zimek’s infection control technology.

“As President of the Board of Directors for Zimek’s Global Health Foundation, we are extremely excited to create meaningful public awareness for the need of life-saving infection control technology and to continue our important research and development capabilities to prevent the spread of infectious diseases,” said Jen Grosman.

Zimek Technologies (www.zimek.com), based in Tampa, Florida, has been developing and marketing its patented automatic Micro-Mist™ decontamination technologies for more than five years. Zimek’s industry-leading technologies are used by the U.S. Department of Homeland Security, Fire and EMS departments, healthcare facilities, public health agencies, transit systems, correctional facilities and local law enforcement agencies across America.